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Abstract 
Background: Clostridium difficile is a leading cause of noscomial infection and is 
responsible for increased morbidity and mortality (Hookman & Barkin, 2009). There 
are limited data available on the nutritional status and dietetic management of these 
patients. 
Aims:  
1. To carry out an observational study to assess the prevalence of the risk of 
malnutrition in patients with Clostridium difficile associated disease (CDAD) and 
compare it to a group of patients in the same hospital.  
2. To investigate dietitians’ beliefs and recommendations of probiotics in CDAD and 
determine the probiotic products and strains being used in this patient group. To 
assess the current enteral feeding practices of dietitians in patients with CDAD.  
Methods: The Malnutrition Screening Tool (MUST) was used to assess the 
prevalence of risk of malnutrition in the patients with CDAD and a hospital 
comparison group. A questionnaire was sent to members of the Irish Nutrition and 
Dietetic Institute to gather information on dietitians’ opinions and use of probiotics 
and their enteral feeding practices in patients with CDAD.  
Results: There was no significant difference in the prevalence of malnutrition risk 
(MUST of 1 or more) between the CDAD group (75.5%) compared to the hospital 
comparison group (66.7%).  The questionnaire response rate was 41% with 215 
questionnaires undergoing analysis. One-third (34.5%) of dietitians considered 
probiotics to have a role in the prevention of CDAD yet only 11% used them in 
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practice. Almost two-thirds (65.4%) believed that they have a role in the treatment of 
CDAD but only 40% regularly used them in practice.  A yogurt drink containing 
Lactobacillus rhamnosus GG was mostly commonly available probiotic product for 
use by dietitians. When enterally feeding patients with CDAD, the majority of 
dietitians use a polymeric feed (79.6%). 
 
Conclusion: Both patient groups studied were at similar nutritional risk. There are 
mixed beliefs among Irish dietitians on the role of probiotics in CDAD. Probiotics 
are frequently recommended by dietitians in their clinical practice with little 
standardisation in practice. The probiotic strain that is most commonly being used in 
patients with CDAD does not have strong evidence to support its use.  
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Part 1 - Clostridium difficile associated disease 
1.1 Clostridium difficile 
The human gastrointestinal tract (GIT) contains up to 1014 microorganisms comprised 
of around one thousand different bacterial species (Backhed et al., 2005).  Some of 
these microorganisms live permanently in the GIT while others are introduced with 
food or other contaminants and pass through the tract.  The stomach contains very 
few resident bacteria due to its low pH. The upper intestine also contains small 
numbers of microorganisms due to the presence of bile salts and the action of 
peristalsis.  A dramatic increase in the number and variety of microorganisms, in 
particular, anaerobes is found in the colon.  One such anaerobe, estimated to form 
part of the faecal flora in approximately 3% of healthy adults, is the gram positive, 
spore-forming Clostridium difficile (C.difficile) (Viscidi et al., 1981).  The bacterium 
was first described in 1935 by Hall and O’Toole as part of the normal intestinal flora 
of newborn infants (Hall & O'Toole, 1935).  The bacterium is present in over 20% of 
hospitalised patients (Starr, 2005) and has been identified in 4-20% of patients in long 
term care facilities (Simor et al., 2002).  It is a major cause of nosocomial infection, 
and has been associated with an increased incidence of morbidity and mortality, in 
hospitals and long term care facilities (Loo et al., 2005; McDonald et al., 2005; Pepin 
et al., 2005a). In 1978, C. difficile was identified as the pathogen responsible for 
pseudomembranous colitis (PMC) (Bartlett et al., 1978).   
Acquisition of C. difficile occurs by oral ingestion of spores. These spores are 
resistant to the acidity of the stomach and germinate into the vegetative form in the 
alkaline environment of the small intestine.  Disruption of the commensal flora of the 
colon, typically through exposure to antimicrobial medication, allows C. difficile to 
flourish and produce toxins.  The two main exotoxins that are produced are toxin A 
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and toxin B, both of which are cytotoxic and enteropathic in the human intestine.  
Both toxins appear to have cytotoxic effects through disruption of the actin 
cytoskeleton within cells (Rupnik et al., 2005).  The toxins loosen the junctions of 
the epithelial cells that line the colon allowing for penetration between epithelial 
cells (Starr, 2005). This begins the cascade of a tissue damaging inflammatory 
process that involves releasing destructive leukotrienes and cytokines, with the 
subsequent death of epithelial cells by apoptosis. The cytokines identified as being 
involved are interleukins (IL) 6, IL8, IL 1β, leukotriene B4 and interferon γ. 
Epithelial cells and monocytes have been found to be more sensitive to C. difficle 
toxin A induced death than lymphocytes (Mahida et al., 1996).  More recently, a 
third toxin (binary toxin) encoded by the cdtA and cdtB genes has been found in 10% 
of strains (Goncalves et al., 2004). The role of this third toxin in disease development 
is still unclear (Pituch, 2009). It has been suggested that it has a clinically relevant 
role (Barbut et al., 2005).  A correlation between the amount of toxin produced and 
the extent of clinical disease is not thought to exist (Akerlund et al., 2006).  
1.2 Definition of Clostridium difficile associated disease (CDAD) 
The Health Protection Surveillance Centre (HPSC) of Ireland has adopted the 
definition of CDAD recommended by the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) study group for C. difficile and the European 
Centre for Disease Prevention and Control (ECDC) (Kuijper et al., 2006).  In Ireland, 
Clostridium difficile associated disease (CDAD) is diagnosed when patients have one 
or more of the following criteria: diarrhoeal stools or toxic megacolon with either a 
positive laboratory assay of C. difficile toxin A and/or toxin B in stools or a toxin 
producing C. difficile organism detected in stool culture or by other laboratory 
methods.  PMC can only be diagnosed by endoscopy and/or colonic histopathology.  
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In all cases, diarrhoea is defined as three or more loose or watery bowel movements 
in a 24-hour period.  Similar criteria are used to diagnose recurrent CDAD (Cohen et 
al., 2010).  The infection is classified as severe when there is admission to an 
intensive care unit (ICU) for treatment of CDAD or its complications, surgery for 
toxic megacolon, perforation or refractory colitis or death within 30 days of diagnosis 
if CDAD is either the primary or a contributory cause.  Admission to a healthcare 
facility for treatment of community associated CDAD is also classified as severe 
infection. According to the HPSC, CDAD can also be classified according to its 
origin as follows:  “Health care associated” CDAD or “Community associated” 
CDAD.  The HPSC classifies acquisition as “unknown” when CDAD presents in a 
patient who was discharged from a healthcare facility 4-12 weeks before the onset of 
symptoms (HPSC, 2008). 
CDAD has been classified as recurrent if an episode of CDAD occurs within eight 
weeks following the onset of a previous episode, provided that the CDAD symptoms 
from the earlier episode resolved with or without therapy.  Older age, low quality of 
life score and being female are known risk factors for disease recurrence (McFarland 
et al., 1999).  Following a first episode of CDAD, 24% of patients relapse within two 
months (Sunenshine & McDonald, 2006).  Having one recurrence of CDAD 
increases the risk of subsequent recurrences (McFarland et al., 1999).  Re-infection 
with different strains of C. difficile has been found in a large proportion of 
recurrences (Barbut et al., 2000).  The risk of recurring infection increases to 50-65% 
of patients with two or more previous episodes (Rohde et al., 2009).   
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1.3 Clinical manifestations of CDAD 
The spectrum of C. difficile human disease ranges from asymptomatic colonisation to 
potentially fatal colitis.  Fulminant, life threatening PMC is the extreme end of the 
spectrum of disease and occurs in 3-5% of those affected (Jobe et al., 1995; Rubin et 
al., 1995). The symptoms of CDAD usually begin soon after colonisation, with 
median time to onset of 2-3 days (McFarland et al., 1989; Johnson et al., 1990; 
Samore et al., 1994; Kyne et al., 2000).  Typically, CDAD presents as diarrhoea, 
abdominal cramps, fever and leukocytosis occurring from several days to 10 weeks 
after antibiotic therapy (Kelly et al., 1994; Kyne et al., 1999; Bartlett et al., 2002).   
Histologically, the disease is characterized by focal epithelial ulceration associated 
with inflammatory exudates (Price & Davies, 1977). Severely ill patients may have 
no diarrhoea due to dilation of the colon (toxic megacolon) and paralytic ileus that 
may result from loss of colonic muscular tone (Kelly et al., 1994; Kyne et al., 1999; 
Bartlett et al., 2002). In severely ill patients, with no response to treatment, a 
colectomy may be required (Bartlett, 2002). In general, complications of diarrhoea 
threaten the already compromised health and well being of the hospitalised patient.  
Severe diarrhoea can result in haemodynamic and metabolic instability due to fluid 
and electrolyte imbalance.  Incontinence of diarrhoeal stool is a major cause of 
perianal skin damage. An unusual manifestation of CDAD was described by 
Dansinger et al., (1996) who reported that up to half of patients with indolent C. 
difficile infection develop manifestations of protein losing enteropathy involving 
ascites, peripheral oedema and hypoalbuminaemia.  Inflammation of the bowel may 
result in leakage of albumin across the lumen causing colonic loss of albumin with 
inadequate compensatory hepatic synthesis (Hookman & Barkin, 2009).  
Psychological problems are often overlooked, as diarrhoea can be exhausting and 
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embarrassing for the patient (Thorson et al., 2008). Complications result in extended 
hospital stay (on average by 3-7 days), an increase in unrelated infections and a two 
to three times increased risk of mortality (McFarland, 2006).  Kuijper et al., (2006) 
have estimated the cost of CDAD to the healthcare system as between €5-15,000 per 
case in the United Kingdom.  CDAD results in a total expenditure of $1.1 billion per 
year in the United States (Kuijper et al., 2006).  
1.4 Immune response to CDAD  
The host immune response to C. difficile colonisation and toxin production is crucial 
in influencing disease severity, but not all patients have a similar immunological 
response (Jiang et al., 2007).  The earliest research in this area reported an antibody 
response in 64% of adults to toxin A and in 66% of adults to toxin B.  Antibody 
levels to toxin B were higher in the serum of convalescent CDAD patients when 
compared to those of a control population (Viscidi et al., 1983).  Kyne et al., (2000) 
reported that asymptomatic carriage of C. difficile was strongly associated with an 
immune response to C. difficile toxins, and this was demonstrated by high serum 
levels of IgG antibody against toxin A.   
1.5 Changing epidemiology of CDAD 
In recent years, there has been an unexpected increase in CDAD infection with large 
outbreaks in North America and Europe (Kuijper et al., 2006).  In many of the 
locations where the increase has been identified, the disease has become more serious 
and refractory to standard therapy.  These recent outbreaks have been associated with 
the unique strain of C. difficile that has been identified as B1/NAP1/027 or “ribotype 
027”.  This strain is now affecting relatively healthy adults, including some who have 
not been exposed to the hospital setting or recent antibiotics. B1/NAP1/027 strain is 
characterized as toxinotype III and has a 18-bp deletion within the tcdC gene 
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(putative negative regulator for the production of toxins A and B) as well as a 
deletion at position 117. It produces 23 and 16 times more toxin B and A respectively 
in vitro than previously described (Warny et al., 2005). This strain has a high 
resistance to fluoroquinolones (Pepin et al., 2005a) and the mortality associated with 
the new strain has been estimated to be between 6-12% (Pepin et al., 2005b; Smith, 
2005; Paltansing et al., 2007).   
An increased incidence of the disease has also been identified in the community 
setting; again affecting people who would traditionally have been at low risk (Wilcox 
et al., 2008).  Mc Farland et al., (2007), observed patients with community-acquired 
CDAD were younger, had less severe disease and that most had no prior exposure to 
antibiotics.  It has been suggested that this may be because CDAD is an emerging 
problem, or that possibly that the disease was overlooked in the past (Weese, 2010).  
A variety of hypotheses has been proposed to explain the current outbreaks of CDAD 
in the community.  Levels of exposure to the organism and its spores may have 
increased due to the possible colonisation of recently discharged patients from 
hospitals, increased asymptomatic carriage and increased contact with asymptomatic 
carriers (Bauer et al., 2008a). Weese (2010) commented that animals and 
contaminated food may be a source of C. difficile, especially in community-
associated CDAD. 
1.6 CDAD in Ireland  
Until recently there was limited information from the Republic of Ireland on CDAD. 
However, in May 2008, it became a notifiable disease.  In 2009, there were 1897 new 
cases of CDAD reported (HPSC, 2009) and this decreased to 1696 new cases in 2010 
(HPSC, 2010).  In both years, the disease was more prevalent in females (59% in 
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2010) and in those over 65 years of age (HPSC, 2009; HPSC, 2010).  Further 
information about the disease in Ireland was captured during a one month national 
enhanced surveillance in March 2009.  Typing and antimicrobial susceptibility of 211 
cases of C. difficile infection from 33 healthcare facilities was conducted.  The results 
found that the majority of patients had been treated with antibiotics in the previous 
eight weeks prior to developing CDAD. 10% of the cases were community-associated 
and 83% were health-care associated.  The most common ribotypes identified were 
027, 106, 078, 044,014 and 001 (Fenelon et al., 2009). 
1.7 Risk factors for the development of CDAD 
There are a number of identifiable risk factors known to increase the likelihood of 
colonisation and development of CDAD.  The most common risk factors are 
exposure to antibiotics, advanced age and hospitalisation.  Other factors which are 
attributed to increased risk are; recent gastrointestinal surgery or procedures, 
immunosuppressive therapy, severe underlying disease, use of enteral tube feeding 
(ETF) and proton pump inhibitors (PPIs) (Bignardi, 1998).  
1.7.1 Antibiotics 
There are multifactorial mechanisms by which antibiotics lead to increased 
susceptibility to the acquisition of C. difficile.  Antibiotics destabilise the GIT 
microflora and can alter the integrity of epithelial surfaces (Levy, 2000).  In addition, 
they increase peristalsis by acting as colonic irritants.  The extent to which they affect 
colonic microflora depends on the composition of the original microflora, the 
spectrum of activity and dosage of the antibiotic, the route and duration of 
administration and concentration of the active drug in the GIT.  The most commonly 
reported antibiotics implicated in the development of CDAD are clindamycin, 
cephalosporins and fluoroquinolones (Bartlett, 1992).  CDAD usually begins 4-9 days 
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after the antibiotic therapy has stopped but it can occur up to eight weeks post 
treatment (Rohde et al., 2009). Approximately 5-30% of patients receiving 
antibiotics, particularly broad spectrum antibiotics, develop diarrhoea either during 
the course of treatment or up to two months after the course finished (Hogenauer et 
al., 1998). 
1.7.2 Hospitalisation and length of stay 
The risk of developing CDAD is highly correlated with the length of hospital stay 
(Clabots et al., 1992).  This is most likely due to the increased risk of exposure to 
spores while in hospital (Imhoff & Karpa, 2009).  The hands of health care workers 
contaminated with C. difficile spores are the most probable vehicle for the spread of 
spores during non-outbreak periods (Fekety et al., 1981; McFarland et al., 1989).  
Spores of C. difficile are resistant to alcohol and standard hospital germicides (Wult 
et al., 2003a).  To limit the spread of CDAD a number of infection control measure 
are required, these include; staff education, use of patient isolation, protective 
clothing, hand hygiene, environmental clean cleaning of medical equipment and good 
antibiotic stewardship (Vonberg et al., 2008). 
1.7.3 Increasing age 
Older age is considered a risk factor for the acquisition of C. difficile.  A Swedish 
group reported that the rate of CDAD per 100,000 persons older than 65 years was 20 
times higher than that in persons younger than 20 years of age (Karlstrom et al., 
1998).  Factors which are thought to be involved in the increased risk include age-
related changes in faecal flora, immune system dysfunction or more severe 
underlying disease.  
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Studies have shown a decrease in the level of beneficial and protective bacteria in the 
GIT in later life, and an increase in species diversity (Woodmansey, 2007).  There is 
a decrease in the number of bifidobacteria with increasing age (O’Connell, 2009).  
Bifidobacteria are capable of inhibiting the growth of many pathogenic bacterial 
species; and any reduction in the number of beneficial bacteria increases the risk of 
growth of pathogenic organisms.  Such alterations in GIT microflora with age could 
result in a reduced functionality and immune responsiveness in the gut and increase 
susceptibility to infections (Woodmansey, 2007). Weakening of the immune system 
also occurs with increasing age, and this can increase susceptibility to infection.  
There is a reduction in the production of antibodies and T-cells.  Natural killer (NK) 
cells may also be reduced in number and activity (Takeda & Okumura, 2007). 
1.7.4 Intensive care setting 
Being a patient in ICU is acknowledged to be an independent risk factor for the 
development of CDAD (Bignardi, 1998).  Patients admitted to ICU are bed-bound, 
have more severe underlying disease and decreased bowel motility.  They are 
generally mechanically ventilated, receiving narcotics and at risk of developing 
bowel ischemia.  A decrease in bowel motility may allow those colonised with C. 
difficile to develop colitis by increasing the exposure time of the toxin to its receptor 
(Modena et al., 2005). 
1.7.5 Proton pump inhibitors (PPIs) 
Dial et al., (2007) estimated that the increased risk of developing CDAD with current 
use of PPIs is 2.9 (95% CI 1.6-3.4).  Gastric acid production is a key host defence 
mechanism. PPIs inhibit an individual’s defence against ingested bacteria by 
reducing the acidity of the gastric contents.  C. difficile spores are resistant to acid, 
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but vegetative cells are easily killed by gastric acid, reducing inocula by 99%.  A 
study by Jump et al., (2007) found forms of C. difficile survived exposure to gastric 
contents if the pH was greater than, or equal to, five.  There is also risk of recurrent 
CDAD with the use of PPIs therapy. Patients receiving PPIs have been found to be 
4.17 times more likely to have recurrence when compared to their counterparts not 
receiving PPIs (Cadle et al., 2007).  
1.7.6 Pre existing illness 
The suggestion that pre-existing mucosal injury pre-disposes to C. difficile 
colonization is supported by the fact that patients with inflammatory bowel diseases 
(IBD) are at greater risk of acquiring CDAD than the general population (Issa et al., 
2007).  Two recent retrospective studies have reported a two - to threefold increase in 
the frequency of C. difficile infection in patients with IBD over a five to six year 
period (Issa et al., 2007; Rodemann et al., 2007).  These patient groups are exposed 
to many of the risk factors for CDAD.  They are often prescribed antibiotics for 
treatment of other gastrointestinal pathogens and require frequent hospitalization for 
management of exacerbations of their IBD.  In addition, many take 
immunosuppressive medications.  CDAD in patients with IBD carries a higher risk of 
mortality than in patients without underlying IBD (Hookman & Barkin, 2009).  A 
recent multivariate analysis reported that patients with IBD and C. difficile had a 
fourfold higher mortality than patients admitted to hospital with IBD or C. difficle 
alone.  Higher mortality, more frequent endoscopy and surgery were found in patients 
with ulcerative colitis compared to Crohn’s disease (p < 0.05) who had associated C. 
difficile (Ananthakrishnan et al., 2008).   
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1.7.7 Enteral tube feeding (ETF) 
C. difficile can be a cause of diarrhoea during enteral tube feeding.  One prospective 
cohort study of residents in a long term care facility demonstrated that ETF was an 
independent risk factor for C. difficile colonisation (Odds Ratio 6.5, p = 0.006) 
(Simor et al., 1993).  A prospective cohort study to determine the incidence of C. 
difficile acquisition and CDAD in tube fed and non-tube fed patients was conducted 
by Bliss et al., (1998)  Seventy-six patients receiving enteral tube feeding were 
matched for age, ward and disease severity with 76 patients not on enteral tube 
feeding.  Acquisition of C. difficile was significantly greater in tube fed patients (p = 
0.03) and more tube fed patients developed CDAD (p = 0.03).  In this study, both 
patient groups were on high levels of antibiotics.  
There are a number of proposed reasons for the association of CDAD with ETF.  
Firstly, enteral feeding provides a high frequency portal for inoculation of C. difficile 
spores deep into the gut (O'Keefe, 2010).  Environmental factors have been proposed, 
as spores may be passed from the contaminated hands of healthcare workers during 
manipulation of the tube feeding system and following inadequate hygiene measures.  
There may also be contamination if decanting of formula is required, in the absence 
of adequate quality control protocols.  The method of administration of enteral 
feeding may also play a role, with post-pyloric feeding increasing the risk, as feed is 
delivered below the gastric acid barrier and this may facilitate the introduction and 
survival of C. difficile organisms.  Bliss et al., (1998) reported that the incidence of 
CDAD was greater in tube fed patients who received post-pyloric tube feeding at 
some time during the study when compared to those who received pre-pyloric feeding 
continually or those without a feeding tube.  It should also be noted that patients who 
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require enteral feeding, in particular those requiring post-pyloric feeding are usually 
sicker patients with a higher rate of complications and are more often on antibiotics. 
 
1.7.8 Other risk factors 
Cancer chemotherapy is another risk factor for the development of CDAD. The 
antimicrobial activity of several chemotherapeutic agents being thought to be the 
causative factor (Anand & Glatt, 1993).  Increased risk is also thought to be linked to 
the immunosuppressive effects of neutropenia (Gorschluter et al., 2001). CDAD 
mortality rates are higher for Caucasian than other ethnic/racial groups.  This has 
been attributed to the increased access to healthcare by elderly white people and to 
the fact that they are more likely to receive treatment with antibiotics and, as a result 
are at increased risk of developing C. difficile (Redelings et al., 2007). 
1.8 Treatment for CDAD 
There is no treatment required for asymptomatic carriers of CDAD (Johnson et al., 
1992).  For those who are symptomatic, the first approach in their treatment should 
be, if possible, discontinuation of the precipitating antibiotic(s).  It has been shown 
that 15-23% of CDAD will resolve with the discontinuation of antibiotics (Teasley et 
al., 1983; Olson et al., 1994) .  Supportive therapy with replacement fluids and 
electrolytes may be required depending on disease severity.  Antiperistaltic agents 
should be avoided as, theoretically, they can increase the risk of precipitating toxic 
megacolon by slowing the clearance of C. difficile toxin from the intestine (Aslam et 
al., 2005; Bouza et al., 2005).  Metronidazole, vancomycin, teicoplanin and 
bacitracin have been used to treat CDAD.  These antibiotics are known to inhibit C 
difficile growth and toxin production (Bricker et al., 2005).  Most cases will respond 
to metronidazole or vancomycin and will show improvement of symptoms within one 
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to two days of starting therapy (Gerding, 2005).  Treatment for ten days is indicated 
for mild CDAD (HPSC, 2008).  Approximately 78-97% of patients treated for an 
initial infection will respond positively (Sunenshine & McDonald, 2006).  However, 
in some cases, the C. difficile spores can remain in the gut even after aggressive 
treatment.  Spores that remain hidden within the colonic diverticula can avoid gut 
peristalsis and antibiotic treatment (Tedesco et al., 1985). 
With the emergence of the B1/NAP1/027 strain and its associated increased 
virulence, interest in the disease has increased. Investigation into methods of 
preventing and treating the disease has intensified.  A number of emerging 
therapeutic options for CDAD treatment are being developed. Medications used to 
treat other infections are being studied as alternatives to metronidazole and 
vancomycin.  Due to the evidence that increased risk of recurrent CDAD is associated 
with poor host humoral response (Wilcox, 2004), the use of intravenous 
immunoglobulins to treat severe or refractory CDAD has had some promising results.  
For prevention of the spread of the bacterium, sporicidal cleaning agents have been 
developed.  Probiotics are another of the options that are being studied for their role 
in both prevention and treatment of CDAD.  
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Part 2 – The prevalence of malnutrition in patients who 
develop Clostridium difficile associated disease 
1.9 Malnutrition  
Malnutrition is commonly defined as, ‘a state in which deficiency, excess or 
imbalance of energy, protein and other nutrients causes adverse effects on body 
form, function and clinical outcome’ (Stratton et al., 2003).  In recent years, there has 
been a greater understanding of the pathophysiology of malnutrition associated with 
disease or injury which is commonly observed in the clinical setting.  The presence 
of inflammation results in an alteration of nutrient requirements, with the acute phase 
response resulting in an increase in energy expenditure and nitrogen excretion.  
Anorexia often accompanies inflammation and promotes further loss of lean tissue if 
nutritional intake is inadequate.  In critical illness or injury, an acute inflammatory 
response occurs which has a rapid catabolic effect on lean body mass (Hill et al., 
1997).  In the chronic disease state, the loss of muscle mass and function occurs at a 
slower rate over a longer period of time.  
Representatives from the international clinical nutrition support community formed 
an International Guideline Consensus Committee and developed three aetiologically-
based terms for the diagnosis of malnutrition in adults in the clinical setting.  In 
chronic starvation without inflammation, the term ‘starvation-related malnutrition’ 
should be used.  ‘Chronic disease-related malnutrition’ is the term recommended 
when chronic disease and mild to moderate inflammation are present.  ‘Acute disease 
or injury-related malnutrition’ should be used when inflammation is acute and of a 
severe degree (Jensen et al., 2010). 
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1.10 Malnutrition in the clinical setting  
In health care facilities, there is evidence that malnutrition is present in 15-60% of 
patients (Stratton et al., 2003; Sorensen et al., 2008).  Variation in prevalence data 
occurs because of different methods of nutritional assessment and different patient 
groups studied (Elia et al., 2005a).  Irish data show that 11% of a mixed group of 
surgical and medical patients were malnourished (Corish et al., 2000).  The most 
recent information on the prevalence of malnutrition in patients in Irish hospitals 
comes from the Nutrition Week Survey (NSW), conducted in January 2010.  This 
data collection was part of a wider BAPEN survey which has an ongoing aim to 
obtain prevalence data on malnutrition.  The Malnutrition Universal Screening Tool 
(MUST) was carried out on all new admissions complying with specified inclusion 
criteria 1,2 ,over a specific three day period.  The nutritional status of 1602 patients 
was recorded in 29 hospitals and 17 care homes.  One-third of patients were at risk of 
malnutrition (33%); 25% were at high risk and 8% at medium risk.  These Irish 
results are very similar to those reported from the United Kingdom (UK) data (34% 
in UK hospitals found to be at risk of malnutrition) (Russell & Elia, 2011).  
Malnutrition was common in all types of hospitals, all types of wards, diagnostic 
groups and at all ages.  Eighty-six percent of patients identified as at risk of 
malnutrition were admitted directly from home suggesting that the risk of 
malnutrition originates in the community (Russell et al., 2011).  
                                                             
1 Inclusion criteria for Nutrition Screening Week (NSW) BAPEN: all adult patients admitted to 
medical, surgical, orthopaedic/trauma, care of the elderly, stroke and oncology wards between 00.01 
hours on the 12th of January to 23.59 hours on the 14th of January 2010.  
2 Exclusion criteria for NSW BAPEN: patient under 18 years of age, already established on nutrition 
support (oral nutritional supplements, Percutaneous Gastrostomy (PEG) feeding or Parenteral 
Nutrition) 
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1.11 The prevalence of malnutrition and CDAD 
A number of the risk factors associated with the acquisition of C. difficile are also the 
risk factors associated with malnutrition.  There is limited information in the 
literature on the prevalence of malnutrition in patients with CDAD. One study 
assessed prevalence of malnutrition using MUST in 76 patients at time of diagnosis 
of CDAD.  In this group, 57% of the patients were malnourished (MUST score of 2 
or more) (Wong et al., 2008).  No other studies have focused on the prevalence of 
malnutrition in this patient group and there are no Irish data available, although it is 
thought that prevalence is likely to be similar to that observed in the UK.  
1.12 CDAD and risk factors for malnutrition 
1.12.1  Increased age  
As previously discussed, one of the risk factors for the acquisition of C. difficile is 
increased age.  Although not observed in the recent Irish study (Russell & Elia, 
2011), some studies have shown that elderly patients are more at risk of malnutrition 
than younger patients (McWhirter & Pennington, 1994).  A number of reasons have 
been identified that contribute to the changes in body weight and composition of the 
elderly and which can result to the development of malnutrition.  Physiological 
changes include age-related changes to the GIT.  Selective neurodegeneration of the 
ageing enteric nervous system, resulting in symptoms of dysphagia, reflux and 
constipation, often occurs (Saffrey, 2004).  Changes are also seen in the pancreas, 
liver and small intestine with increasing age (Popper, 1986; Dreiling et al., 1991).  
There is a reduction in overall energy intake and this can occur due to a decrease in 
appetite and early satiety.  Changes in satiety are a result of alterations to the GIT 
sensory function.  There is also an impairment of the receptive relaxation of the 
gastric fundus, with rapid antral filling and distension (Morley, 2001).  Daily food 
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intake has been reported to decrease by up to 30% between the ages of 20 to 80 years 
(Wurtman et al., 1988).  The sense of smell is known to decline with age; this results 
in a reduced intake and interest in food.  Hormonal alterations and the increased 
activity of cytokines are also linked to the anorexia that occurs with ageing.    
Social factors such poverty, isolation and reduced ability to prepare and cook food 
can all have an impact on the nutritional status of older people living in the 
community setting (Ahmed & Haboubi, 2010).  Dentition is often impaired with 
increasing age.  There can be loss of teeth and, in cases where dentures are worn, ill-
fitting dentures will impact on oral intake (Nakanishi et al., 1999).   
Changes occur to body composition over time; body fat increases with a decrease in 
fat-free mass due to a loss of skeletal muscle (Prentice & Jebb, 2001).  The increase 
in body fat with increasing age is related to reduced physical activity, reduced 
growth hormone secretion, diminished sex hormones and reduced resting metabolic 
rate observed in older people (Ahmed & Haboubi, 2010).  
1.12.2  Length of hospital stay  
A further risk factor to the development of malnutrition is length of hospital stay.  
Studies have shown that during a hospital admission, a patient’s nutritional status 
deteriorates and, as a result, those with a longer hospital stay are at increased risk of 
malnutrition.  Several studies have found evidence to suggest that hospitalized 
patients receive less than optimal nutritional care due to lack of training and 
awareness of malnutrition among hospital staff (Dupertuis et al., 2003).  During a 
hospital stay, patients are frequently placed nil per os (NPO) without being 
artificially fed, and this can occur on multiple occasions.  Patients may undergo 
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procedures prior to, or during, meal service resulting in interruptions and/or missed 
meals, and meals can often be considered unpalatable.  
Mc Whirter and Pennington (1994) investigated changes in nutritional status in 
general surgical and medical patients that occurred from hospital admission to 
discharge.  Their study showed that 40% of patients were undernourished on 
admission.  A further assessment on discharge indicated that a mean weight loss of 
5.4% occurred as did a gradual decline in nutritional status in 14% of overweight, 
26% of  mildly malnourished and 37% of moderately malnourished patients.  
Braunschweig et al., (2000) observed a 31% decline in nutritional status from 
admission to discharge.  Naber et al., (2004) investigated nutritional status on 
admission to, and discharge from, hospital using three methods of nutritional 
assessment including the Subjective Global Assessment (SGA).  Using this 
classification, 45% of patients were classified as malnourished on admission and 
51% were classified as malnourished on discharge.  In a study carried out in patients 
admitted to two Dublin teaching hospitals, weight loss during the hospital stay 
occurred in 65% of the overweight and obese, 66% of normal weight and 43% of the 
underweight patients (Corish et al., 2000).  It is difficult to compare these studies 
adequately due to the different methods of nutritional assessment used but overall, 
they indicate that the nutritional status of patients in hospital deteriorates during their 
period of hospital admission.   
1.12.3 Enteral tube feeding (ETF) 
As with older age and length of stay, the use of ETF is also associated with patients 
who are malnourished or at risk of malnutrition.  ETF is used to feed patients who 
cannot attain adequate oral intake from food and/or oral nutritional supplements or 
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who cannot eat/drink safely.  The National Institute of Clinical Excellence (NICE) 
guidelines (2006) state that healthcare professionals should consider ETF in people 
who are malnourished or at risk of malnutrition and have inadequate or unsafe oral 
intake and a functional, accessible gastrointestinal tract.  Nutrition support should be 
considered in people who are malnourished as defined by any of the following: 
 A Body Mass Index (BMI) less than 18.5 (kg/m2); 
 Unintentional weight loss greater than 10% in the last 3-6 months;  
 BMI less than 20 (kg/m2) and unintentional weight loss greater than 10% 
within the last 3-6 months.  
NICE also provide guidelines for the introduction of nutrition support in people at 
risk of malnutrition, defined as follows: 
 Have eaten little or nothing for more than 5 days and/or are likely to eat 
little or nothing for the next 5 days or longer;  
 Have poor absorptive capacity and/or have high nutrient losses and/or 
have increased nutritional needs from causes such as catabolism.  
In summary, ETF is used in those patients who are sicker and are at risk of 
malnutrition or who are malnourished.  
1.13 Impact of malnutrition  
Malnutrition is known to predispose to disease and adversely affect outcome.  It has 
detrimental effects on both physical and psychological health (Stratton et al., 2003a).  
Malnutrition has been associated with higher rates of complications, and this has 
been shown in a number of studies as summerised in Table 1.1.  These complications 
are associated with higher hospital costs (Messner et al., 1991; Correia & Waitzberg 
2003) higher mortality (Coats et al., 1993; Correia & Waitzberg, 2003) and longer 
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hospital stay (Coats et al., 1993; Correia & Waitzberg, 2003). In the UK, the cost of 
malnutrition was calculated to be responsible for over 10% of the total health care 
budget. This is twice the amount that is spent on obesity and its related co-
morbidities (Elia & Stratton, 2009).  In Ireland, the cost of malnutrition on the health 
budget was calculated to be 10% of the €13.8 billion budget (Rice, 2010). 
Table 1.1 Physical and psychosocial effects of malnutrition  
Adverse effect of malnutrition  Consequence  
Impaired immune response  Predisposes to infection 
 
Reduced muscle strength and increased 
fatigue 
Inactivity, inability to work effectively 
and poor self care 
Reduced respiratory muscle strength  Poor cough pressure 
Inactivity, especially in bed bound 
individuals  
Predisposes to pressure ulcers and 
thrombo embolisms 
Impaired thermoregulation  Hypothermia 
Impaired wound healing  Increased wound infection, prolonged 
recovery from illness and increased 
length of hospital stay  
Impaired psycho social function  Apathy, depression, self neglect  
Source: Adapted from The “MUST” Report (Elia, 2003) 
1.14 Nutritional screening  
Nutritional screening is an assessment to identify those at risk of malnutrition and 
who require further nutritional assessment.  All nutritional organisations and 
healthcare accrediting groups agree that nutrition screening is essential.  It identifies 
those patients who are at nutritional risk so that appropriate nutritional assessment 
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and intervention can occur.  Nutrition screening tools try to incorporate objective and 
subjective parameters that are sensitive to changes in nutritional status.  It is accepted 
that no single marker is adequate and numerous factors have to be taken into account.   
There is no universal agreement on the best method of performing nutritional 
screening.  Currently, many different measures are used, either alone or in 
combination, to gather information about an individual’s nutritional status.  Green 
and Watson (2006) identified over 70 tests and tools to detect malnutrition.  It is also 
believed that many unpublished screening tools are being used in the clinical setting.  
A number of the published screening tools have been critically reviewed and their 
advantages and disadvantages identified.  Those commonly used are the SGA 
(Detsky et al., 1987), the Nutritional Risk Screening Tool (2002) – NRS 2002 
(Kondrup et al., 2003a), the Mini Nutritional Assessment (MNA) (Guigoz et al., 
1994) and MUST (Elia, 2003). 
The European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines for 
nutritional screening recommend MUST, NRS-2002 and MNA (Kondrup et al., 
2003b).  Of the 29 Irish hospitals that participated in NSW (2010), 28% were using 
MUST and a further 6% were using MUST with the MNA or a local tool.  Only 3% 
were using the MNA alone (Russell et al., 2011).  
1.14.1 Malnutrition Universal Screening Tool (MUST) 
MUST is the screening tool with the strongest support in the UK and Ireland.  It is 
recommended as a screening tool by NICE, BAPEN and the British Dietetic 
Association (BDA).  In 2008, the Irish Department of Health and Children strongly 
supported the use of MUST in Irish hospitals in the guideline document “Food and 
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nutritional care in hospitals, guidelines for preventing under-nutrition in acute 
hospitals” (Department of Health and Children, 2008).  
MUST has been developed to detect protein-energy malnutrition and the risk of 
developing malnutrition using evidence based criteria (Elia, 2003).  The three 
independent criteria used are; BMI, unintentional weight loss and acute disease effect 
producing or likely to produce no nutritional intake for greater than five days. 
Together, the three components are better predictors of outcome than the individual 
component (Elia, 2003).  MUST has content validity (comprehensiveness of the 
tool), face validity (issues that are relevant to the purpose of the test) and internal 
consistency (Wood et al., 2004; Stratton et al. 2006). It has been shown to have 
predictor validity in the hospital setting for length of hospital stay, mortality and 
discharge destination. In the community setting, it has predictive validity for general 
practitioner visits and hospital admission in free living individuals (Stratton et al., 
2002, Elia, 2003).  It has excellent reproducibility between users in different 
healthcare settings across the UK (Elia, 2003) and has been shown to have excellent 
agreement with a dietitian’s assessment of malnutrition (Elia, 2003).  In comparison 
with a number of other screening tools, MUST has been found to have “fair to good” 
to “excellent” concurrent validity (Elia et al., 2005a).  
1.14.2 Mini Nutritional Assessment (MNA) 
The original MNA was developed to provide a simple and reliable way to screen the 
nutritional status of persons over 65 years and to add a nutritional component to a 
comprehensive geriatric assessment.  MNA screening is likely to identify risk of 
developing undernutrition at an early stage since it includes questions about physical 
and mental health which frequently affect the nutritional status of elderly. It is a 
28 
 
combination of a screening and an assessment tool. The predictive validity of MNA 
has been evaluated by demonstrating its association with adverse health outcomes 
(Ek et al., 1996), social functioning, mortality and higher rates of visits to the GP 
(Anderson et al., 1984; Berner, 2003).  The tool has been validated specifically for 
the elderly (Guigoz et al., 1996) and has been found to be sensitive and reliable 
(Gazzotti et al., 2000; Bleda et al., 2002; Holm & Soderhamn, 2003).  However 
MNA has a low efficacy with regard to predicting future malnutrition or adverse 
health outcomes for older people when screened at baseline (Rasmussen et al., 2010). 
In 2001, the short form MNA (MNA –SF) was developed based on the original 
MNA.  It was developed as a standalone screening tool and identifies malnutrition 
using 6 questions.  The MNA – SF has been found to have 98% sensitivity, 100% 
specificity and 99% diagnostic accuracy for predicting malnutrition (Kaiser et al., 
2009). 
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Part 3 - Probiotics and Clostridium difficile associated 
disease 
1.15 Functional Foods 
Probiotics, prebiotics and synbiotics are classified as a group of foods called 
‘Functional Food’ (FF).  
“A food can be regarded as ‘functional’ if it satisfactorily demonstrates to 
affect beneficially one or more target functions in the body, beyond adequate 
nutritional effects, in a way that is either an improved state of health and 
wellbeing and/or reduction of risk of disease” (Diplock et al., 1999). 
FF must remain a food, and it must demonstrate its effects in amounts that can be 
normally consumed in the diet (Diplock et al., 1999). 
1.15.1 Probiotics 
Probiotics are live microorganisms that when administered in adequate amounts 
confer a beneficial effect on their host, by improving microbial balance and exerting 
health benefits beyond inherent general nutrition (FAO/WHO, 2001).  The concept 
of probiotics emerged from observations early in the 19th century by the Russian 
immunologist, Elie Metchnikoff.  He postulated that lactic acid bacteria offered 
health benefits and promoted longevity.  In recent years, knowledge of the role of 
probiotics in health has increased. There is a growing body of scientific literature and 
a rise in the number of commercially available probiotic products.  Numerous health 
effects are now associated with probiotic use. While some of these are well 
supported by evidence, probiotics are often used to treat conditions for which data 
regarding their efficacy is lacking or conflicting (Williams, 2010). 
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1.15.2 Prebiotics  
Prebiotics are “selectively fermented ingredients that allow specific changes in both 
the composition and/or activity in the GIT microflora that confers benefit upon a 
host’s wellbeing and health” (Gibson et al., 2004).  Fermentation of the prebiotics by 
endogenous anaerobic microorganisms occurs in the colon.  Short chain carboxylic 
acids and lactic acid are produced and, these in turn, provide metabolic substrates for 
the colonocytes.  
Prebiotics can occur naturally in foods or be added to food products.  The common 
prebiotics include inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides 
(GOS), soya-oligosaccharides, xylo-oligosacchardies, pyrodextrins, isomalto-
oligosaccharides and lactulose.  The majority of studies have used FOS, GOS and 
inulin which have a long history of safe use. The reported benefits of prebiotics are 
still in the early stage of investigation but their efficacy has been examined in 
conditions such as constipation, diarrhoea, osteoporosis, obesity and type II diabetes 
mellitus (Roberfroid, 2000). 
1.15.3 Synbiotics 
Synbiotics are a mixture of prebiotics and probiotics. They beneficially affect the 
host by improving the survival and implantation of the live microbial dietary 
supplements in the GIT (Gibson et al., 2004).  It is thought such products can 
potentially offer the properties of both probiotics and prebiotics. Some researchers 
feel that synbiotics should be more than a mixture of the two ingredients; that a 
synergy must exist between the ingredients (Jardine, 2009). To date most of the 
research has been on probiotics and prebiotics individually and there is less 
information about synbiotics.   
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1.16 Mechanism of action of probiotics  
The mechanisms of action of probiotics remain an area of research.  Many of the 
effects have been studied and established in animal models or in vitro assays. In 
humans, the direct demonstration of the effects of probiotics on relevant biomarkers 
is still incomplete (Rijkers et al., 2010).  There are a number of proposed 
mechanisms through which probiotics could have an effect.  Many have been shown 
to inhibit the growth and development of pathogenic bacteria, alter the composition 
of the GIT microflora and modulate the innate immune system.  The suggested 
mechanisms for their effects on human health are proposed to be: 
 Competitive inhibition of other organisms through competition for 
fermentable substrates and adhesion sites within the gut; 
 Lowering gut pH through production of organic acids;  
 Production of bacteriocins; 
 Stimulation of the immune system;  
 Regulation of gut motility; 
 Strengthening gut barrier function;  
 Binding and metabolism of toxic substances; 
 Release of gut protective metabolites.  
(O’Connell, 2009) 
1.17 Probiotic availability 
A probiotic is defined by its genus (e.g. Lactobacillus), its species (e.g. rhamnosus) 
and strain designation (often a letter or a number e.g. GG).  Frequently, product 
manufacturers will generate a consumer friendly name; these names may be 
trademarked (™) or be a registered trademark (®) and are not the scientific name.  
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The FAO/WHO has a number of criteria that must be met for an organism to be 
classified as a probiotic.  The organism must be characterised to strain level using 
phenotypic and genotypic techniques.  There must be proof that the probiotic strain is 
safe for human consumption and is not contaminated in the form in which it is 
delivered. There should be evidence of its functional efficacy from in-vivo studies 
using animals and humans (FAO/WHO, 2002).   
Probiotics are available in a wide range of commercial forms; capsules of freeze dried 
or lyophilized cultures, heat dried culture supernatants and mixed into dairy and other 
foods.  They are available as a combination of organisms of varying quality and 
viability.  The majority of commercial cultures for the food industry contain either 
Lactobacillus species or Bifidobacterium species.  Some Escherichia. coli (E. Coli) 
species, Bacillus species and yeasts are also used. In the last few years, the range of 
food products containing probiotics has increased considerably. Products are 
available in supermarkets, in health foods stores and on the internet.  Europe 
traditionally has a strong position in the probiotic food market. In 1997, probiotic 
yogurts and milk accounted for 65% of the European FF market, with a market value 
of $889 million (Young, 1998).  Daily dose dairy probiotic drinks are the largest 
growing probiotic product type in the European market (Saxelin, 2008).  In Europe, 
Lactobacillus rhamnosus GG (L. rhamnosus GG) appears to be the most widely used 
probiotic on the food market.  L. rhamnosus GG containing foods are available in at 
least 15 European countries under various brand names (Saarela, 2009).   
1.18 Commonly used probiotics  
The most common probiotic genii used in food and in clinical trials are the bacteria 
Bifidobacteria and Lactobacilli and the yeast Sacharomyces boulardii.  Yeast 
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probiotics differ from bacterial probiotics in physiological structure, size and their 
impact on antibiotics, with yeast not being affected by antibiotics (Czerucka et al., 
2007). 
1.18.1 Bifidobacteria  
Bifidobacteria are gram positive polymorphic rods.  They are non-spore forming, 
non-motile and catalase-negative bacteria (O’Connell, 2009).  Bifidobacteria have 
been widely used in food products for the past twenty years.  There are upwards of 30 
species of bifidobacteria identified (Leahy et al., 2005).  They have been isolated 
from many sources such as sewage, human and animal faeces, and the rumen of 
cattle, dental caries and honey bees (Felis & Dellaglio, 2007).  Bifidobacteria account 
for 3-6% of microflora in the GIT and are considered as key commensal bacteria in 
human microbial interactions, playing a pivotal role in a healthy GIT (Benno et al., 
1984; Satokari et al., 2003). The proportion represented by bifidobacteria species 
varies between individuals and depends on lifestyle factors such as diet, exercise and 
stage of life. The dosage of bifidobacteria in food or other products can depend on the 
method of administration.  The scientific literature appears to support a minimum 
probiotic dosage of 109 colony forming units (CFU) per day if a measurable benefit to 
the host is to be observed (O’Connell, 2009).   
1.18.2 Lactobacilli 
Lactobacilli are gram positive, non-spore forming, catalyse-negative, usually non-
motile and typically nitrate-reducing, rod-shaped bacteria.  They utilise glucose 
fermentatively and may be homofermentative, thereby producing lactic acid from 
glucose or they may also be heterofermentative i.e. they can produce lactic acid, 
carbon dioxide, ethanol and/or acetic acid (Saarela, 2009). Their production of 
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organic acids and resultant lowering of pH gives them an advantage over other 
microbes (Saarela, 2009).  In 2008, the number of lactobacilli species identified was 
around 120 (Saarela, 2009).  However, this number is continually changing as new 
species are identified or some species are merged to form subspecies or transferred 
into another genus. Some species and strains are broadly used as starters and adjunct 
cultures to drive food and feed fermentation and have been used for thousands of 
years for this purpose.  The notable products are dairy products (cheese and yogurts), 
fermented vegetables (olives, pickles and sauerkraut), fermented meats (salami and 
sausages), sourdough breads and other cereal-based commodities.  
L. rhamnosus GG has received the most clinical attention to date.  L. rhamnosus GG 
was discovered in 1985 by natural selection of healthy human microflora using the 
ideal characteristics of a probiotic (Silva et al., 1987).  L. rhamnosus GG has been 
shown to secrete a low molecular weight compound that inhibits a broad spectrum of 
gram positive and negative bacteria and anaerobic bacteria (Silva et al., 1987).  It has 
been shown to inhibit the attachment of E. coli, Klebsiella pneumonia and 
Pseudomonas aeruginosa to uroepithelial cells and intestinal epithelial cells (Chan et 
al., 1985; Mack et al., 1999).  It has also been found to suppress bacterial enzyme 
activity (Gorbach, 2000). 
1.18.3 Saccharomyces boulardii (S. boulardii) 
S. boulardii is the most common yeast used as a probiotic.  Since its discovery in the 
1920s by a French microbiologist, Henri Boulard, it has been used as a probiotic in 
Europe and has been investigated in clinical trials worldwide.  S. boulardii is not 
endogenously found in the GIT of humans (Imhoff & Karpa, 2009).  It has an 
optimum growth temperature of 370C, is resistant to low pH and is tolerant to bile 
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acids (Fietto et al., 2004; Graff et al., 2008a; Pardo et al., 2009).  Survival at this 
temperature makes it one of the few types of yeast able to live at human body 
temperature.  S. boulardii is resistant to antibacterial agents and survives gastric 
acidity (Graff et al., 2008a; Buts, 2009).  
S. boulardii is administered in capsules of lyophilized or heat dried product.  When S. 
boulardii is given orally, it achieves a steady state concentration within three days 
and is cleared within three to five days following discontinuation (Blehaut et al., 
1989; Elmer et al., 1999; Graff et al., 2008b).  Lyophilized S. boulardii is distinct 
from dietary probiotic products and could be considered an example of a “probiotic 
drug”(Czerucka et al., 2007).  
Studies in animals and cell models indicate S. boulardii has beneficial effects against 
a number of pathogenic toxins, preserves cellular physiology, interferes with 
pathogen attachment or assists in re-establishing short chain fatty acid (SCFA) 
levels.  It may also act as an immune regulator both within the GIT lumen and 
systemically (McFarland, 2010).  Castagliuolo et al., (1999) reported that 54 kDa 
serine protease produced by S. boulardii directly degrades C. difficile toxins A and 
B.  It also produces proteases capable of degrading C. difficile toxin A and B receptor 
sites on the cell surfaces of enterocytes unlike any other strains of Saccharomyces 
(Pothoulakis et al., 1993; Castagliuolo et al., 1999).  It has been proposed that once 
the toxin receptors have been acted upon by the protease, C. difficile is unable to 
produce disease as the bacterial toxins cannot attach to the inactivated receptor sites.  
This yeast may also stimulate chloride absorption and modulate C. difficile toxin B 
levels thereby reducing the symptoms of CDAD and permitting the re-establishment 
of normal GIT microflora.  It is proposed that there has to be clearance of C. difficile 
36 
 
before there can be inactivation of toxin receptor sites by S. boulardii (McFarland et 
al., 1994; Imhoff & Karpa, 2009).  Two studies have shown S. boulardii has an 
effect on the immune system resulting in up-regulation of total and specific anti-
toxin A secretory IgA expression in animal models of CDAD (Buts et al., 1994; 
Qamar et al., 2001).  These actions of S. boulardii have lead to a number of trials 
investigating the role of the yeast in CDAD.  
1.19 Dosage of probiotics   
Commercially available products typically have at least 106 CFU but may have as 
many as 1012 CFU (Verna & Lucak, 2010).  Probiotics have a limited lifespan and, as 
a result, repeated dosing is needed to achieve constant concentrations within the GIT.  
One week after the discontinuation of oral probiotics, there are no longer detectable 
amounts in the stool (Spiller et al., 2008).  
Confusion occurs among the general public and health professionals as to which 
probiotics are best for good health. The wide range of probiotic strains in 
commercially available products and the quality control of probiotics are some of the 
reasons why confusion arises. Also, there is no consensus on the effective dosage of 
probiotics.  In clinical trials, doses have varied from 107 to 1011 per day.  In most 
studies using the bacteria lactobacilli, the dose typically used ranged from 1-20 
billion colony forming units per day (Williams, 2010).  In the clinical trials with the 
yeast S. boulardii, the dose ranged from 250 to 300 mg per day for durations of 
between three days and six months (McFarland, 2010). In addition, different 
probiotic species and genii may have different immunological and physiological 
effects in various disease states (Verna & Lucak, 2010).  In products providing a 
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combination of probiotics, the probiotics may interact and have a different impact on 
host intestinal microflora than if given as a single probiotic preparation.    
As probiotics contain live organisms, the administration of antibiotics together with 
probiotics could kill a large number of the organisms and, as a result, reduce the 
efficacy of the probiotics (Williams, 2010).  It has been recommended that patients 
consume bacteria derived probiotics separately from antibiotics, leaving at least a 
two hour gap between consumption.  Anti-fungal medications may also interact with 
yeast probiotic products and reduce their efficacy (Williams, 2010).  It is 
recommended by one commercial manufacturer that S. boulardii should not be taken 
with any oral systemic anti-fungal medications (Williams, 2010). 
1.20 Regulation of probiotics  
The regulation of probiotics depends on how they are to be consumed, for example 
whether they are included in a food, used as a dietary supplement or sold as an over–
the-counter or prescribed medication.  Within Europe, there are no defined lists of 
compounds that are accepted for use as prebiotics or probiotics.   Quality assurance 
can also vary with the type of product, indication for use and country in which the 
product is sold.  If the product makes a claim promising a health or nutritional 
benefit, this is regulated by European legislation. The legislation 2000/13/EC 
prohibits a company from stating that a foodstuff has the properties to prevent, treat 
or cure human disease or from making reference to any such properties.  The 
regulation 2006/1924/EC on Nutrition and Health claims allowed on food products 
permits only standardised nutritional claims or specifically authorised health claims 
to be made.  This regulation provides consumer assurance that misleading claims 
cannot be made.  When a health claim is made, the format of the nutritional label is 
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specified in accordance with article 4(1) of Directive 90/496/EC.  In Ireland, the 
Food Safety Authority of Ireland (FSAI) is responsible for the enforcement of all 
aspects of food legislation, including food labelling.  
1.21 The variation of probiotics products 
For optimal probiotic functionality, the probiotic product should contain sufficient 
quantities of the specific probiotic strain throughout the storage period until 
consumed.  The pH, storage temperature and exposure to other microbes all impact 
on the viability and stability of the probiotic strain in a food product.  How the 
products are manufactured may significantly affect the potency of the probiotic over 
time.  Lyophilized products are stable at room temperature for one year provided 
they are protected from moisture (Graff et al., 2008a).  Products containing heat 
dried probiotics must be refrigerated.  All probiotic products should be stored 
according to manufacturers’ guidelines and all have a limited shelf life.  Probiotic 
supplements produced by different manufacturers differ widely.  Even the same 
product produced by the same manufacturer may vary due to the combination of 
probiotics they contain and bioactivity at the time of production.  
Concerns have been expressed regarding the accuracy, quality and quantity of 
probiotic products available on the market.  A number of studies have been 
conducted that illustrate the difficulties with product stability and labelling despite 
the legislation that exists to protect consumers. A gradual reduction in viable cell 
count occurs in probiotic products regardless of the producer’s expiry date, calling 
into question the accuracy of expiry dates on probiotic containers  (Jayamanne & 
Adams, 2006).  A study examined 58 probiotic products from Europe, the UK, 
Canada, Asia and Japan.  Only 38% contained the dose described on the label and 
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29% did not contain strains listed on the label (Masco et al., 2005).  A further study 
using polymerase chain reaction reported that two of five products tested contained 
no bifidobacteria and two of the products contained Lactobacilli that were not 
included on the product label (Drisko et al., 2005).  A review of brewer’s yeast found 
the tablets contained no viable yeast at all (Sargent & Wickens, 2004).  Marcobel et 
al., (2008) tested 14 commercial probiotic products and many of the probiotic 
products contained unadvertisied additional lactobacilli and bifidobacteria, whereas, 
others were missing species listed on the product label.  These findings would 
indicate that the manufacturers of probiotic products should be more tightly regulated 
and consumers must be wary of the product information on the products they are 
consuming.   
1.22 Safety of probiotics  
The safety of probiotics generally relates to the fact that they contain living 
organisms.  Potential risks include transfer of antibiotic resistant genes, translocation 
of living organisms from the intestine to other areas of the body, persistence of the 
probiotic in the small or large bowel or the development of adverse reactions relating 
to interactions with the host microflora.  The incidence of bacteraemia attributable to 
probiotic strains remains extremely low (Salminen et al., 2002),the estimated risk of 
developing bacteraemia from ingested Lactobacilli being less than 1 per million 
individuals (Borriello et al., 2003).  The typical adverse reactions reported in clinical 
trials are mild to moderate nausea, vomiting, abdominal pain, cramps, rash, diarrhoea 
and constipation (Kligler & Cohrssen, 2008).  Constipation and increased thirst have 
also been related to S. boulardii (Karpa, 2007) while the risk of developing 
fungaemia from S. boulardii is estimated at 1 per 5.6 million users (Karpa, 2007).  A 
population based study in Finland found no increase in the number of cases of 
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Lactobacillus bacteraemia despite a massive increase in consumption of a product 
containing L. rhamnosus GG.  The incidence of Lactobacillus bacteraemia was 
0.3/100,000 inhabitants per year over a 5 year period (Salminen et al., 2002; 
Salminen et al., 2004).  Williams (2010) commented that the overall risk of 
developing an infection from ingested probiotics is low, particularly in a generally 
healthy population.  
Boyle et al., (2006) suggest probiotics should be used cautiously in immune 
compromised individuals including those in a debilitated state or with malignancies.  
Caution should also be exercised in those with artificial heart valves, in patients with 
a history of rheumatic heart disease and those with central venous catheters.  Any 
administration of probiotics to patients who are severely ill, in the intensive care 
setting or who have central line catheters should be monitored closely for episodes of 
unexplained fever (Buts, 2009).  Concern has been expressed about the use of 
probiotics in pre-term infants (Boyle et al., 2006).  An increase in infectious 
complications could also be anticipated should probiotics be administered by 
jejunostomy, as this mode of delivery allows for an increase in the number of viable 
bacteria in the small intestine, as by passing of the acidic contents of the stomach 
occurs.  Lactobacillus has been reported to cause bacteraemia in patients with short 
bowel syndrome, possibly due to altered gut integrity (Kligler & Cohrssen, 2008).  
Lactobacillus preparations are contra-indicated in patients with hypersensitivity to 
lactose or milk (Kligler & Cohrssen, 2008) while S. boulardii is contraindicated in 
patients with yeast allergy (Williams, 2010).  Neither should it be taken with any 
systemic oral antifungal products.  If patients are on antifungal medications, a 
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staggered dosing regimen is suggested if a decision is made to use probiotics (Elmer 
et al., 1995). 
1.23 Consumer attitudes towards probiotics 
Probiotics can be a very attractive option for patients for whom traditional 
pharmacological therapies can be marginally effective and their disease/illness is 
impacting on their quality of life.  The current marketing of probiotic containing 
foods, together with the widespread availability of probiotics, reinforces the 
perception that probiotics are a ‘natural’ product.  Individuals can commence this 
alternative therapy without any advice from a medical professional.  However, 
studies would indicate consumer knowledge about these products is variable.   
A focus group of 100 consumers was used to assess attitudes towards the probiotic 
cultures Lactobacillus and Bifidobacterium (Bruhn et al., 2002).  Responses varied 
from those who were knowledgeable to those who were “repulsed” and unaware.  
Some individuals associated “culture” and “bacteria” with harmful bacteria and, 
therefore, expressed concern with their use.  A number of consumers believed that 
probiotic cultures were unnecessary and a well balanced diet should provide the 
necessary bacteria.  More detailed information on labelling and directions for 
consumption and the possible side effects from over consumption of probiotics was 
also raised as concerns by the group.  In a Brazilian study, 34% of consumers defined 
probiotics as foods that contributed to weight reduction only, 29% defined them as 
foods that contributed to the intestinal environment while 21.5% of participants were 
unaware of the benefits of probiotics.  Overall, the authors considered that consumers 
were confused about probiotic foods and their benefits (Vianna et al., 2008). A study 
of a New Zealand population found 25.4% of a random sample of consumers had 
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previously used probiotic products. The majority of the users had been recommended 
probiotics by the media but other common sources who recommended the products 
were friends and doctors (Schultz et al., 2011). A number of studies have found that 
probiotic users have similar profiles. There are more likely to be female (Block et al., 
2007), educated (Block et al., 2007; Landstrom et al., 2007a), users of other non 
prescription supplements (Landstrom et al., 2007a) and also of European origin 
(Schultz & Lindstrom, 2008). From the perspective of the Irish population, a survey 
of Irish consumers was conducted in 2000 by Bogue and Ryan. 90% of respondents 
were aware of FF or the concept of FF. There was a high awareness of the benefits of 
FF ingredients such as calcium, vitamin C and iron but consumers were less familiar 
with the benefits of phytoestrogens, oligosaccharides and probiotics.  Respondents 
would be more likely to purchase FF if there was more detailed information about 
the FF concept on the product label.  As with previous studies of consumers, the 
authors concluded that the consumers did not fully understand the concept of FF and 
the associated benefits. Further qualitative research may help understand more about 
consumers’ perceptions of health enhancing foods and the various health messages 
generated by public health bodies (Bogue & Ryan, 2000). 
1.24 Dietitians’ attitudes to probiotics 
Dietitians are health professionals that assess, diagnose and treat, diet and nutrition 
related problems at an individual and wider public health level. Dietitians use the 
most up to date public health and scientific research on food, health and disease, 
which they then translate into practical guidance to enable people make appropriate 
lifestyle and food choices (BDA, 2010). Dietitians are the healthcare professional 
most likely to educate consumers and assist in scientific research into the benefits 
and effects of FF use (de Jong et al., 2004). They are in a key position to influence 
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consumers to use or avoid FF.  There is no study examining dietitians’ beliefs or 
attitudes towards probiotics alone. There are a number of studies investigating their 
attitude towards FF, the group of foods into which probiotics are classified.  The 
results from these studies have been mixed.  An American study reported that in a 
group of 162 dietitians there was a positive view of FF. More than 80% of dietitians 
were confident about the effectiveness of FF in the prevention of illness and 
treatment of chronic illness, and at least 89% were confident of their safety (Lee et 
al., 2000).  In a study of dietitians’, nurses’ and physicians’ trust in FF and their 
willingness to recommend them, dietitians were more willing to recommend FF than 
the other groups of health professionals studied.  There was also greater trust and 
interest in the FF products among the dietitians when compared to the other two 
groups (Landstrom et al., 2007b). The need for scientific evidence for particular FF 
before recommending them to clients was required by the dietitians in this study 
however (Landstrom et al., 2007b). 
In a Dutch study of dietitians, FF were considered useful only in specific cases with 
defined health problems.  However, the authors concluded that confusion existed 
among dietitians about claims, safety, efficacy and the product handling aspects of 
FF (de Jong et al., 2004).  McConnon et al., (2004) studied the differences in 
perception of FF between the public and nutritionists. There were some evident 
differences with the consumer being more worried about the benefits and the 
nutritionists being concerned over the control and responsibility of the products. An 
Irish study found consumers and dietitians had a similar perception of FF, but 
knowledge about FF was greater in the dietitians (Morrissey, 2007). 
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1.25 Dietitians’ knowledge of probiotics and professional practice 
In Dutch dietitians 57% had a limited knowledge of FF (de Jong et al., 2004). Two 
thirds of  a group of American dietitians were confident of the role of FF in the 
maintenance of good health and prevention of chronic diseases, but fewer dietitians 
were knowledgeable about the role in acute disease (Lee et al., 2000). The Dutch 
dietitians got most of their information from journals, magazine articles or the 
internet. Swedish dietitians got their information from scientific statements and the 
food industry (Landstrom et al., 2007b). There were varying findings among the 
groups on the practice among dietitians. Swedish dietitians were willing to 
recommend FF to patients (Landstrom et al., 2007b). American dietitians 
recommend FF for prevention rather than treatment (Lee et al., 2000). Nutritionists 
in the UK were hesitant to recommend FF possibly due to the lack of scientific 
evidence supporting some products (McConnon et al., 2004). 
1.26 CDAD and probiotics 
From a review of the mechanistic actions of probiotics, it can be seen that there are a 
number of ways that both bacterial and yeast probiotics could be of benefit in the 
prevention and treatment of CDAD.  A large number of clinical trials and case studies 
have used different probiotic species, at varying doses and for differing lengths of 
time to assess their impact on the disease.  
1.26.1 Probiotics in primary prevention of CDAD 
The proposal that probiotics could replace the missing elements of the normal GIT in 
the prevention of CDAD has been investigated for nearly twenty years.  There is 
relatively little evidence for a preventative role because of a lack of published data. 
The necessity to have large exclusion criteria, difficulty in recruiting adequate patient 
numbers to provide definitive evidence are the main issues in prevention studies 
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(Imhoff & Karpa, 2009).  Of the studies that have been published, many have had too 
few participants to show statistical significance between groups while many others 
have been poorly designed.  
One study investigated the ability of 2 x 1010 CFU per day of Lactobacillus 
acidophillus and bifidobacterium to prevent CDAD.  Of the 138 patients recruited, 
2.95% of the probiotic group were C. difficile positive compared to 7.25% of the 
placebo group.  Even though the results look favorable, the study was inadequately 
powered to show statistically significant differences between the two groups.  
Another flaw identified in the study was that it may not have captured a true at risk 
patient group as patients requiring more than 20 days of antibiotic therapy were 
withdrawn from the study after day 20.  It has been established that longer duration 
of antibiotic use is associated with greater risk of CDAD; therefore, in this study 
patients who developed CDAD past the 20 day period in both the treatment and 
control group were missed (Plummer et al., 2004).  Another observational analysis 
did suggest a benefit from a combination of lactobacilli/bifidobacteria in CDAD 
prevention.  There was an estimated reduction in CDAD of 66%. There were 
limitations to the study results, as the data were gathered retrospectively and no 
placebo group was included in the study design.  The fact that historical controls 
were used for comparison and that antibiotic usage and C. difficile strains may have 
changed over time, meant the groups could not be regarded as truly comparable 
(Graul et al., 2009).   
1.26.2  Probiotics in the prevention of antibiotic-associated diarrhoea (AAD) as 
a primary outcome, with CDAD as a secondary outcome  
Several studies have investigated the capability of probiotics and yeasts to prevent 
antibiotic-associated diarrhoea (AAD) and, as a secondary outcome, have assessed 
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their effectiveness in the prevention of CDAD.  The studies by Arvola et al., (1999), 
Thomas et al., (2001) and Plummer et al., (2004) had insufficient numbers to truly 
identify the benefits of probiotics in preventing CDAD.  The yeast S. boulardii has 
been studied in four clinical trials for the prevention of AAD with positive outcomes 
(Surawicz et al., 1989a; Mc Farland et al.,1994; Kotowska et al., 2005; Can et al., 
2006).  The dose of S. boulardii used in these studies ranged from 500 mg to 1 g 
daily during antibiotic therapy or continued for up to two weeks after antibiotic 
therapy.  When these studies were analysed to assess the role of S. boulardii in the 
prevention of CDAD as a secondary outcome, statistical significance was not 
achieved. In three of the studies, a trend towards significance was reported (Surawicz 
et al., 1989a; McFarland et al., 1994; Kotowska et al., 2005).  
One randomized double-blind placebo-controlled trial did demonstrate a positive 
outcome from probiotics administered in the yogurt drink, Actimel™. Actimel™, 
contains a unique Lactobacillus casei strain, Lactobacillus casei imunitass, and two 
yoghurt associated bacteria Streptococcus thermophilus and Lactobacillus bulgarius.  
The drink was taken twice daily during antibiotic therapy and continued for one 
week after antibiotic therapy was discontinued. The subjects were over 50 years of 
age and were receiving either oral or intravenous antibiotics.  A significant reduction 
in the incidence of AAD was observed in the probiotic group (p=0.007) and there 
was a significant reduction in the incidence of CDAD (p=0.001).  No patient in the 
probiotic group and nine patients in the control group developed CDAD.  The 
absolute risk reduction ratio was 17% (Hickson et al., 2007).  Since publication of 
this study, it has been criticised.  Wilcox & Sandoe (2007) state, that many patients 
were excluded if they were “too high risk” and had more than two recent courses of 
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antibiotics.  Overall, only 7% of the patients screened were deemed eligible to 
participate in the trial.  The control group received milk products which may have led 
to more episodes of diarrhoea as the lactose contained in the product could have 
triggered secondary lactose intolerance. Healthcare staff were not sufficiently 
blinded to treatment allocation as products were in different containers.  It is also not 
clear that both groups were equally tested for C. difficile toxins when diarrhoea 
occurred.  Another issue that has been raised is that Streptococcus thermophilus and 
Lactobacillus bulgarius are essential to the yogurt making processes and their 
sensitivity to bile makes survival and colonic colonization unlikely.  Despite the 
initial promising results portrayed by this study, it does not appear to have the 
strength it was first thought to have. 
1.26.3 Probiotics in prevention of recurrence of CDAD  
There are some case reports and clinical trials investigating Lactobacillus and S. 
boulardii in the prevention of recurrent episodes of CDAD. Gorbach, in 1987, 
reported the use of L. rhamnosus GG (1010 CFU) administered to five patients.  
These patients had suffered two to five relapses of CDAD over a two to five month 
period, despite antibiotic treatment.  The treatment period with L. rhamnosus GG 
was seven to ten days.  Of the patients treated, four had no further relapses and one 
patient improved initially but required a further dose of metronidazole.  In another 
study, L. rhamnosus GG (5 x 109) at a dose of 125 mg was given twice daily for two 
weeks to four children, who had experienced three to five relapses of CDAD.  All 
four children had a reduction in stool frequency. However, two children suffered 
relapses one to two months later requiring additional treatment (Biller et al., 1995).  
Even though these are positive findings, limitations are inherent in these studies as 
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with all case reports and, caution should be exercised before drawing definitive 
conclusions.   
Following the positive results from the case reports, two double-blinded, 
randomized, placebo-controlled trials were conducted using the Lactobacillus 
species. Wullt et al., (2003b) investigated the use of Lactobacillus plantarum 299v (5 
x 1010 CFU/day) in patients who had one previous episode of CDAD in the previous 
two months.  Patients were randomized to receive 400 mg of metronidazole orally 
three times daily for ten days and a fruit drink containing either the probiotic or 
placebo.  Eleven of the twelve from the treatment group and all those in the placebo 
group achieved a clinical cure by days eleven to thirteen.  In the follow up period, 
four of eleven patients (36.4%) who received the probiotics and six of nine patients 
(66.7%) in the placebo group experienced recurrence of CDAD symptoms; however, 
this result was not significant due to the study being inadequately powered.  A 
further study by Lawrence et al., (2005) investigated the role of L. rhamnosus GG in 
the prevention of recurrence of CDAD.  Adults with recurrent CDAD were 
randomized to receive either 320 mg of inulin and L. rhamnosus GG (2.8 x 10 11 
CFU) or a placebo or 360 mg of inulin orally twice daily while on antibiotic therapy.  
The supplement was continued for an additional 21 days after the antibiotic therapy 
was concluded.  In three of the eight lactobacillus patients, and one of the seven 
control patients, recurrence occurred.  The C. difficile therapy also differed between 
the groups and additional systemic antibiotics and gastric suppressive therapies were 
used in individual subjects.  The prebiotic, inulin, was used in both groups and may 
have prevented differences being observed between the groups (Imhoff & Karpa, 
2009).  Although these two studies were randomized and placebo-controlled, they 
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did not show positive outcomes for probiotics, perhaps due to the number of 
limitations previously described. 
S. boulardii has been shown to have a more influential role in managing CDAD 
recurrence and there are some case reports and two positive double blind randomised 
control trials (RCT) using this yeast.  In an open trial, there was successful 
eradication of CDAD in eleven of thirteen patients when S. boulardii was 
administered in combination with vancomycin (Surawicz et al., 1989a). Kimmey et 
al., (1990) reported on the case of 6 patients with recurrent CDAD; S. boulardii was 
commenced in the patients prior to discontinuing vancomycin therapy and continued 
for a further 3 months. There were no recurrences of diarrhoea or colitis while taking 
S. boulardii and this continued for a following 18 months.  Following from this, two 
randomized double blind control trials were conducted. Mc Farland et al., (1994) 
recruited 60 patients with recurrent CDAD.  S. boulardii was found to provide 
significant benefits, with nine of twenty-six patients (34.6%) experiencing recurrence 
in the probiotic group compared to twenty-two of thirty-four (64.7%) in the placebo 
group (p=0.04), a reduction in occurance of 46.5%.  There was a similar positive 
result in the trial conducted by Surawicz et al., (2002) during an eight week study.  
However, only when high dose vancomycin (high dose = 2 g vancomycin, low dose 
= 500 mg vancomycin) was administered in conjunction with S. boulardii, did the 
yeast significantly reduce the recurrence of CDAD. Three of the eighteen S. 
boulardii patients (16.7%) experienced recurrence compared to seven of fourteen 
(50%) of the patients receiving high dose vancomycin and placebo (p=0.05).  In a 5-
month follow up period, of those who received the probiotic and high dose 
vancomycin, none of the 16 followed up experienced recurrence, while 3/13 (23%) 
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of those given the placebo and high dose vancomycin experienced recurrence. These 
two studies do show positive results and promise for the role of S. boulardii in the 
prevention of CDAD recurrence. However, in the literature a number of valid flaws 
have been identified in these two studies and are discussed in a review paper by 
Miller (2009). In the study by Mc Farland et al., (1994) the study design did not 
control for the dose or the duration of antibiotic.  There was no benefit of the 
probiotic in patients who had developed CDAD for the first time. The benefit 
occurred only in the patients with recurrent CDAD.  Furthermore, this study was 
conducted before the NAP1/027/BI strain had been identified, so its potential benefit 
on the current outbreaks of CDAD may not be as large. In the second study 
conducted by Surawicz et al., (2000) the antibiotic therapy was not randomized in 
the probiotic and placebo groups.  The benefits were only seen in a sub-group of 
patients in a study that already had a small number of patients. Safety concerns about 
the use of S. boulardii in certain groups of patients are often quoted as reasons why 
the routine use of this yeast in the prevention of CDAD recurrence is not yet fully 
supported (Bauer et al., 2009).   
1.26.4 Meta-analyses of probiotics and CDAD 
The studies discussed previously have been included in a number of meta-analyses 
examining the efficacy of probiotics in CDAD.  Dendukuri et al., (2005) conducted a 
systematic review, four studies were included.  The benefit of probiotic therapy seen 
in two studies was restricted to subgroups characterized by severe CDAD and higher 
doses of vancomycin (McFarland et al., 1994; Plummer et al., 2004).  The authors 
considered that the two other studies were methodologically flawed (Surawicz et al., 
2000; Wullt et al., 2003b).  Of the studies conducted in which the prevention of 
CDAD was a secondary outcome, four studies were identified (Surawicz et al., 
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1989a; McFarland et al., 1995; Lewis et al., 1998; Thomas et al., 2001). These 
studies had too few cases of CDAD and provided no evidence for probiotic 
prophylaxis.  The conclusion from the review was that there was insufficient 
evidence to support the use of probiotics in the prevention and treatment of CDAD 
and further better designed and larger studies were required.  
A meta analysis was conducted by Mc Farland (2006), again looking at the role of 
probiotics for the prevention of AAD and the treatment of CDAD.  The review 
reported on the analysis of six RCT’s, the probiotics had a significant efficacy in the 
treatment of CDAD (RR=0.59, 95% CI 0.41, 0.85 p=0.005). Only S. boulardii was 
effective for treating CDAD. The author concluded that a number of different 
probiotics strains showed promise as effective therapy for AAD and CDAD.    
However, this analysis was criticized in letters to the editor by (Lewis, 2007) and 
Dendurkuri (2007) who stated that both prevention and treatment studies were 
combined, and the “pooled” odds ratio was driven by a single positive study.  
Dendurkuri (2007) further commented that uncritical reading of Mc Farland’s meta-
analysis was “misleading and risked the use of possibly ineffective, potentially 
hazardous therapies”.  
In 2008, a Cochrane review was conducted on the role of probiotics for the treatment 
of C. difficile associated colitis. Only four studies met the inclusion criteria and the 
data could not be pooled because of variations in patient recruitment, the types of 
probiotics used, high dropout rates and variations in concommitant antibiotic 
therapy.  From the data analysed, the two conclusions reached were that firstly; 
“probiotics are an unproven alternative or addition to antibiotics to cure infection 
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with C. difficile” and “the studies used did not provide enough evidence to support 
the use of probiotics for treating C. difficile infection” (Pillai & Nelson, 2008).  
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1.27 Conclusion  
CDAD is the most common cause of nosocomial infection, typically resulting in 
symptoms of diarrhoea, abdominal cramps and fever, all of which compromise the 
health of the vulnerable hospitalized patient.  In recent years, with the emergence of 
new virulent strains, the disease has become more severe and resistant to treatment.  
Research into all aspects of the disease remains ongoing.   
To have accurate information on the nutritional status of this patient group is 
important.  Although the prevalence of malnutrition in many disease states has been 
well documented in the literature, yet there are little data available on the nutritional 
status of patients with CDAD. Nonetheless, it is logical to assume that malnutrition 
occurs frequently in this patient group, particularly when the risk factors of 
prolonged hospital stay; ETF and increasing age are associated with both the 
acquisition of CDAD and with the development of malnutrition. The aim of this 
research was, therefore, to investigate the nutritional status of Irish patients who 
develop CDAD and to compare these data with those of medical and surgical patients 
within the same hospital and to published Irish data on the prevalence of 
malnutrition.  
The use of probiotics for the prevention and treatment of CDAD is relevant to the 
professional practice of dietitians.  To date, the scientific evidence for their efficacy 
shows promise but conclusive evidence remains unavailable.  Some studies surveyed 
dietitians’ opinions and use of FF, however none have specifically looked at their use 
of probiotics.  With a large range of commercial products available and an emerging 
body of research in probiotics, it is important to establish that the practices of 
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dietitians are evidence-based, safe and consistent. This study will investigate Irish 
dietitians’ opinions and recommendations for the use of probiotics in patients with 
CDAD and other clinical conditions. Information about probiotic products being 
recommended and used within Irish healthcare facilities and the factors that influence 
probiotic selection will be obtained.  
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CHAPTER 2 - Prevalence of malnutrition in patients who 
develop CDAD 
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2.1 Introduction 
Clostridium difficile is the most common cause of diarrhoea resulting from 
nosocomial infections (Johnson & Gerding, 1998).  There are a number of 
identifiable risk factors for its acquisition; of these, advanced age and length of 
hospital stay also predispose to malnutrition.  It has been well established that the 
presence of malnutrition is detrimental physiologically and clinically, impairing 
quality of life and delaying recovery from illness (Stratton et al., 2003).  Data 
suggest that disease-related malnutrition doubles the risk of mortality in hospital 
patients and triples mortality in older patients (over 65 years) both in hospital and 
following discharge (Stratton et al., 2006a; Stratton et al., 2006b).  One UK study 
reported that 57% of patients (n = 76) were malnourished at time of diagnosis of 
CDAD (as per MUST classification) (Wong et al., 2008).  Although it is generally 
assumed that patients who develop CDAD are at increased risk of malnutrition, there 
is little information in the literature to substantiate this.  There are no data available 
on the nutritional status of Irish patients who develop this condition and how this 
compares to other patients admitted to hospital.    
Nutritional screening is an assessment to identify those at risk of malnutrition and 
who require further nutritional assessment.  MUST has been developed to detect 
protein-energy malnutrition and the risk of developing malnutrition using evidence-
based criteria (Elia, 2003).  MUST takes into consideration three factors: BMI, 
weight change and food intake and assigns equal weight to these three components, 
as they have been shown to have statistically significant effects when considered 
individually or together.  BMI indicates chronic protein-energy malnutrition; 
however, this alone will not always detect patients at risk of malnutrition.  Change in 
weight reflects an acute change in protein energy status and unintentional weight loss 
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from outside the normal intra-individual range suggests the presence of underlying 
disease processes or psychological problems that predispose to malnutrition.  Recent 
weight loss in ill patients is correlated with undernutrition-related complications and 
these, in turn, are linked to poorer healthcare outcomes.  Diminished food intake also 
predicts deterioration in nutritional status. 
2.2 Aims 
The aim of this study was to assess the prevalence of malnutrition using the MUST 
screening tool in patients at St Vincent’s University Hospital on diagnosis of C. 
difficile associated disease (CDAD group) and to compare this to the prevalence of 
malnutrition observed in a comparison group of patients in the same hospital. 
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2.3 Methods and Materials 
2.3.1 Study Design and setting  
This was a prospective study in which all data were collected in a major academic 
teaching hospital in Dublin, St Vincent’s University Hospital (SVUH).  The hospital 
has 479 inpatient beds and admits both medical and surgical patients.  
Initially, the data collection for this study was one component of a collaborative 
research project between the microbiology department of SVUH and the care of the 
elderly department of the Mater Misericordiae Hospital, Dublin.  This research 
project was titled “Immune Response and Molecular Epidemiology of Clostridium 
difficile-associated Diarrhoea (CDAD)”: A Prospective Study.  The collaborative 
study set out to establish: 
1. The epidemiology of prevalent C. difficile strains using molecular typing methods 
and, from this information, the outcomes of infection and the rates of re-infection 
versus relapse in recurrent CDAD; 
2. The immune response to C. difficile surface layer proteins and their importance in 
predicting recurrent diarrhoea and/or disease severity; 
3. The genetic determinants of the innate and acquired immune response to C. 
difficile.  
 
Nutritional information (weight, height, BMI, Mini Nutritional Assessment 
(Appendix 1)) and method of nutritional intake) was one aspect of the data collected 
for the collaborative research project.  These data were collected by the research 
dietitian (YH) for 16 cases on the SUVH site.  Data gathered for completion of the 
59 
 
screening tool MUST (Appendix 2) were also collected.  As the desired number of 
patients for the collaborative research study had been achieved by March 2009, 
further subject recruitment (n = 18) in SVUH continued independent of the 
SVUH/Mater collaborative research project. 
Data on the comparison group were gathered during a one day MUST compliance 
audit that was conducted by the SVUH multidisciplinary Nutrition Committee in 
November 2010.  The data were collected by a multidisciplinary group that included 
the research dietitian.  
2.3.2 Ethical approval 
Ethical approval to carry out this study was granted by the ethics committee of the 
Dublin Institute of Technology [DIT reference 74/08] and the ethical and medical 
research committee for St Vincent’s Healthcare Group.  The audit committee of St 
Vincent’s Healthcare Group and the SVUH Nutrition Committee granted permission 
to use the data collected in the MUST compliance audit for the purpose of providing 
a comparison group for this study.   
2.3.3 Participants  
Patients in the CDAD group were in-patients in SVUH who had a stool sample 
positive for C. difficile toxin A or B.  Initially, the subjects were identified by the 
researchers working on the collaborative SVUH/Mater project.  Once the subject had 
given consent to participate, the dietitian was informed and the nutritional data were 
collected.  For the remaining subjects, the dietitian identified patients by regular 
contact with the microbiology laboratory.  Subjects were recruited between August 
2008 and May 2010.  Not all patients diagnosed with CDAD during this time were 
recruited.  This was due to re-submission to the ethics committee in SVUH for 
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further permission for patient recruitment and also occasional difficulties in the 
system of identifying patients with CDAD.   
The comparison group patients were a group of patients from five wards (two 
surgical and three medical) who were hospital inpatients on the audit date (total of 94 
beds).  The length of stay of these patients prior to audit varied.  The data were 
collected on the 24th November, 2010. Only patients for whom the date of admission 
was available were included in the hospital comparison group (n = 59 patients were 
audited on the day). Due to time limitations matching for the age and sex of the 
comparison group to the CDAD was not possible. The other hospital patient group 
was hoped to reflect a general hospital patient, with varying age, clinical conditions 
and length of stay.   
In the CDAD group 34 subjects were recruited and there were 36 subjects recruited 
for the hospital comparison group.  
2.3.4 Exclusion criteria 
  
2.3.4.1 CDAD group  
Patients were excluded if they were under 18 years of age or outpatients.  Patients 
were not included if they were already enrolled in another investigational study or 
clinical trial and if, at time of diagnosis, were patients in ICU.   
2.3.4.2 Hospital comparison group 
Patients who were deemed too unwell or were not at their bedside at the time of audit 
were excluded.  Patient suitability was based on the discretion of those collecting the 
data in consultation with ward nursing staff.    
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2.3.5 Consent 
 
2.3.5.1 CDAD group  
In the CDAD patient group, a consent form was signed by both the participant and 
the research dietitian and was filed in the patient’s medical notes (Appendix 3).  In 
cases where patients were unable to give written consent, the next of kin was 
contacted and verbal consent was obtained and documented on the consent form and 
filed in the medical notes.  
2.3.5.2 Hospital comparison group  
As agreed with the Audit and Nutrition Committees in SVUH, verbal consent for the 
data collected for the MUST audit to be used as comparison group data for this study 
was deemed sufficient.  This was provided by all patients who participated in the 
MUST audit.  
2.3.6 Data collection  
Detailed clinical data were obtained in the CDAD group within 72 hours of diagnosis 
of CDAD.  All data for the comparison group was collected on the 24th of November 
2010.  For each case in both groups, baseline demographic details of age, gender and 
date of admission were collected.  Information was determined by patient interview, 
medical chart review and review of nursing records.  The data collection, patient 
interview and anthropometric measurements were conducted by the research dietitian 
for the CDAD group.  For the comparison group, the data were collected by a 
member of the multidisciplinary audit team that included the research dietitian.  
Patients were allocated into diagnostic categories in accordance with BAPEN NSW 
recommendations for diagnostic categories. The diagnostic categories are systems 
based, and in patients with infection or cancer they are included within the relevant 
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diagnostic category. The eight categories are central nervous system, gastrointestinal, 
respiratory, cardiovascular, gentio/renal, musculoskeletal, others and not known.  
Information was recorded on a standardised form for both groups (CDAD group, 
Appendix 4; Hospital comparison group, Appendix 5).  All patient identifiers were 
removed and each patient was allocated a unique study number. 
2.3.6.1 Nutritional Assessment  
The main outcome measure of this study was the assessment of nutritional risk in 
patients with CDAD. Although there is no universally accepted definition of 
malnutrition nor is any one screening tool accepted as a gold standard, the MUST 
screening tool was selected to determine nutritional risk in this study. This screening 
tool is supported by the UK and Irish Departments of Health and expert bodies in 
both countries (BAPEN, ISPEN, INDI, and Nutrition Society). Within the study 
hospital itself, MUST has been shown to perform well against the previously used 
screening tool and other commonly advocated tools (Keaskin et al., 2010). MUST 
takes into consideration three independent criteria and has been shown to have 
excellent agreement with a dietitian’s assessment of malnutrition. Additionally 
advantages to its use include surrogate measures for current and previous weight and 
height. This is particularly useful in patients with CDAD, as this group is older and 
frequently frail or bedbound.  
2.3.6.2 Anthropometry  
The weighing of subjects was conducted where possible by the research dietitian or 
member of the audit team.  Weight was measured to the nearest 0.01 kilogramme 
using ward scales (CDAD, n = 28; hospital comparison group, n = 32).  Scales used 
in SVUH are Seca 710 electronic column scales and Seca 955 electronic chair scales 
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(Seca Hamburg, Germany).  All hospital scales are calibrated annually.  In cases 
where patients could not be measured accurately, recalled weight (if reliable and 
realistic) was used (CDAD, n = 6; hospital comparison group, n = 4) (Elia 2003, 
Stratton et al., 2003).  
To obtain height in patients who were mobile and able to stand, height was measured 
using a wall mounted stadiometer (Seca 220, Hamburg, Germany or Seca 222, 
Hamburg, Germany) according to standard methodology (Elia, 2003) (CDAD, n = 2; 
hospital comparison group, n = 9).  The subject’s height was measured with the 
patient standing straight and stretched, heels against the wall and the measurement 
taken with the head in the Frankfort Plane position.  In patients that were unable to 
stand, ulna length (CDAD, n = 23; hospital comparison group, n = 18) was used to 
calculate height.  To calculate the patient’s ulna length, the patient’s arm (left) was 
bent diagonally across the chest, with the palm is facing inwards and fingers pointing 
towards the shoulders.  The measurement is taken using a measuring tape (Seca 201, 
Hamburg, Germany) between the central and most prominent parts on the styloid 
process and the centre of the olecranon at the elbow.  If ulna length was not able to 
be conducted, recalled height was asked and used if deemed to be reliable and 
realistic (CDAD, n = 9, hospital comparison group n = 9) (Elia, 2003; Stratton et al., 
2003).  
2.3.6.3 MUST classification  
For both patient groups, MUST was completed in accordance with the guidance 
document (Elia, 2003).  For step one, the weight and height obtained for the patient 
was used to determine the patient’s BMI (weight (kg)/ height (m2)) and was scored 
according to MUST classification.  For step two of MUST, three methods were used 
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to obtain the percentage of unplanned weight loss in the previous 3-6 months.  Where 
previous weights were documented in patients’ notes the difference from current to 
previous weight was calculated (CDAD, n = 15; hospital comparison group, n = 8).  
If a weight history was not documented, the patient was asked about their weight 
history for the previous 3-6 months (CDAD, n = 15; hospital comparison group, n = 
22).  In subjects where reliable records or reports could not be obtained, subjective 
criteria (the presence of loose fitting clothes or jewellery) was used (CDAD, n = 4; 
hospital comparison group, n = 6). To determine a score for step three of MUST (the 
acute disease affect on inability for nutritional intake for greater than 5 days) in both 
patient groups, a combination of patient interview, review of the medical and nursing 
notes and information from the nursing staff was used.  
2.3.6. 4 MNA – CDAD group  
For completion of the MNA screening tool the anthropometric details required for 
current BMI (questions b) and weight loss (question f) were gathered in accordance 
with the methods described above.  Details required for the assessment questions on 
current oral intake (question a), mobility (question c), psychological problems 
(question d) and neuropsychological problems (question e) were obtained from 
patient interview, nursing and medical notes and nursing staff.   
2.3.7 Hygiene  
All hygiene guidelines for dealing with patients and equipment were adhered to as 
per HPSC C. difficile document (HPSC, 2008) (Appendix 6) and the SVUH infection 
control manual (Appendix 7).  
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2.3.8 Statistical analysis 
Data from the standardised forms from both groups were entered and stored on a 
Microsoft Excel (version 2007) database (Microsoft Corporation, Redmond, 
Washington).  For statistical analysis, a codebook was prepared.  Each variable was 
given a unique variable name and a numerical code was assigned to all applicable 
variables (hospital comparison / CDAD group, gender and ward classification).  The 
data set was transferred to the Statistical Package for Social Sciences (SPSS) for 
Windows Version 19 (IMB, SPSS Statistics, United States) for analysis.  All data 
were checked prior to analysis being performed.  For categorical variables (sex, 
CDAD/ hospital comparison group, ward and diagnostic criteria), frequencies were 
analysed, maximum and minimum values were reviewed and it was established if 
any cases were missing.  For the continuous variables (age, length of stay (LOS), 
MUST, BMI, weight and height), descriptive statistics were reviewed for out of 
range values indicating incorrect figures or errors in the database.  The characteristics 
of both the CDAD and hospital comparison patient groups were described using 
descriptive statistics.  The normality of distribution of continuous variables in both 
datasets was assessed using the result of the Kolmogorov-Smirnov test in 
conjunction with an assessment of histograms, skewness and kurtosis values.  As the 
distribution of all continuous variables was skewed, the Mann-Whitney U-test was 
used to test for differences in continuous variables (age, weight, LOS, MUST and 
BMI) between the CDAD and comparison groups.  Chi-squared (or Fishers Exact 
Probability) tests were used to investigate differences between categorical variables 
(sex, ward and diagnostic criteria) in both groups. Direct logistic regression was 
performed to assess the impact of four variables (age, sex, BMI and MUST) on the 
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likelihood of having CDAD. Statistical significance was set at a probability of less 
than 5% (p < 0.05).   
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2.4 Results 
2.4.1 Subjects characteristics  
All details for age, gender and date of admission were collected on 34 patients in the 
CDAD group and 36 patients in the hospital comparison group.  Of patients in the 
CDAD group, 14.7 % (n = 5) were diagnosed with CDAD on admission to hospital, 
the remaining patients in this group acquired C. difficile during their hospital 
admission.  Table 2.1 describes the patient characteristics.  There was a statistical 
difference in the age of the patients in each group (p = 0.002) with 85% (n =29) of 
patients in the CDAD group aged sixty five years or older compared to 50% (n = 18) 
in the hospital comparison group.  There was no difference in LOS or primary 
diagnosis between the two groups. There was a trend towards significance between 
the groups in gender (p = 0.082) and if medical or surgical patients in the groups (p = 
0.057).  
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Table 2.1 Subject characteristics of CDAD and hospital comparison group  
 
 CDAD group 
 
n = 34 
n (%) 
Hospital 
Comparison 
group 
n = 36 
n (%) 
p value* 
Gender 
Female 
Male 
 
24 (70.6) 
10 (29.4) 
 
17 (47.2) 
19 (52.8) 
 
0.0821 
 
Age (years) 
Median (interquartile range) 
 
82 ( 72 -86.3) 
 
64.5 (53.5 -77) 
 
0.0022 
Ward Location 
Medical 
Surgical 
 
21(61.8) 
13 (38.2) 
 
13 (36.1) 
23 (63.9) 
 
0.0571 
Length of Stay (days) 
Median (interquartile range) 
 
12.5 (3.8 -29.8) 
 
15 (10 -28.5) 
 
0.3472 
Primary Diagnosis: 
Central Nervous 
System 
Gastrointestinal  
disease 
Respiratory 
Cardiovascular 
disease 
Genitourinary/renal 
Musculoskeletal 
Other 
 
1 (2.9)  
 
9 (26.5) 
 
4 (11.8) 
10 (29.4) 
 
3 (8.8) 
3 (8.8) 
4 (11.8) 
 
4 (11.1) 
 
11 (30.6) 
 
3 (8.3) 
4 (11.1) 
 
0 (0) 
8 (22.2) 
6 (16.7) 
 
 
 
 
 
0.1111 
kg (kilogramme)  
*p < 0.05 = statistically significant  
1Chi-squared test used to determine difference between groups; 2Mann-Whitney U test used to 
determine difference between groups 
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2.4.2 Risk of malnutrition   
Malnutrition or risk of malnutrition was observed in 75.5% of the CDAD group and 
66.7% of the hospital comparison group as classified by a MUST score of 1 or more.  
This classification includes those at medium and high risk of malnutrition.  There 
was no statistical difference between the CDAD and hospital comparison group.  
Table 2.2 describes the nutritional status of patients in each group.  In the CDAD 
group, underweight (BMI < 20 kg/m2) contributed to 38% of patients being classified 
as “malnourished” (medium to high risk).  In the hospital comparison group, only 
22.2 % were underweight using BMI <20 kg/m2.  Of patients in the CDAD group, 
26.5% had a BMI less than 18.5 kg/m2 while in the comparison group, 13.9% had a 
BMI less than 18.5 kg/m2.  Although the MNA identified a greater number of CDAD 
patients as malnourished or at risk of malnutrition (85.3% compared to 75.5% 
identified using MUST), this was not statistically significant (p = 0.207). Table 2.3 
describes a subgroup of those aged 65 years in the CDAD and hospital comparison 
group. No significant difference between the weight, BMI and MUST scores in this 
sub group. 
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Table 2.2 Nutritional status of CDAD and hospital comparison group  
 CDAD group 
 
n = 34 
n (%) 
 
Hospital Comparison 
group 
n = 36 
n (%) 
 
p value* 
Weight (kg) 
Median (inter quartile range) 
 
57.2 (47.3-68.0) 
 
70.1 (56.9 -83.4) 
 
 
0.0041 
BMI (kg/m2) 
Median (inter quartile range)  
<20 
20-24.9 
>25 
 
21.0 (18.2-25.1) 
14 (41.2) 
11 (32.4) 
9 (26.5) 
 
24.15 (20.5-29.6) 
8 (22.2) 
11 (30.6) 
17 (47.2) 
 
0.0151 
0.8111 
0.8291 
0.1371 
MUST 
Score 0 = low risk 
Score1 = medium risk  
Score 2 = malnourished 
or high risk  
 
8 (23.5) 
6 (16.7) 
20 (58.8) 
 
12 (33.3) 
6 (16.7) 
18 (50) 
 
 
0.2671 
MNA  
Score 0-7 
(malnourished) 
Score 8-11 (at risk of 
malnutrition ) 
Score 12-14 (normal 
nutritional status) 
 
18 (52.9) 
 
11 (32.4) 
 
5 (14.7) 
  
 
 
 
*p < 0.05 = significant  
1Mann-Whitney U test used to determine difference between groups 
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Table 2.3 Nutritional status of CDAD and hospital comparison group of 
subjects aged 65 years and older 
 
 CDAD group 
 
n = 29 
n (%) 
 
Hospital Comparison 
group 
n = 18 
n (%) 
 
p value* 
Weight (kg) 
Median (inter quartile range) 
 
57.0 (47.1- 68.5) 
 
58.8 (54.0 -74.1) 
 
 
0.2601 
BMI (kg/m2) 
Median (inter quartile range)  
<20 
20-24.9 
>25 
 
21.2 (18.2-25.3) 
12 (41.4) 
10 (34.5) 
7 (24.1) 
 
22.2 (19.1-28.9) 
5 (27.8) 
8 (44.4) 
5 (27.8) 
 
0.3641 
0.9161 
0.8941 
0.0601 
MUST 
Score 0 = low risk 
Score1 = medium risk  
Score 2 = malnourished 
or high risk  
 
0 (0) 
7 (24.1) 
22 (75.9) 
 
0 (0) 
5 (27.8) 
13 (72.2) 
 
 
0.6811 
*p < 0.05 = significant  
1Mann-Whitney U test used to determine difference between groups 
 
2.4.3 Nutritional intake in CDAD group  
Five patients were receiving ETF at the time of the study assessment.  Two of these 
patients were NPO and the remaining three were consuming some oral diet 
supplemented with oral nutrition supplements (ONS).  All five patients were 
receiving a polymeric enteral feed and only one patient was not being provided with 
a source of fibre from the feed.  Of those patients in the CDAD group, 47% were 
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prescribed ONS in addition to their hospital diet.  In each case, the ONS prescribed 
were polymeric.   
Two patients were prescribed a multivitamin and mineral supplement, and nine 
patients were prescribed probiotics, the dose ranging from once per day to three 
times per day.  Either “probiotics” (n =3) or “Everybody” (n = 6) was written in the 
medication kardex.  There was no reference made to the probiotic strain.  
2.4.4 Dietetic referral of CDAD patients 
At the time of the study assessment, 55.5% (20 patients) with CDAD had been 
referred to a dietitian.  Of those referred, 65% (13 patients) had been prescribed 
ONS.  All five tube-fed patients had been referred; two were on nasogastric (NG) 
feeds and three were on NG feeds to supplement their oral intake and had also been 
prescribed ONS.  30 % (6 of the 20 patients) in the CDAD group that were classified 
as high risk of malnutrition (i.e. with a MUST score of 2) had not been referred a 
dietitian. 
2.4.5 Direct logistic regression 
Direct logistic regression was performed to assess the impact of a number of factors 
on the likelihood of having CDAD. The model contained four variables (sex, age, 
BMI and MUST), the full model containing all predictors was statistically significant 
X2 (4 n = 70) = 15.11, p =0.04 indicating that the model was able to distinguish 
between respondents who had CDAD and were the comparison group. The model as 
a whole explained between 19.4% (Cox and Snell R square) and 25.9% (Nagelkerke 
R squared) of the variance in CDAD status, and correctly classified 51.4% of cases. 
As shown in table 2.4 only age made a unique statistical significant contribution to 
the model (p = 0.043).  
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Table 2.4 Direct logistic regression predicting likelihood of reporting CDAD 
 B S.E. Wald Df p Odds 
ratio 
95.0 % C.I for 
Odds Ration 
 Lower Upper  
Age 0.036 0.018 4.092 1 0.043 1.037 1.001 1.074 
BMI -0.095 0.063 2.285 1 0.131 0.909 0.803 1.029 
MUST 0.062 0.205 0.092 1 0.762 1.064 0.712 1.590 
Sex -0.598 0.573 1.088 1 0.297 0.550 0.179 1.692 
Constant  -0.287 2.255 0.016 1 0.899 0.750   
,  
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2.5 Discussion  
2.5.1 Nutritional status of CDAD group and hospital comparison groups 
There was no statistical difference in MUST score between the CDAD group and the 
hospital comparison group indicating that both groups were at equal nutritional risk. 
However, a major limitation of this finding was that the groups were not matched for 
age and sex. The CDAD group were older females on medical wards, whereas the 
comparison group were younger and a greater percentage on surgical wards. Despite 
these factors the findings of this study indicate that the CDAD group have a high rate 
of malnutrition as defined by BMI. This is highlighted when compared to other data 
on malnutrition in one other group of CDAD patients and published Irish data of 
nutritional status in different hospital patient groups (table 2.5).    
The high rate of malnutrition found in this CDAD patient group is supported when 
compared to the UK study of Wong et al., (2008). A comparable percentage of 
patients with CDAD in these studies were observed to be at risk of malnutrition.  The 
UK study reported that 57% of their CDAD patients were at risk of malnutrition, a 
similar percentage to that observed in this Irish group of CDAD patients (58.8%).  
Further comparison of these two groups of CDAD patients with the BAPEN data on 
nutritional status of the general hospital population highlights that the prevalence of 
nutritional risk is nearly double in CDAD patients. Using MUST to determine 
malnutrition risk in the hospital setting, data from the 2010 NSW indicates that 
malnutrition risk was identified in 33% of patients admitted to hospital most of 
whom were at high risk of malnutrition (25%) with 8% at medium risk.  Using these 
data, the authors estimated a ward prevalence of malnutrition as 39% (assuming there 
was no mortality and no “malnutrition” develops during the hospital stay) (Russell & 
Elia, 2011). Previous data from an Irish setting found a prevalence of malnutrition in 
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11% of medical and surgical patients on admission to two teaching hospitals (Corish 
et al., 2000).  Both BMI and upper arm anthropometry were used to define 
undernutrition.  
The use is of the MNA again highlighted that CDAD patients are a group at high risk 
of malnutrition as a similar number was classified at high risk by each screening tool. 
The MNA identified more patients in the CDAD group as at risk of malnutrition 
compared to MUST but this was difference was not statistically significant.  There 
were discrepancies between the two screening tools in patients identified as being at 
risk; six patients classified as high risk using MUST were classified by the MNA as 
only being “at risk” (n = 4) or “normal” (n =2).  The MNA has been validated 
specifically for the elderly (Guigoz et al., 1996) and it may not be valid to use with 
these patients as both the CDAD and comparison patient groups included patients 
under 65 years of age.  The usefulness of the MNA as a malnutrition screening tool 
in the acute setting could be questioned as it was originally validated for use in 
relatively healthy older people (Rasmussen et al., 2004) and, therefore, it may not be 
suitable for frailer older populations (Bauer et al., 2008b).  Communication and 
comprehension deficits in some older people limit its usefulness with such patient 
groups and this factor was encountered in the study patient group.  The MNA is 
thought to be most effective for nutritionally screening those aged over 65 living in 
the community, older residents in sub-acute care and those living in nursing homes 
(Bauer et al., 2008b). Despite its limitations in using the MNA observed in this 
study, the MNA is advocated as a nutritional screening tool particularly for use in the 
elderly. In this study similar findings for nutritional risk were obtained using both 
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methods.  This supports the use of use of MUST as a screening tool able to identify 
nutritional risk in this patient group. 
Table 2.5 The nutritional status of the CDAD groups compared to other Irish 
nutritional status data.  
 
 CDAD group Wong et al., 
2008 
Corish et al., 
2000 
BAPEN 
2011 
  CDAD patients Medical and 
surgical 
admissions 
Nutrition 
Screening Week 
2010 
 
n 34 76 569 1527 
BMI ( kg/m2) 
median  
 
21.0 
 
-- 
 
-- 
 
26.3 
< 20 (%) 
20-25 (%) 
> 25 (%) 
41.2 
32.4  
26.5 
26  
-- 
-- 
13.5  
9  
46  
8  
32  
60  
MUST  
Score 0 (%) 
Score 1 (%) 
Score 2 or more 
(%) 
 
23.5 
16.7 
58.8 
-- 
-- 
57  
-- 
-- 
-- 
67 
8  
25 
-- data not provided/available 
2.5.2 Nutritional status of patients 65 years and older in CDAD and 
comparison groups   
As the two study groups were not controlled the CDAD group were an older group of 
hospitalised patients compared to the comparison group. It would be expected that 
those with CDAD would be older as older age is considered a risk factor for the 
acquisition of C. difficile.  This was also supported in the regression analysis 
77 
 
performed on the data. The variable age, was found to be the statistically significant 
variable in predicating the likelihood of having CDAD. In Ireland, the incidence of 
CDAD increases with age with those aged over 65 years at highest risk of infection 
(Health Protection Surveillance Centre, 2011). When those over 65 years of age in 
both groups were compared there was no statistical difference seen between weight, 
BMI and MUST score of these two groups. However, when the subjects over 65 
years in the CDAD group are compared to Irish data of elderly populations, the high 
nutritional risk of the CDAD group is evident.  True comparisons are very difficult to 
make as the patient groups were free living individuals, yet the vast contrast in BMI 
emphasises that those with CDAD are a very malnourished group. One Irish study 
reported that only 3% of healthy older people had a BMI lower than 20 kg/m2 
(Corish & Kennedy, 2003).  More recent data on the Irish free-living population 
found that 1% of men and 2% of women over 65 years had a BMI less than 20 kg/m2 
(Morgan et al., 2008).  In those aged between 18-64 years, only 0.3% of men and 1% 
of women had a BMI less than 18.5 kg/m2; the mean BMI for men over 65 years was 
28.1 kg/m2 and women over 65 years was 27.3 kg/m2 (Irish University Nutrition 
Alliance, 2011). The Irish Longitudinal Study on Aging (TILDA) published results 
of a national study of 8000 older people aged 50 years and older in May 2011. Three 
quarters of the subjects were overweight (44%) or obese (34%), only 1% of the 
population were underweight (BMI < 18.5 kg/m2) (Barrett et al., 2011).  
2.5.3 BMI 
BMI is frequently quoted as an indicator of nutritional status and reflects chronic 
protein energy malnutrition.  MUST and the Malnutrition Advisory Group of 
BAPEN use the lower boundary BMI value of 20 kg/m2 to indicate the clinical risk 
of underweight; the risk becomes even greater below a BMI of 18.5 kg/m2.  These 
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cut-off values are based on physiological and clinical observations which show loss 
of body function as BMI decreases and the apparent normal body function in many 
older subjects with a BMI above 20 kg/m2.  RCTs of nutritional supplementation 
suggest benefits are more likely in older subjects with a BMI below 20 kg/m2 with 
less benefit seen in those with a BMI over 20 kg/m2 (Stratton et al., 2003).  There is 
some debate over the appropriate level of BMI to define undernutrition, for example, 
WHO classifies normal or ideal BMI as 18.5 – 24.9 kg/m2 (WHO, 1998) while 
BAPEN and the NICE  guidelines consider that a BMI of between 18.5 and 20 kg/m2 
indicates possible risk of protein-energy malnutrition. If a BMI of <20 kg/m2 was 
used as the sole determinant of malnutrition, a prevalence of malnutrition of 41.2 % 
in the CDAD group compared to 22.2% in the hospital comparison group would be 
observed.  The rate of 41.2% is high when compared to other Irish data on the BMI 
of Irish hospitalised patients that was previously reported in a study carried out in 
two Dublin hospitals. This study found only 13.5% of a mixed group of medical and 
surgical patients had a BMI below 20 kg/m2 (Corish et al., 2000) (Table 2.5).  A true 
comparison is difficult, as the data in the older study was taken within 48 hours of 
the patient’s admission to hospital, whereas in this study population, the data were 
collected at various stages during hospital admission. In addition the percentage of 
patients with BMI <20 kg/m2 in the study CDAD group is higher than the 26% with 
a BMI <20 kg/m2 reported in the study by Wong et al., (2008). The high percentage 
of patients with low BMI’s perhaps indicates that the presence of chronic 
malnutrition is more common in patients with CDAD.  
The differences observed in the BMI between the CDAD and comparison group 
could question the use of the MUST as the indicator of nutritional risk in this patient 
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group. There are a number of limitation of MUST, firstly MUST allows for the use 
of surrogate and self-reported measurements for weight, weight loss and height. The 
reliability and accuracy of these measurements can be questioned at the individual 
level and in some cases are relying on subjective criteria. In the elderly population in 
the presence of cognitive impairment it can be difficult and unreliable. In the CDAD 
patient group the majority of the data for recent weight loss was based on self-
reported or estimated data rather than accurate measurements which could impact on 
the reliability of this information. In addition MUST assign equal weight to these 
three components of the tool (BMI, weight loss and oral intake). It could be 
questioned does a low BMI indicating chronic protein-energy malnutrition have a 
greater impact on outcome compared to recent weight loss or short term reduced oral 
intake in the CDAD patient group. However, it has been found BMI alone will not 
always detect patients at risk of malnutrition. As MUST take into consideration a 
BMI less than 20 kg/m2 it will captured that chronically malnourished group as being 
at nutritional risk. As the majority of CDAD patients are the older population the 
surrogate measures for weight and height are often the only way to obtain data due to 
issues with mobility. In the CDAD patients there are a number of limitations when 
interpreting BMI. CDAD can result in manifestations of protein losing enteropathy 
involving ascites and peripheral oedema (Dansinger et al., 1996). Alterations in fluid 
balance, such as the presence of oedema, can make it difficult to accurately quantify 
the amount of excess extracellular fluid present. Although there are guidelines 
available to estimate body weight for the presence of excess fluid (Wicks & Madden, 
1994) these only provide and approximation of oedema free body weight and lack 
precision. Future studies should consider if a low BMI is associated with in increased 
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risk of C. difficile acquisition and disease outcome. It would be useful measurement 
for the HPSC to collect in their surveillance data.     
2.5.4 Identification of malnutrition in the patients with CDAD  
The failure of nursing and medical staff to identify some patients in the CDAD group 
who were at nutritional risk highlights the concern that malnutrition is frequently not 
identified in healthcare facilities.  This ongoing problem has been highlighted in the 
declaration released at the 2011 international conference “Fight Againist 
Malnutrition – Two Decades On”.  One of the four aims of the conference 
declaration is to improve the identification of malnutrition.  The declaration is 
endorsed by the EU, Polish Society for Enteral and Parenteral Nutrition, ESPEN, 
European Nutrition for Health Alliance and the medical nutrition industry.  The wide 
support for this declaration indicates that malnutrition and its identification is a major 
problem.  In SVUH, there is a mandatory requirement to carry out MUST nutritional 
screening on each patient admitted.  However, compliance with this requirement 
remains an issue.  A hospital audit was carried out on 63 patient records on one day 
in February, March and April 2011.  Completion of the screening tool ranged from 
44-59% over the three day audit resulting in a number of medium and high risk 
patients who had not been identified on admission (Nutrition Committee SUVH, 
2011).  Despite the well-known medical and economic impact of malnutrition, it still 
remains unidentified in hospitalised patients.  Previous Irish data showed that 40% of 
malnourished patients were referred for nutritional intervention (Corish et al., 2000).  
Another study reported that of 40% patients at nutritional risk, only a small number 
had been identified and no nutritional plan or monitoring systems were in place 
(Rasmussen et al., 2004).  More recently, the presence of nutrition problems were 
observed in up to half the patients studied but these were only partly documented by 
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health care professionals.  Clinical judgement was used to identify malnutrition in the 
majority of patients, BMI was not calculated and nutritional problems were not 
documented in many cases (Volkert et al., 2010).  The previously discussed NSW 
2010 data also highlights the difficulty that remains with nutritional screening and 
identification of malnutrition in Irish healthcare facilities. 72% of the hospitals did 
not have a nutritional screening policy and only 38% of the hospital audited 
nutritional screening (Russell & Elia, 2011). From the perspective of the study 
hospital the documented failure to identify high risk patients highlights the 
importance of the nutritional screening all patients. A comprehensive nutrition 
screening protocol will detect all patients at high nutritional risk and if implemented 
would have detected the six patients. Within any care setting there will always be 
groups of patients who are at greater nutritional risk than others. A universal policy 
of nutritional screening allows for all such patients to be detected and not only those 
thought to be “at risk”. The finding that nutritional supplements were being 
prescribed to patients that were not under the care of the dietetic service would 
warrant further investigation at a hospital level. The introduction of education about 
nutritional supplements to the relevant health care staff would be advisable to ensure 
appropriate supplements are being prescribed. Another option that may be the use of 
particular nutritional supplements being incorporated into care plans related to the 
nutritional screening tool.  
2.5.5 Provision of probiotics to the CDAD group 
Although this study had only a small patient sample, it does highlight that probiotics 
are being used in this patient group.  However, the use of probiotics in patients with 
CDAD in SVUH was inconsistent in this study.  Only 25% were prescribed 
probiotics and, among these, the dose of probiotics varied.  No hospital-wide 
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guidance on the use of probiotics in CDAD or other conditions exists in SVUH.  In 
addition the probiotic product supplied to patients contained L. rhamnosus GG for  
which there is no conclusive evidence to support  its use as an adjunct to antibiotic 
therapy (Hickson, 2011). 
2.5.6 Enteral nutrition and CDAD 
In this study, only a small number of patients with CDAD were on ETF at the time 
they became infected with CDAD.  It should be noted that the total sample size was 
small and that no patient had a gastrostomy in situ.  It has previously been 
demonstrated that ETF is an independent risk factor for C. difficile colonisation 
(Simor et al., 1993). Additionally post pyloric tube feeding significantly increases 
the risk for the development of CDAD in hospitalized patients (Bliss et al., 1998).  
One study in a Dublin teaching hospital followed 73 subjects who developed CDAD 
through their hospital admission.  Of these, 4.1% of patients were on PN and 30.1% 
were receiving nutrition via a NGT or PEG.  NGT insertion/feeding were associated 
with more severe disease.  However, this association was not statistically significant 
(Kyne et al., 1999).   
2.5.7 Future considerations for patients with CDAD 
The purpose of this study design was to assess the nutritional risk as the time of 
CDAD diagnosis. From extrapolation of the literature describing the effects of 
infection it is commonly believed that CDAD is both a cause and effect of 
malnutrition. However no literature specific to CDAD is available to support this 
hypothesis. As this was an observational study whose primary outcome was the 
MUST score of patients only limited data on the other factors associated with CDAD 
development were collected. Accurate testing of the hypothesis that malnutrition 
contributed to the likelihood of CDAD acquisition was not the primary outcome of 
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the study and cannot be determined retrospectively as it would require the 
availability of data on all possible contributors to malnutrition before a causal 
relationship could be determined. Future work should look at above hypothesis as 
well as the impact of CDAD on a patient’s nutritional status.   
It is well established that nutritional status declines during hospital admission 
(Braunschweig et al., 2000; Corish et al., 2000; Rasmussen et al., 2004).  The Dublin 
study of 73 subjects who developed CDAD during their hospital admission 
mentioned previously classified 12.3% of their subjects as malnourished, defining 
malnutrition as weight loss of greater than 10% of body weight.  However, no 
anthropometric data were provided at initial diagnosis of the disease (Kyne et al., 
1999).  Another significant factor for malnutrition risk in this patient group is 
diarrhoea.  Diarrhoea is most commonly defined as a minimum of three liquid stools 
per day (WHO, 2005).  It is characterized as a symptom of a disease in which the 
large or small intestine becomes irritated and this results in rapid movement of faecal 
matter through the large intestine.  Diarrhoea leads to poor absorption of nutrients 
due to the rapid transit in the gut, deterioration of the absorptive mucosa and loss of 
specific transporters.  It may produce a secretory state in the small intestine, 
preventing or reducing net absorption.  Many studies have shown that there is 
evidence of carbohydrate malabsorption with diarrhoea with several focussing on the 
disaccharide lactose as the enzyme lactase, responsible for lactose digestion, can be 
reduced in enteric infection (Duggan & Nurko, 1997).  Undigested carbohydrate may 
draw fluid from the intestinal lumen due to osmosis (Duggan & Nurko, 1997).  Fat 
malabsorption may increase severity of the diarrhoea due to fatty acid induced 
colonic secretions (MacLean et al., 1978).  A study of faecal output and nitrogen 
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content over a 24-hour period in eleven patients with CDAD reported a mean faecal 
nitrogen loss was 38 mg/kg/body weight/day.  The authors recommended that faecal 
nitrogen loss should be considered in nitrogen balance studies in these patients 
(Tayek et al., 1987).  Loss of nutrients may also increase during diarrhoeal disease of 
bacterial origin.  Cellular debris increases, intestinal flora proliferates and undigested 
solids may adsorb minerals including zinc and reduce their bioavailability. 
If diarrhoea is persistent (usually classified as lasting more than 14 days), this will 
have severe medical and nutritional implications (WHO, 1988).  A close association 
between diarrhoea and malnutrition is documented in the literature (Checkley et al., 
2008) with general acceptance that poor nutritional status, as assessed by 
anthropometric measurements, leads to greater risk of diarrhoea (Chowdhury et al., 
1990; Checkley et al., 2002) and that pre-existing malnutrition is associated with 
increased severity of diarrhoeal disease.  If left untreated, diarrhoea-induced 
malnutrition can increase morbidity.  
A further aspect of the pathophysiology of malnutrition is the disease process itself.  
In recent years, there is a greater understanding that a combination of under - or 
overnutrition associated with acute or chronic inflammation from the disease state 
leads to altered body function and will worsen nutritional status (Jensen et al., 2010).  
The clinical manifestations of CDAD result in systemic symptoms such as fever, 
anorexia, nausea and malaise. Leucocytosis, raised C-reactive protein and low 
albumin levels are frequently seen.  Infection impairs nutritional status and body 
composition in a number of ways.  Firstly, infection is characterised by anorexia and 
can range from as little as 5% to almost complete loss of appetite (Yaqoob & Calder, 
2003).  This will promote loss of lean tissue if nutritional intake is inadequate.  
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Infection is also associated with increased basal metabolic rate during fever.  Each 
one degree in body temperature is associated with a 13% increase in metabolic rate 
which in turn increases energy requirements.  The infection itself can result in 
nutrient loss and malabsorption.  In CDAD, as previously discussed, the symptoms 
of the disease can result in malabsorption and nutrient losses.  A further consequence 
of inflammation as a result of the disease is altered metabolism and redistribution of 
nutrients.  This is a result of the production of proinflammatory cytokines and 
immunoglobulins by leucocytes.  The synthesis of these acute phase protein results in 
the loss of amino acids from skeletal and muscle tissues (Yaqoob & Calder, 2003).  
Each of these factors impact on a patient’s nutritional status, including those 
identified as being at low nutritional risk at initial nutritional screening.  This 
highlights the need for nutritional screening to be carried out at regular intervals. 
2.5.8 Limitations 
There are two main limitations of this study. Firstly is the small sample size so, 
interpretation of the results must be with caution.  An additional criticism which was 
previously discussed was that the hospital comparison group was not matched to the 
CDAD group. As the hospital comparison group patients selected in this study came 
from patients on both medical and surgical wards who were at different time points 
in their admission, it was anticipated that the patient group would reasonably 
accurately reflect the nutritional status and malnutrition risk of the general hospital 
patient. Many advantages and disadvantages of matching are quoted in the literature. 
Matching controls for confounding variables can be relevant when there is a 
substantial difference in the occurrence of possible confounders between cases and 
controls.  Matching can increase a study’s effectiveness by forcing case and controls 
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to have a similar distribution across confounding variables (Rose & van der Lann, 
2009).  However, matching may introduce bias, as when trying to match the cases 
with controls, some of the cases may be excluded as they cannot be matched. This 
will therefore create a sample of cases that is not a true representative of the study 
population.  The variables chosen to match are very important.  If the controls are 
matched to cases based on a variable that is not a true confounder, this can impact on 
the study’s accuracy (Rose & van der Lann, 2009). However, the failure to control 
for age and sex in this study may be the reason why no difference was seen between 
the MUST score in the two groups. There was a trend towards more females and 
more medical patients in the CDAD group.  
 
2.6 Conclusion  
Despite the lack of a significant difference in the prevalence of nutritional risk as 
determined by MUST between patients with CDAD and the other hospital group, this 
study highlights that those with CDAD are at high risk of malnutrition. The data also 
indicate that these patients are older, female and have a lower BMI perhaps implying 
that they are more likely to be chronically malnourished. Both the groups studied had 
a similar prevalence of nutritional risk, however it is clear irrespective of the method 
used to ascertain nutrition risk that those patients with CDAD are at higher risk of 
malnutrition.   
The study assessed malnutrition only at time of diagnosis and further study as to the 
effect of the disease on the nutritional status of patients with CDAD is warranted.  
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CHAPTER 3 - Dietitians’ opinions and use of probiotics in 
CDAD and enteral feeding practices in CDAD 
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3.1 Introduction  
As CDAD is a disease associated with altered GIT microflora, the idea that 
probiotics may play some role in preventing the development or recurrence of the 
disease is very appealing.  The mechanisms of action of probiotics imply that there 
are a number of ways that both bacterial and yeast probiotics could be of benefit in 
CDAD.  Over the past few decades, a number of probiotics have been investigated 
for their effectiveness in the primary prevention of CDAD, the prevention of AAD 
and subsequent development of CDAD as a secondary outcome, and prevention of 
recurrence of CDAD.  Unfortunately, the results of these studies remain 
inconclusive.    
Dietitians are one of the healthcare professionals involved in the care of patients with 
CDAD in both hospital and community settings.  As a result of increased availability, 
consumer awareness and use of probiotic products, dietitans are often asked for 
advice on these products.  It is vital that dietitians understand fully the scientific basis 
of FF claims, including probiotics, as they are the healthcare professional with 
primary responsibility for nutrition education and medical nutrition therapy 
(Anderson et al., 1998).  Information on dietitians’ opinions about probiotics and the 
recommendations they currently make on their use in dietetic professional practice 
has not been previously reported.  To gather this information, a questionnaire was 
designed to assess Irish dietitians’ opinions about probiotics and the 
recommendations they currently make on the use of these products in a number of 
clinical conditions, but with a specific focus on CDAD.  
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3.2 Aims  
The aims of this study were to: 
 Investigate Irish dietitians’ beliefs and recommendations regarding probiotics 
in patients with CDAD and other clinical conditions;  
 Obtain data on the probiotic products and strains currently in use in Irish 
healthcare facilities and assess the factors determining use of these products 
and if guidance on their use exists; 
 Assess the current enteral feeding practices of dietitians in patients with 
CDAD. 
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3.3 Methodology  
3.3.1 Participants 
A self-completed questionnaire was chosen as the most appropriate research tool to 
facilitate access to dietitians working in a range of professional settings and varied 
geographical locations within the Republic of Ireland (ROI).  When this study was 
undertaken, there were 550 members of the the Irish Nutrition and Dietetic Institute 
(INDI) with ROI addresses; each was sent a postal questionnaire.   
The study design and methodology was approved by the ethics committee of the 
Dublin Institute of Technology (DIT).  Permission to access its members was 
approved by the executive council of the Irish professional body for dietitians, the 
INDI.  
3.3.2 Study questionnaire  
The study questionnaire consisted of five pages and included an introductory page 
explaining the background and rationale to the research (Appendix 8).  The 
questionnaire was divided into four sections and consisted of a combination of 26 
closed and open questions.  Advantages to closed questions are that they are specific, 
provide the same frame of reference for all respondents and allow for quantative 
analysis (Wall et al., 2002).  Disadvantages to closed questions are they can limit the 
depth of participant response and consequently data collection (Bowling, 2009).  
Open questions are often difficult to define, neither being strictly qualitative nor 
quantitative, but can capture and identify issues that were not taken into 
consideration in the closed questions (O'Cathain & Thomas, 2004).  
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3.3.2.1 Demographic and professional data 
Data on gender, place of employment, size of dietetic department in place of work, 
number of years qualified, work setting and patient specialty were collected.  
3.3.2.2 Dietitians’ opinions 
Participants were asked if they believed probiotics had a role in the prevention and 
treatment of CDAD.  They were also asked if they recommend probiotics in their 
clinical practice.  A list of six clinical areas in which some studies have shown 
positive results for probiotic use was included in the questionnaire.  Participants were 
asked if they recommend probiotics in these conditions.  The names of other clinical 
conditions in which they recommend probiotics were requested.  
3.3.2.3 Provision of probiotics in the clinical setting  
This section of the study questionnaire asked if the healthcare facilities in which the 
participating dietitians worked provided probiotics to patients/clients and, if so, were 
policies or guidelines on the use of probiotics available for some or all conditions in 
which they were used.  Participants were also asked to identify the form, strain and 
brand of probiotic used in the healthcare facility in which they worked, and what 
factor(s) determine the probiotic(s) products used. Current practice in recommending 
the use of probiotics in the prevention or treatment of CDAD was ascertained, 
specifically dietitians’ recommendations for probiotic use in patients prescribed 
antibiotics, and those with CDAD or non-CDAD diarrhoea. Dietetic 
recommendations for vitamin and mineral supplementation in patients with CDAD 
were also elicited.   
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3.3.2.4 Enteral feeding, CDAD and probiotics 
The fourth section requested information about dietitians’ practices using probiotics 
in patients fed via enteral tubes and the enteral feeds most commonly recommended 
for patients with CDAD. 
3.3.2.5 Pilot questionnaire 
The survey questionnaire was piloted among dietitians (n = 11) working in one 
nutrition and dietetics department in an acute academic teaching hospital to ensure 
that the questions asked could be clearly understood and that the directions for 
answering the questions were unambiguous.  Piloting of questionnaires ensures that 
questions are worded clearly and they are appropriate for the target population (Wall 
et al., 2002).  Following the pilot study, changes were made to some of the questions.  
The option of “do not know” as an answer in the questions about dietitians’ opinions 
was included [questions: 2 (a) and 2 (b)].  The wording of the question was changed 
to reflect that dietitians recommend probiotics rather than the dietitian administering 
probiotics to patients [questions: 3 (l), 3 (m), 4 (a) and 4 (b)].  
3.3.3 Data collection 
In order to maximise the response rate to the postal questionnaire, the  
recommendations in the systematic review on the topic by Edwards et al., (2009) 
were followed.  A stamped addressed envelope was included with each questionnaire 
to make responding easier.  A prize was offered to participants as an incentive to 
respond.  A further call for participation offering an online method of response was 
also offered.   
 In order to identify the winner of the prize, the questionnaires were coded.  These 
identification codes were removed once the data were collected.  A request for 
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further participation in the study was made using the INDI newsletter.  This offered 
an opportunity to respond to the questionnaire online up to four weeks after the 
initial closing date with the aim of increasing the response rate.   
3.3.4 Statistical analysis 
A codebook was prepared.  Each question in the questionnaire was given a unique 
variable name, and numbers were assigned to each of the possible responses to each 
question.  For the three open ended questions, the responses were reviewed and 
common themes identified.  Six themes were identified and assigned a numerical 
code and a further numerical code was assigned to those responses that did not fall 
into the six themes.  A data file was created following the format of the codebook 
using Microsoft Excel (version 2007) database (Microsoft Corporation, Redmond, 
Washington).  The data set was then transferred to the Statistical Package for Social 
Sciences (SPSS) for Windows Version 19 (IMB, SPSS Statistics, United States) for 
analysis.  Prior to analysis being performed, the data were checked for errors.  All the 
variables in the data set were categorical variables and checked by reviewing the 
descriptive statistics.  The minimum, maximum, number of valid and missing cases 
were reviewed to ensure that all values were within the possible values for that 
variable (Pallant, 2007).  Once the data file contained no errors, descriptive statistics 
were used to describe the dataset.  As all the variables were categorical, frequency of 
occurrence was used to describe the study variables. In the analysis of the questions 
regarding use of probiotics in practice, the responses from dietitians working in the 
“other category” were excluded. Many of these were not working directly with 
patients/clients and therefore probiotic use was not applicable. Chi- squared tests 
were performed to investigate differences between the opinions and the practices of 
dietitians who worked in the hospital setting compared to the community setting and 
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for differences between more and less experienced dietitians.  For comparison of the 
use of probiotics among dietitians, dietitians who responded that the use of probiotics 
was not applicable to their practice were excluded from analysis.  Due to the small 
number of dietitians with greater than 25 years or less than one year professional 
experience, age was grouped into three categories (less than one year to five years 
experience, five to fifteen years experience and greater than sixteen years 
experience).  In cases where the lowest frequency in a cell was less than five Fisher’s 
Exact Probability Test was used instead. Statistical significance was set at a 
probability of less than 5% (p < 0.05).   
95 
 
 
3.4 Results 
3.4.1 Response rate  
There was a 40.9% (225/550) response rate to the questionnaire.  All responses were 
returned via the postal method, there were no responses via the additional online 
method that had been offered.  Eleven responses were excluded from statistical 
analysis as they were returned by student or transition members of the INDI (n = 2), 
retired or non-practicing members (n = 4), questionnaire was not applicable to 
current work (n = 3) or contained incomplete information (n = 2).  Therefore, of the 
225 questionnaires returned, 214 were included in the analysis.  
3.4.2 Participant characteristics 
Forty-three hospitals were represented by the questionnaire responses.  These 
included responses from 10 academic teaching hospitals and from hospitals within 
each of the four Health Service Executive (HSE) areas.  Responses were received 
from six private hospitals and from one hospital in the United Kingdom (Appendix 
9).   
Each of the four HSE areas was represented by responses from the community 
setting, with the largest response from the Dublin Mid-Leinster region.  Of those 
employed in the community, 75.6% (n = 31) worked in primary care, 22% (n = 9) 
had a mixed case load and worked in both health promotion and primary care and 
2.4% (n = 1) worked only in health promotion.   
The employment in the ‘other’ category was private practice (n = 8), consultancy (n 
= 1), industry (n = 2), charity (n = 1), education (n = 2), research (n = 1) and other 
HSE organisations (n = 3).   
96 
 
In each category, the majority (47.7%; n = 102) of dietitians had six to 15 years 
experience and worked with adults (79.3%; n = 158).  Many treated both medical and 
surgical patients.  There was a subgroup of hospital dietitians who identified part or 
all of their case load as working in critical care (n = 18).  The demographic and 
professional characteristics of the respondents are described in Table 3.1.   
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Table 3.1 Demographic and professional characteristics of dietitians (n =214) 
 
Gender  
                    Female  
                    Male  
n (%) 
 
212(99) 
2(1) 
Place of employment  
                    Hospital  
                    Community  
                    Other  
 
155(72.4) 
41(19.2) 
18(8.4) 
Years qualified as a dietitian  
                    Less than 1 year  
                    1-5 years  
                    6 to 15 years  
                    16 -25 years  
                    Greater than 25 years    
 
4(1.9) 
67(31.3) 
103(48.8) 
28(13.1) 
12(5.6) 
Patients worked with  
                    Adults  
                    Paediatrics  
                    Both adults and paediatrics  
                    Not applicable 
 
158(79.3) 
31(14.5) 
23(10.7) 
2(0.9) 
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3.4.3 Dietitians’ opinions about probiotics in the prevention and 
treatment of CDAD 
There was no consensus among dietitians about the role of probiotics in both the 
treatment and prevention of CDAD (Table 3.2).  More than half (52.8%) responded 
that they did not know if there was a role for probiotics in the prevention of CDAD 
whereas almost two-thirds believed that they could play a role in the treatment of 
CDAD (Table 3.2).  There was no significant difference in the opinions of dietitians 
working in community and hospital settings on the role of probiotics in the 
prevention (p = 0.285) or treatment of CDAD (p = 0.680).  There was also no 
relationship between dietitians’ opinions about probiotics in the prevention (p = 
0.119) or treatment of CDAD (p = 0.107) and the number of years qualified. 
Additional comments were made by respondents about the role of probiotics in the 
prevention of CDAD (n = 116) and their role in the treatment of CDAD (n = 124).  
In the prevention of CDAD, a similar proportion commented on the positive 
scientific evidence (19.8%; 23/116) as those who thought the scientific evidence was 
lacking or inconclusive (18.1%; 21/116).  One individual had positive experiences 
with probiotics in preventing CDAD; however; 20.3% (24/116) commented on their 
lack of experience or knowledge in the area.  Of those who supported the use of 
probiotics in the prevention of CDAD, the proposed mechanisms of action of 
probiotics were mentioned by 29.3% (34/116).   
Similar themes emerged in response to the use of probiotics for the treatment of 
CDAD.  The positive evidence for a role for probiotics in treatment was mentioned 
by 29% (36/124) and the mechanism of action of probiotics in the treatment of 
CDAD by 29% (36/124).  For those who did not know or who did not believe that 
probiotics had a role in the treatment of CDAD, the negative scientific evidence 
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(30/124) or their own lack of experience (12/124) was quoted.  More dietitians 
reported positive personal experience in the use of probiotics in the treatment of 
CDAD (5/124).  A small number of respondents commented that a number of other 
factors (5/124) such as the medical team or the patients influenced the use of 
probiotics.  
Table 3.2 Dietitians’ opinions on the role of probiotics in the prevention and 
treatment of CDAD (n = 214) 
Dietitians’ response Role of probiotics in 
the prevention of 
CDAD  
(%) 
Role of probiotics in 
the treatment of 
CDAD  
(%) 
Believe probiotics have a role 33.6 65.4 
Do not believe probiotics have a 
role  
13.6 3.7 
Do not know if probiotics have a 
role 
52.8 30.9 
Not applicable to dietetic practice 10.7 10.7 
 
3.4.4 Recommendations for probiotics in the prevention and treatment of 
CDAD 
Most (65%) dietitians do not use probiotics for the prevention of CDAD although 
almost two-thirds use them for the treatment of CDAD.  Practice among those using 
probiotics for the treatment of CDAD varies (Table 3.3).  There was no statistical 
difference between years qualified and use of probiotics in the prevention of CDAD 
(p = 0.285) or treatment of CDAD (p = 0.73).  There was also no statistical 
difference between dietitians working in community or hospital settings in their use 
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of probiotics for the prevention of CDAD (p = 0.581) and their use of probiotics for 
the treatment of CDAD (p = 0.45).  
Table 3.3 Dietitians’ use of probiotics in the prevention and treatment of CDAD 
(n = 196) 
Dietitians’ response Use of probiotics in the 
prevention of CDAD  
(%) 
Use of probiotics in the 
treatment of CDAD  
(%) 
Always use probiotics 9.8 36.4 
Never use probiotics 65.0 27.6 
Occasionally use 
probiotics 
14.5 25.2 
Not applicable to practice 10.7 10.7 
 
3.4.5 Dietitians’ recommendations for the use of probiotics in other 
clinical conditions  
Thirty-three (15.4%) respondents would never recommend probiotics in their clinical 
practice.  There was no association between those who recommend probiotics and 
years qualified (p = 0.390).  Of those who recommend probiotics (84.6%), this was 
most frequently for the management of irritable bowel syndrome (IBS) (82.3%, n = 
149).  The use of probiotics in the other five clinical conditions that were provided as 
options for the dietitians is illustrated in Figure 3.1.  Respondents also provided other 
conditions for which they would recommend probiotics.  Antibiotic treatment and 
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antibiotic-associated diarrhoea were conditions in which probiotics were 
recommended most often. Dietitians also reported recommending probiotics for the 
treatment of thrush, diarrhoea, diverticular disease, constipation, radiation enteritis, 
cystic fibrosis, pouchitis, autism, sports nutrition, on an individual basis, 
gastrointestinal distension, malnutrition and acute diarrhoea in children. 
 
 
3.4.5.1 Probiotic use by dietitians with non-Clostridium difficile diarrhoea 
There is variation in the use of probiotics in patients with diarrhoea that is not due to 
C. difficile.  Forty two percent (n= 82) of dietitians working in hospital and 
community settings stated that they would occasionally use probiotics when a patient 
develops diarrhoea while on antibiotics in the absence of C. difficile toxins.  When 
diarrhoea occurs, C. difficile is not isolated and the patient is not on antibiotics, 
102 
 
40.8% of dietitians would recommend the use of probiotics whereas 34.7% would 
never recommend them in this situation. 
3.4.6 Probiotic provision and guidance in healthcare facilities  
 
3.4.6.1 Commencement of probiotics  
In the hospital and community setting, respondents indentified “dietitians” as the 
healthcare professional most likely to recommend the commencement of probiotics 
in patients with CDAD.  They also indicated that medical staff are the healthcare 
professional group next most likely to recommend the administration of probiotics to 
patients (Figure 3.2). 
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3.4.6.2 Probiotic products supplied by healthcare facilities 
To establish the probiotic products supplied by healthcare facilities, only the 
responses from hospital dietitians were analysed (n = 155) as probiotics are not 
supplied to patients within the community.  Of the 43 hospitals, 93% (n = 40) buy 
probiotic products for provision to patients.  Two hospitals no longer provide 
probiotics for financial reasons and the dietitian in one hospital (maternity) reported 
that probiotics are never used.  
Eleven different products were reported as available for patients (Appendix 10).  
There were some inconsistencies between dietitians working in individual hospitals 
as to the products available.  Overall, it was evident that the yogurt drink 
“Everybody” (Yoplait franchise produced by Glanbia plc Consumer Foods Division, 
Dublin) was the most commonly available commercial product.  This product 
contains the probiotic strain L. rhamnosus GG.  The factors influencing the probiotic 
supplied within hospitals were catering department choice (40.7%; n = 63) and 
clinical evidence for the product supplied (16.8%; n = 26).  Twenty dietitians 
(12.9%) reported that a combination of both factors mentioned above determined the 
product supplied.  Despite over half the dietitians surveyed reporting that clinical 
evidence for the product influenced the product supplied, almost half (48.4%; n = 75) 
did not know the strain present in the products used.  
3.4.6.3 Guidelines /policies on the use of probiotics 
To establish if there is guidance available to dietitians on their use of probiotics, the 
study questionnaire investigated the existence of policies or guidelines in this area.  
Responses from dietitians working in hospital and community settings only were 
analysed (n = 196).  Of these, 4.1% (n = 8) responded they had a policy or guideline 
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in their place of work for the use of probiotics while 4.6 % (n = 9) responded they 
had a policy or guideline in their place of work for the use of probiotics in CDAD.  
The response to this question varied within individual hospital and community 
settings, indicating that in those settings where a policy exists, not all staff were 
aware of its existence.  Among the additional comments provided by respondents (n 
=55) at the end of the questionnaire, 21.8% (n =12) identified the need for policies or 
guidance on probiotic use.  
3.4.7 Enteral nutrition and CDAD  
No standardardisation of practice was observed among dietitians in the use of 
probiotics with enteral tube feeding (Figure 3.3).  Approximately one-third of 
dietitians (30.6%) reported recommending the use of probiotics occasionally in 
patients with CDAD who were being enterally fed and a similar proportion (36.2%) 
recommended their use in other clinical conditions when enteral nutrition was 
required.  There was no statistical association between the place of work (p = 0.229) 
or years practicing (p = 0.340) and the use of probiotics in ETF patients with CDAD.  
Neither was an association seen between the use of probiotics in ETF in other 
conditions and dietitians’ place of work or years of experience.  The enteral feed 
most commonly used in patients with CDAD by the majority of dietitians was a 
polymeric feed (79.6%); few dietitians recommended the use of semi-elemental 
(7.1%) or elemental (0.5%) feeds.  There was no consensus on the provision of 
dietary fibre to patients with CDAD; 31.6% provide no fibre to patients with CDAD, 
27%  use a mixture of a non-fibre containing feed with a fibre containing feed, while 
only 17.9% stated that they would always recommend a fibre-containing feed. 
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3.4.8 Vitamin and mineral supplementation and CDAD 
The majority of dietitians (57.9%) reported recommending vitamin and mineral 
supplementation during an episode of CDAD if warranted by the patient’s nutritional 
status, while 17.3% consider both diagnosis and nutritional status when deciding 
whether to recommend additional vitamin and minerals.  Only one dietitian reported 
routinely recommending a vitamin and mineral supplement in patients who develop 
CDAD.  
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3.5 Discussion  
In recent years, there has been a greater awareness of the potential role of probiotics 
with the emerging evidence of their efficacy in some human diseases, and the 
increased availability of probiotic products to consumers.  Dietitians are key 
healthcare professionals who can influence the use of probiotics both among 
consumers and other healthcare professionals.  There are a number of studies 
investigating dietitians’ attitudes towards FF (Lee et al., 2000; de Jong et al., 2004; 
McConnon et al., 2004; Landstrom et al., 2007b).  In the studies by Lee et al., (2000) 
and Landstrom et al., (2007b) dietitians’ opinions of FF were investigated.  The 
authors did not differentiate between dietitians’ opinions about different FF.  This is 
the first study that has examined dietitians’ beliefs or attitudes towards probiotics 
alone, specifically in relation to their professional practice.  It also highlights some 
aspects of dietetic professional practice currently taking place in the ROI.   
3.5.1 Response rate  
The response rate of 40.9% was lower than anticipated and has the potential to 
introduce some bias to the results, as non-responders can undermine study validity 
and thus generalisability to a wider population (Cook et al., 2009).  A response rate 
of 75% is considered ideal (Bowling, 2009); however; response rates to all types of 
surveys have been declining (Bowling, 2005), especially among healthcare 
professionals.  This has been attributed to an increased demand to participate in 
research activities (Cook et al., 2009). Cook et al., (2009) showed that the average 
response rate to postal surveys among healthcare professionals was 56% (in studies 
published from 1996-2005).  Only 16% of the studies analysed achieved a response 
rate of 75% or over.  In the literature, response rates for postal surveys of dietitians 
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have been between 46.8 and 53% (Cashman et al., 2003; Mackel et al., 2003; de 
Jong et al., 2004).  An online web survey conducted by another Irish dietitian on the 
topic of professional development at the same time and to the same group of 
dietitians had a similar response rate (43.7%) (Fitzpatrick, 2010).   
3.5.2 Participants 
The employment profile of the study participants was similar to that obtained from 
the INDI workforce planning survey of clinical nutritionist/dietitians undertaken in 
May 2010 (INDI, 2010).  This showed that 72% of dietitians were employed in 
public and private hospitals and 28% in the community setting.  It is, possible that 
dietitians with greater experience of managing CDAD were more likely to complete 
the questionnaire.  As 73% of CDAD cases in Ireland occur in hospitals (HPSC, 
2010); this may have resulted in the higher response rate from dietitians working in 
that setting.  Additionally, CDAD is more commonly seen in adults and older 
persons which may account for the lower response from dietitians working in the 
paediatric setting.  
3.5.3 Dietitians’ use and opinions of probiotics and CDAD  
There is no consensus among Irish dietitians on the role and use of probiotics in the 
prevention and treatment of CDAD with more than half of all dietitians surveyed 
(52.8%) reporting that they did not know if there is a role for probiotics in the 
prevention of CDAD.  There was greater support (65.4%) for a role for probiotics in 
the treatment of CDAD.  As might be expected, given the number of dietitians who 
did not know if there was a role for probiotics in the prevention of CDAD, the 
majority do not recommend probiotics for its prevention.  In the treatment of CDAD, 
no consensus on the practice of recommending probiotics was evident. Some 
dietitians recommended probiotics occasionally, and some in all cases, to prevent 
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and/or treat CDAD.  This is despite the lack of published evidence to support the use 
of probiotics in the treatment of CDAD.  Although there appears to be a possible role 
for use of the probiotic S. boulardii in conjunction with high dose vancomycin in the 
prevention of CDAD recurrence (McFarland et al., 1994; Surawicz et al.,2000), 
randomised double-blind placebo trials of sufficient size to detect significant 
differences are still lacking.  Currently, this yeast is not being used as a probiotic in 
Irish hospitals.  
The treatment guidance document for CDAD from the ESCMID (Bauer et al., 2009) 
states that there is insufficient evidence to recommend probiotics in addition to 
antibiotics for the treatment of CDAD.  The guidelines make reference to safety 
issues that have been reported with S. boulardii (Bassetti et al., 1998; Munoz et al., 
2005) and the increased mortality observed in a study when probiotics were used in a 
RCT in patients with acute pancreatitis (Besselink et al., 2004).  The UK guidelines 
from the Health Protection Agency & Department of Health (2008) also comment on 
the use of probiotics in CDAD.  They currently do not recommend probiotics to 
prevent CDAD due to the lack of statistical significance in two meta-analyses by 
Dendukuri et al., (2005) and Pillai & Nelson (2008).  US clinical practice guidelines 
also do not recommend the administration of probiotics to prevent primary CDAD.  
This is due to the lack of evidence and the potential risk of blood stream infection 
from probiotic use (Cohen et al., 2010).  There is also no support for the routine use 
of probiotics from the Australasian Society for Infectious Diseases; again this is 
based on the lack of efficacy and the potential for adverse events reported in the 
scientific literature (Cheng et al., 2011).   
Irish dietetic practice should follow the guidance provided by the review document 
‘Surveillance, Diagnosis and Management of Clostridium difficile in Ireland (HPSC, 
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2008).  Following their review of the evidence on probiotics, the HPSC concluded 
that the routine use of probiotics cannot be recommended.  Probiotics should not be 
used either in the prevention or treatment of CDAD until there is more conclusive 
evidence for their use.  Moreover, the specific probiotics currently used to prevent or 
treat CDAD in Irish health care facilities have even less evidence for their use than 
those referred to in the studies above. 
3.5.4 Dietitians’ recommendations for probiotic use 
Only 15.4% of dietitians never recommend the use of probiotics in their practice.  In 
those recommending probiotics, IBS was the most common condition for which they 
were recommended (by 81.4%).  These findings are comparable to those of US 
gastroenterologists; the majority (98%) of gastroenterologists supported the use of 
probiotics in patients with IBS (Williams et al., 2010).  The symptoms of IBS are 
thought to be due to bacterial overgrowth in the small intestine causing increased 
fermentation and gas production (Wilhelm et al., 2008).  The most commonly 
studied probiotics in IBS are Lactobacillus, Bifidobacterium and the mixture 
probiotic product VSL#3 (Williams, 2010).  The NICE guidelines on the 
management of IBS, published in 2008, reviewed thirteen studies that met their 
inclusion criteria and concluded that probiotics are effective in some people with IBS 
but not in all.  When products were from reputable sources, no harm was identified 
from the ingestion of probiotics.  The NICE guidelines conclude with the 
recommendation that ‘people with IBS who choose to try probiotics should be 
advised to take the product for at least four weeks while monitoring the effect.  
Probiotics should be taken at the dose recommended by the manufacturer’ (NICE, 
2008).  A systematic review on the use of probiotics in IBS conducted by Moayyedi 
et al., (2010) which included 18 papers with 1650 participants concluded that 
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probiotics had a statistical effect in reducing IBS symptoms, but that there was no 
difference in the different types of probiotics used,  all of them showing a trend 
towards benefit.  The main limitation acknowledged in this review was the number 
of different probiotic strains and doses used in the studies reviewed and therefore no 
recommendation on the best probiotic and dose for the treatment of IBS were made.  
This limitation has been reiterated by other authors investigating this topic 
(Williams, 2010).  
For more specific evidence and guidance for the dietetic profession, the British 
Dietetic Association (BDA) gastroenterology specialist group developed UK 
evidenced-based practice guidelines for the dietetic management of IBS in adults.  
Their inclusion criteria were studies that used probiotic products that are available to 
consumers in the UK.  Of the five studies identified, the results were too weak to 
support the therapeutic use of probiotics in IBS.  They advised that interventions 
using probiotics to further improve IBS symptoms can be considered within second 
line dietary treatment.  As with other reviews and guidelines, there was insufficient 
evidence to recommend a specific probiotic.  The dietetic practice guideline 
recommended that patients should be advised that some products in probiotics may 
increase IBS symptoms, that the long term effects of probiotics are unknown and that 
if there is no improvement with one probiotic product, another one may need to be 
tried (Mc Kenzie et al., 2010).  It would seem reasonable for Irish dietitians to 
recommend probiotics for IBS patients in a manner similar to that of UK dietitians.  
However, specific guidance on probiotic products available on the Irish market 
would be useful for practicing dietitians.   
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The lack of support for probiotics in the management of the paediatric condition, 
necrotitsing enterocolitis (NEC), may be explained by the low response rate from 
dietitians who work with children and, that even within paediatrics, the management 
of NEC is a specialist area.  
3.5.5 Use of probiotics in other clinical conditions 
A number of other clinical conditions in which this group of dietitians would 
recommend probiotics were cited.  Antibiotic treatment and antibiotic-associated 
diarrhoea were the most common situations in which probiotics would be suggested 
(by 12% and 8.7% of dietitians respectively).  In comparison  probiotics were 
recommended by 21% Dutch dietitians, for those with recent diarrhoea and after 
antibiotic treatment (de Jong et al., 2004).  This study investigated FF in general 
rather than probiotics specifically, and so contained limited detail on products used 
and doses recommended.  In a study of New Zealand GPs (n = 45), probiotics were 
mostly commonly recommended for diarrhoea (44.4%) (Schultz et al., 2011). 
However, there was no information given on the cause(s) of diarrhoea in this study.  
AAD is a common problem, occurring in 5-25% of patients receiving antibiotics, 
although the rates reported depend on the antibiotics used and the population studied 
(Bartlett, 2002). Probiotics given in conjunction with antibiotics for the prevention of 
AAD have been extensively studied in both children and adults. Several systematic 
reviews document that most of the probiotics tested have been shown to be effective 
in reducing risk of AAD in the general population (Cremonin et al., 2002; D’Souza 
et al., 2002; Hawrelak et al., 2005; Szajewska & Mrukowicz, 2005). L. rhamnosus 
GG and S.boulardii are documented as being most efficacious. These are the strains 
which have been most commonly used in the studies. From a review of all studies, it 
can be concluded that the results of studies using probiotics to reduce AAD are 
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promising but that conclusive evidence is still lacking, additionally it cannot be 
stated that all probiotic strains are effective (McFarland, 2009) Again the findings 
from this study show that this group of dietitian are using probiotics in an area where 
the evidence does not fully support their use.  
3.5.6 Probiotics supplied in hospitals/ healthcare facilities and guidance 
around probiotic use  
From this questionnaire it is evident that probiotics are being provided to patients in 
the majority of hospitals and other health care facilities in Ireland.  The dietitians 
have identified themselves as the primary healthcare professional to recommend 
probiotics in CDAD.  Similarly, in a randomly selected group of Canadian dietitians, 
81% (n = 122) they too believed that dietitians were the most appropriate 
professional to recommend FF (Sheeshka & Lacroix, 2008).  Such beliefs mean that 
dietitians should have a good knowledge of FF, the probiotic products provided in 
healthcare facilities and also the evidence for their use.  The dietitians surveyed in 
this study had poor knowledge of the probiotic strains in the products they supplied 
or recommended.  Around half (47.7%) could not identify even one strain present in 
the product supplied.  The catering departments of healthcare facilities were also 
reported to have the biggest influence on the probiotic supplied.  One issue that is 
very clear from the studies carried out with probiotics in the treatment of various 
clinical conditions is that the positive effect is dose and strain dependent.  The 
administration of a probiotic product that may only contain one strain to a diverse 
hospital population could be described as futile.  The limited knowledge of dietitians 
of the strains being used, despite them taking responsibility for recommending 
probiotics, identifies a deficit in knowledge and professional practice.   
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The presence of policies or guidelines on the administration of probiotics within 
clinical settings appeared to be unclear, with disagreement within departments as to 
the existence of guidelines.  Analysis of the practices of dietitians working in specific 
areas was not possible due to the mixed caseloads of many dietitians.  However, a 
sub-group of 18 (8.4%) dietitians working in critical care was apparent, although it 
should be noted that some dietitians did not work solely in the ICU setting.  ICU is 
the one area where guidance exists for dietitians on the use of probiotics.  The recent 
Canadian Critical Care Guidelines (2009) state that there is insufficient data to make 
a recommendation on the use of probiotics, prebiotics and synbiotics in the critically 
ill (Heyland et al., 2009).  The Committee considered that the studies available are 
inconsistent in their method of reporting outcomes such as septic mortality, 
complications and diarrhoea.  The variability in the probiotics used in studies and the 
choice of control group made the published studies difficult to assess.  The probiotic 
prophylaxis in predicted severe acute pancreatitis (PROPTRIA) trial (Besselink et 
al., 2004) and concerns about risk associated with S. boulardii were also a cause for 
concern for the Committee.  The American Society for Parenteral and Enteral 
Nutrition (ASPEN) Critical Care Guidelines of 2009 reiterate that recommendations 
cannot be made about the use of probiotics in the general ICU population, again due 
to the lack of consistent outcomes (McClave et al., 2009).   
The safety issues highlighted in the literature would appear to be an aspect needing 
consideration.  Although dietitians’ opinions about the safety of probiotics were not 
specifically investigated in this study, some respondents highlighted that they would 
not use them in specific patient groups (i.e. infants and immunocompromised, ICU 
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and paediatric oncology patients).  Safety concerns arising from the use of probiotics 
were not apparent in the questionnaire responses. 
The reasons quoted for not using probiotics by Dutch dietitians related to safety and 
functionality of the products and to products containing bacteria or  “foreign” 
invaders (de Jong et al., 2004).  In another study, nutritionists (Mc Connon et al., 
2004) expressed concern about the risks associated with probiotics; however, this 
study focused on FF as a group of foods and did not seek specific detail on dietitians’ 
opinions on the safety aspects of probiotics.   
3.5.7 Type of enteral feed used in CDAD 
Although the majority of dietitians used a polymeric feed, there was no consistent 
practice in the provision of dietary fibre to patients with CDAD.  A small number of 
studies have investigated the impact of diet on the acquisition and growth of C. 
difficile.  The results of this study showed that few dietitians used elemental enteral 
feeds in their clinical management of CDAD patients.  Elemental diet is thought to 
favour the growth and proliferation of C. difficile.  An in-vitro culture study found 
that elemental diet enhanced the number of C. difficile and induced the production of 
C. difficile toxin (Iizuka et al., 2004).  It has been reported that C. difficile toxin was 
frequently detected in patients undergoing elemental diet therapy who were not 
taking antibiotics.  Faecal C. difficile toxin disappeared soon after the elemental diet 
therapy stopped (Itou et al., 1999; Itou et al., 2000).  Elemental diet contains no 
complex carbohydrate; the absence of dietary fibre and resistant starch disturbs 
microbial balance in the GIT and deprives the colonic epithelium of its chief energy 
source and proliferation regulator.  This reduces fermentation and the production of 
short chain fatty acids (SCFA), especially the SCFA butyrate.  It has been shown that 
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butyrate deficiency in the colon potentiates the growth and toxin production of C. 
difficile organism (May et al., 1994).  It has also been suggested the relatively large 
amounts of amino acids in elemental diet may to provide a favourable environment 
for C. difficile.  A recent review by O’Keefe (2010) stated that elemental feeding as a 
risk factor for C. difficile infection is frequently overlooked.  
To provide guidance for dietitians on the provision of fibre to this patient group, the 
mechanisms of action of fibre in the GIT should firstly be examined.  Studies that 
investigate the impact of fibre on the management of diarrhoea should also be 
reviewed, given that diarrhoea is the major symptom of CDAD.  Fibre intake 
influences nutrient absorption, carbohydrate, fat and sterol metabolism, stool bulk 
and weight, colonic fermentation and gastrointestinal transit time (Kapadia et al., 
1995; Alam et al., 1998).  Fibre also improves gut barrier function, helping to 
prevent translocation of bacteria and toxins from the gut into the systemic circulation 
(Spaeth et al., 1995).  Fibre also promotes increased turnover or regeneration of 
epithelial cells (Rehman et al., 2003).  
The effects of  supplementing enteral feeds with dietary fibre in both healthy 
volunteers and patients in hospital and community settings was investigated in a 
systematic review and meta-analysis of 51 studies (Elia et al., 2008).  The authors 
concluded that fibre supplementation was generally well tolerated.  In the hospital 
setting, incidence of diarrhoea was reduced as the result of fibre administration (OR 
0.68; 95% CI 0.48-0.96).  Results showed a strong effect of fibre in reducing the 
incidence of diarrhoea in patient groups with a high incidence of diarrhoea and a 
smaller or absent effect in those with a low incidence of diarrhoea.  A likely 
mechanism underlying the effect of fibre in reducing diarrhoea is the stimulation of 
116 
 
colonic water and electrolyte absorption by SCFA that are produced as a result of 
anaerobic metabolism of fibre.  SCFA have been shown to reverse fluid secretions in 
the ascending colon during enteral feeding (Bowling et al., 1993).  SCFA production 
depends on the number of types of bacteria species present in the colon, substrate 
source(s) and gut transit time (Wong et al., 2006) , all of which have a number of 
properties that may be of benefit in maintaining normal bowel structure and function, 
and preventing or alleviating colonic based diarrhoea.  SCFAs and acidic pH have 
been shown to contribute to resistance to C. difficile colonisation and proliferation in 
vitro (Rolfe & Iaconis, 1983; Rolfe, 1984).  Different types of dietary fibre affect the 
type and amount of SCFA produced.  Nakao et al., (2002) reported an increase in the 
ratio of anaerobic bacteria to aerobic bacteria with fibre supplementation.  This may 
be beneficial as anaerobic bacteria are thought to protect against the overgrowth of 
potential pathogens, some of which may cause diarrhoea (Bourlioux, 1997).  It is 
thought that lack of dietary fibre could produce an intestinal environment conducive 
to the growth of C. difficile.  The recent review by O’Keefe (2010), speculates that 
the prolonged use of low fibre tube feeds will enhance C. difficile colonization and 
subsequent C. difficile associated colitis by reducing the resistance to pathogen 
adherence and subsequent cytotoxic injury. 
3.5.8 The provision of probiotics via an enteral tube  
A limitation of the present study was that the questions asked of dietitians about their 
use of probiotics with enteral tube feeding did not distinguish between the positions 
of the enteral tube.  Such questions would have provided more detailed information 
on dietetic practice.  It appears that approximately half of all dietitians either 
regularly or occasionally recommend probiotics via enteral feeding tubes in both 
CDAD and other clinical conditions.  There is very little guidance from the scientific 
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literature or the probiotic or enteral feeding tube industries in this area. Danone 
Ireland Limited, the company that produce “Actimel” does not recommend the use of 
probiotics via enteral feeding tubes; the reason provided by the company is that 
clinical evidence is lacking to support its safety if used in this way, as the product is 
intended for oral consumption and has only been tested for oral use (Cox, M. 2010 
pers. comm., 15 May 2010).  Communication with representatives from Yakult, 
Ireland (Yakult) and Glanbia (“Everybody”) indicated that neither company had 
guidelines for the administration of their products via enteral feeding tubes (Jordan, 
D. 2011 pers. comm., 19 January; McGartland, C. 2011 pers. comm., 19 April;).  
Three companies that manufacture enteral feeding tubes that are commonly used in 
Irish healthcare facilities were contacted to seek their position on the administration 
of probiotics via enteral feeding tubes.  No company had recommendations; some of 
their comments compared the administration of probiotics to the administration of 
medications via enteral feeding tubes (Nolan, O. 2010, pers. comm., 4 May; Coakley, 
D. 2010, pers. comm., 14 May; Smith, R. 2010, pers. comm., 14 May).  
The safety issues that arise with probiotics and nutrition support were addressed in a 
recent review by Whelan and Myers (2010).  Patients receiving nutrition support are 
often high risk patients who are frequently critically ill and at risk of bacterial 
translocation or are immunocompromised and, so, have additional risk factors for 
probiotic infection.  They are, also, regularly on medications that increase gastric pH.  
The method of administering nutrition support can increase patients’ risk; post-
pyloric feeding enteral nutrition by-passes the gastric acid barrier completely and this 
can result in  a greater innoculum of the probiotic surviving in the small intestine.  A 
10-fold increase in the dose reaching the small intestine has been reported  (Whelan 
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& Myers, 2010).  Central venous catheters (CVC) are used in the administration of 
parenteral nutrition (PN) and these have been identified as a potential risk factor for 
probiotic infection (Boyle et al., 2006).  The review by Whelan and Myers (2010) 
included 20 case reports and 52 papers with 53 trials (41 RCT’s and 12 non-
randomized trials).  In the case reports examined, 32 patients received various 
methods of nutrition support and probiotics of varying strains and doses.  
Bacteraemia occurred in five cases and fungaemia in 27 cases.  Two patients also 
developed endocardititis (Land et al., 2005; Munoz et al., 2005).  The risk factors 
were variable, but the majority of patients who developed infections had received 
antibiotics and had intravenous access.  In eight patients, the adverse events resulted 
in death.  The cases in which infection developed had used L. rhamnosus GG or S. 
boulardii.  The authors commented this is probably due to these strains being used 
more frequently rather than them having greater virulence.  The presence of a CVC 
also carried a greater risk; many of these patients were in ICU and required a CVC 
for their medical management although it was highlighted that the CVC tips were not 
examined for contamination.  The authors of this review concluded that the risk of 
environmental contamination may also occur and be a greater risk factor than 
administration of probiotics.  In the case reports of S. boulardii fungaemia, the 
patients themselves were not receiving the yeast but patients located beside them 
were (Cassone et al., 2003; Graf & Gavazzi, 2007).  
In the 53 trials examined by Whelan and Myers (2010), the probiotics used varied 
and were administered in varying doses and using a range of administration methods.  
Subjects in the studies were from a variety of locations with a range of disorders.  
Many of the studies showed a reduction in mortality, sepsis or infection; in general 
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the studies showed either no effect or a positive effect of probiotic use on the overall 
outcome.  Only three studies, (one post liver transplant, another in acute pancreatitis 
and a further study in NEC) found significant increases in negative clinical sequelae 
which were largely non-infectious in nature (Besselink et al., 2004; Rayes et al., 
2005; Lin et al., 2008).  In two of the RCT’s, there was increased negative outcome 
in patients in which the probiotics were administered via naso jejunal tube (NJT) 
(Besselink et al., 2004; Rayes et al., 2005).  Whelan and Myers (2010) remark, in the 
three trials with negative outcomes, there are some issues with the study designs.  
One of the trials had low numbers which may result in statistical error (Rayes et al., 
2005) and in the second trial a novel probiotic was used and the study itself has been 
heavily criticized (Besselink et al., 2004).  In many of the studies the probiotic 
strains were not characterized, inconsistent doses were reported, probiotic infection 
occurred at different doses of probiotics, adverse events were either unreported or 
there was a lack of information about the adverse events.  In the cases where patients 
died, it was difficult to attribute the patient’s death to probiotic infection. 
3.5.9 CDAD and mineral and vitamin supplementation 
The symptom of diarrhoea which can often be persistent and severe in CDAD can 
impact on the individual’s nutritional status, especially micronutrient status.  There is 
no guidance in the literature on the provision of additional micronutrients during 
CDAD.  From the results of this study, it can be seen that a dietitian’s decision to 
supplement with vitamins or minerals appears to be generally based on his/her 
clinical judgement.  A more structured approach should be considered as mineral 
balance is always altered when diarrhoea persists for more than a few hours (Wiesen 
et al., 2006).  A range of micronutrient deficiencies during diarrhoeal disease has 
been described; some of the micronutrient deficits identified are copper, iron, 
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magnesium, selenium, zinc, folate and  vitamins A, B12 and D (Tomkins et al., 1993).  
Micronutrient deficiency impairs immune function and increases susceptibility to 
infection (Yaqoob & Calder, 2003). 
Zinc is a micronutrient that has been extensively studied for its role in diarrhoea.  In 
the GIT, it restores mucosal barrier integrity and enterocytes, promotes brush border 
enzyme activity and the production of antibodies and circulating lymphocytes against 
intestinal pathogens (Shankar & Prasad, 1998; Hess et al., 2009; Prasad, 2009).  The 
association between zinc and diarrhoeal associated morbidity was first noted in early 
observational studies that documented increased faecal zinc loss, a negative zinc 
balance and low tissues zinc concentration among children with diarrhoea (Anon, 
Zinc and copper wastage during acute diarrhoea, 1990).  There have been a number 
of studies investigating prophylactic zinc supplementation and its role in diarrhoea.  
A recently published Cochrane review also supports the role of zinc in treating 
diarrhoea in children.  In the 22 trials reviewed, zinc was seen to shorten the duration 
of an episode of diarrhoea.  However, there was no benefit demonstrated in children 
under 6 months (Lazzerini & Ronfani, 2008).  Due to the positive results of studies 
on zinc supplementation in children, the WHO/UNICEF now recommend zinc 
supplementation for the treatment of all episodes of childhood diarrhoea 
(WHO/UNICEF, 2004). Although there is strong evidence to support the 
supplementation of zinc in children, the majority of the studies on zinc 
supplementation have been conducted in children in developing countries and, 
therefore, may not be applicable to the adult population in developed countries.  
Nonetheless, dietitians should be more aware of zinc losses that can occur as a result 
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of CDAD diarrhoea.  In particular, if diarrhoea is persistent, zinc supplementation 
should be considered, especially if nutritional intake is inadequate.  
3.5.10 Limitations and future considerations 
An aspect not considered in the design of this study was dietitians’ personal 
consumption of probiotic products.  In previous studies, this has been reported to 
influence dietitians’ professional practice.  In a study of Korean dietitians, the 
dietitian’s own frequency of consumption of FF had a significantly positive effect on 
their recommendation of such foods and those who ate FF demonstrated a more 
positive attitude towards the efficacy of such foods. The authors of this study 
expressed concern that these findings may result in some dietitians providing 
misleading advice to consumers, because the advice provided was not necessarily 
based on scientific knowledge  (Cha et al., 2010).  An additional factor not explored 
as part of this study was methods dietitians use to obtain information about 
probiotics.  The study of Dutch dietitians showed that they got most of their 
information from journals, magazine articles or the internet, but would have 
preferred if information had been provided by independent scientists instead of 
through product promotions.  Specific information requested was about the safety 
and functionality aspects of the probiotics (de Jong et al., 2004).  
An important issue to be addressed from these study results is that dietetic practice in 
the use of probiotics is not underpinned by scientific research.  Similar findings on 
the opinions and use of probiotics have been reported among gastroenterologists in 
the US. Williams et al., (2010) reported that gastroenterologists believe that there is a 
role for probiotics in patient care but actual practices did not concur with the 
published expert panel based recommendations for evidence based probiotic use.  
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Cha et al., (2010) commented on the need for undergraduate students of nutrition and 
dietetics to learn about FF from a scientific, evidence-based approach and that 
education about FF should be provided as continual professional development for 
practicing dietitians. 
Given the vast amount of research into the efficacy of probiotics in different clinical 
conditions, the need for guidance for healthcare professionals, perhaps in the form of 
clinical practice guidelines should be considered.  One of the most consistent 
findings in health service research is the gap between best practice as identified by 
scientific research and the actual clinical care provided (Grol & Grimshaw, 2003; 
Brown et al., 2004).  Several studies have suggested that 10-40% of patients do not 
receive care that is based on current scientific evidence and that this deficit in 
evidence-based practice results in care that is either unnecessary or is potentially 
harmful in ≥20% of cases (Avezum et al., 2000; Grol & Grimshaw, 2003; Leape et 
al., 2003; Mc Glynn et al., 2003).  A cross-sectional survey in a Swedish University 
Hospital explored dietitians’, occupational therapists’, and physical therapists’ 
attitudes towards evidence-based practice.  All professions were reported to have 
positive attitudes towards evidence-based practice and support the use of evidence in 
decision making about patient care.  Although the groups had good knowledge about 
research terminology, they lacked understanding of the specific terminology relating 
to evidence-based medicine.  Lack of time was given as a barrier to the use of 
evidence-based care (Heiwe et al., 2011). 
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3.6 Conclusion  
This is the first study to describe Irish dietitians’ opinions on, and use of, probiotics, 
and their current practice in the management of CDAD.  The role and efficacy of 
probiotics in the prevention and management of CDAD is an area of emerging 
research and understanding.  We need a greater understanding of the complex 
interaction between the human gastrointestinal microflora, pathogens, probiotics and 
antibiotics and to increase our knowledge about the role of probiotics in CDAD.  The 
low cost, good safety profile and low risk of infection make probiotics a favourable 
option in the prevention and treatment of CDAD, provided sufficient evidence 
becomes available to support their use.  Studies of appropriate statistical power and 
adequate follow up are necessary to provide insight into the efficacy of particular 
bacterial and yeast strains and the doses of these strains that are most likely to 
prevent CDAD and its recurrence, and treat CDAD should it develop.   
The findings of this study indicate that Irish dietitians have mixed views about the 
role of probiotics in CDAD.  Despite this, they frequently recommend probiotics in 
their clinical practice either orally or via enteral feeding tubes, with little 
standardisation of practice apparent.  The probiotic strain recommended or available 
to prevent or treat CDAD frequently does not contain the strain for which evidence 
exists.  Guidelines or polices in Irish healthcare facilities for probiotic use are lacking 
or not consistently referred to by Irish dietitians.  Guidance on the use of probiotics 
in CDAD should be sought from current scientific literature and the development of 
consensus practice guidelines for dietitians managing patients with CDAD is 
essential. 
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Although the majority of Irish dietitians use a polymeric feed when enterally feeding 
patients with CDAD, practice on the provision of dietary fibre to this patient group is 
variable.  The provision of additional vitamin and mineral supplementation is also 
dependent on the dietitian’s clinical judgement.  The enteral feeding practices of Irish 
dietitians in this patient group need to be compliant with scientific evidence. From 
the review of the literature there are a number of considerations for dietetic practice. 
Those at high risk of developing CDAD elemental and semi elemental feeds should 
be avoided. A source of fibre should be provided when enterally feeding a high risk 
patient. In cases of CDAD where diarrhoea occurs the provision of additional 
vitamins and minerals should be considered to account for increased losses.  
  
Irish dietitians in this study identifed themselves as the main healthcare professional 
to recommend probiotics.  However the survey found that there was underutilization 
of current scientific evidence and guidelines to conform with evidence-based 
practice.  Health professionals need to remain competent in their knowledge of this 
developing area of research and be able to translate research findings into their 
professional practice (Schultz et al., 2011).  To achieve this, it is vital that 
information on FF is correctly communicated to those involved in nutrition education 
and health promotion (Blades, 2000).  Given the increasingly widespread availability 
and use of probiotics in both community and hospital healthcare settings, Irish 
dietitians need to acquire a thorough understanding of these products, including the 
risks and benefits of probiotic treatment and the effectiveness of probiotics using 
different modes of delivery.  If probiotics are recommended to prevent or treat 
disease in patients, consideration must be given to quality control and documentation 
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of the efficacy of such treatment.   It is imperative that dietitians develop their 
knowledge about probiotics so that they are able to convey science based information 
to their clients and healthcare professionals and their credibility as nutrition experts 
is strengthened (Hetherwick et al., 2006).    
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4.1 Conclusions and Recommendations 
This study looked at a number of aspects involved in the dietetic management in 
patients with CDAD in Ireland. The first study’s aim was to assess the nutritional 
status of patients with CDAD and compare this to a group of hospital patients. The 
study found there was no significant difference in MUST scores between a group of 
patients with CDAD and a comparative hospital patient group. However the CDAD 
group did have a significantly lower BMI and were a significantly older. In addition, 
when the data from the CDAD group were compared to malnutrition data from other 
Irish studies, there was a higher prevalence of malnutrition (as determined by BMI) 
and of malnutrition risk (as determined by MUST) in the CDAD group in this study. 
These findings would indicate that hospitalised patients with CDAD are at high risk 
of malnutrition.  
The second study investigated dietitians’ opinions and uses of probiotics in CDAD 
and other clinical conditions. It also looked at the enteral feeds being provided to 
these patients should tube feeding be required. This study showed that Irish dietitians 
have inconsistent views on the role and use of probiotics in different clinical 
conditions. What has emerged from the work is that probiotics are being 
recommended by dietitians in clinical conditions for which insufficient evidence 
exists, in particular patients with CDAD. It is also clear that a variety of probiotic 
products are being supplied within Irish health care facilities, that knowledge of the 
specific benefits and limitations for particular strains is poor and that very little 
guidance for their use exists. The study also showed that general enteral feeding 
practices varies among dietitians, specifically in the provision of feeds containing 
dietary fibre.   
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From the findings of this study and reviewing the literature a number of conclusions 
and recommendations are made: 
 The dietetic profession should continue to support and be involved in the 
promotion, training and implementation of nutritional screening for all patient 
groups in both the hospital and community setting.  
 Dietitians should be aware of the risk factors for the development of CDAD; 
in those patients at high risk who require enteral feeding the provision of 
feeds containing dietary fibre and the avoidance of elemental and semi 
elemental feeds should be considered. Supplementation of micronutrient 
intake including zinc in patients who develop CDAD may be beneficial. 
Medical and nursing staff should be aware that patients with CDAD are a 
patient group at high risk of malnutrition and instigate care plans that address 
this risk.  
 Probiotics should not be recommended for use in either the prevention or 
treatment of CDAD, until there are further supportive trials in the area. The 
author is unwilling to make a recommendation endorsing any product for any 
patient group for the treatment or prevention of CDAD as this would 
contravene current evidence. The probiotic S. bouldarii for which there is 
some limited evidence is not available in Ireland. However, in countries 
where this product is available international guidelines do not recommend it 
use due to safety concerns.  
 There is a need for education for practicing dietitians on the role of probiotics 
in clinical practice.  This education should be continuous to capture the 
emerging evidence in the area.  The information provided should be 
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independent of commercial influence and provide a balanced view of the 
scientific evidence.  
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Appendix 1 – The Mini Nutritional Assessment form  
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Appendix 2 – The Malnutrition Universal Screening Tool and supporting documents  
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Appendix 3 – Consent form for patients with Clostridium difficile associated disease 
 
PARTICIPANT INFORMATION AND CONSENT FORM 
STUDY TITLE: 
Nutritional status of patients with Clostridium difficile-associated Diarrhoea (CDAD) 
This is part of a larger study that is examining:    
Immune Response and Molecular Epidemiology of Clostridium difficile-associated 
Diarrhoea (CDAD): A Prospective Study. 
The principle investigator is: Dr Lorraine Kyne 
Researcher: Yvonne Hickey  
You are being invited to participate in a research study. Thank you for taking time to read 
this.  
WHAT IS THE PURPOSE OF THIS STUDY? 
Clostridium difficile is a bacterium, which causes diarrhoea in some patients who have 
taken antibiotics. Different strains of C. difficile diarrhoea have been responsible for 
major outbreaks of diarrhoeal illnesses in the UK and Canada. As part of this study we 
want to look at the nutritional status of patients diagnosed with C. difficile diarrhoea. 
Also to examine how C. difficile diarrhoea affects nutritional status of patients over a 
defined time period.  
WHY HAVE I BEEN CHOSEN? 
You have been invited to participate in this study because you are suffering from diarrhoea, 
caused by the C. difficile bacterium.  We will be asking all patients with C. difficile diarrhoea 
to consider participation in the study. We hope to enrol approximately 150 patients over 
the next 18 months 
WHAT WILL HAPPEN IF I VOLUNTEER? 
Your participation is entirely voluntary.   If you initially decide to take part you can 
subsequently change your mind without difficulty.    This will not affect your future 
treatment in any way.  Furthermore your doctor may decide to withdraw you from this 
study if he or she feels it is in your best interest.  If you agree to participate, you will be 
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requested to complete an interview. We will record information from your medical records 
on treatment, tests and general health. In addition, information will be gathered regarding 
your recent weight history and dietary intake. We will also take measurement of you 
weight, height, tricep skinfold thickness, upper arm and calf circumference and hand grip 
strength. While you are in the hospital a researcher will contact you to re assess your 
dietary intake and nutritional status, and will repeat the measurements that were initially 
taken.  
ARE THERE ANY BENEFITS FROM MY PARTICIPATION? 
By participating in this study you will help researchers identify the nutritional status of 
patient who develop C. difficile diarrhoea and how it is affected after people develop C. 
difficile diarrhoea .  
ARE THERE ANY RISKS INVOLVED IN PARTICIPATING? 
We do not anticipate any discomfort or potential risks associated with participation in this 
study. 
WHAT HAPPENS IF I DO NOT AGREE TO PARTICIPATE? 
If you decide not to participate in this study your treatment will not be affected in any way. 
CONFIDENTIALITY 
Your identity will remain confidential.  A study number will identify you.   Your name will 
not be published or disclosed to anyone. 
COMPENSATION 
The researchers are adequately insured by virtue of their participation in the clinical 
indemnity scheme. 
IS THIS STUDY SAFE AND BENEFICIAL? 
The St. Vincent’s Healthcare Group, Ethics and Medical Research Committee have reviewed 
and approved this study. 
WHO IS ORGANISING AND FUNDING THIS RESEARCH? 
The main study is funded by a grant from the Health Research Board and is organised by Dr 
Lorraine Kyne, Consultant Geriatrician, Mater Hospital. 
Research Team CONTACT PHONE: 01 716 6345 
Principal investigator: Dr. Lorraine Kyne, Phone: 01 803 4242 or 01 716 6301  
Consultant Physician in Medicine for the Older Person, Medicine for the Older Person Day 
Ward, Mater Misercordiae University Hospital.  
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Researcher:   
Yvonne Hickey, Dietitian, St Vincent’s University Hospital 
Dr. Lynda Fenelon, Consultant Microbiologist, St Vincent’s University 
 
PLEASE TICK YOUR RESPONSE IN THE APPROPRIATE BOX 
I have read and understood the Participant 
 Information        YES     NO  
 
I have had the opportunity to ask questions and discuss 
the study       YES     NO  
 
I have received satisfactory answers to all my questions  YES     NO  
 
I have received enough information about this study  YES     NO  
 
I understand that I am free to withdraw from the study  
at any time without giving a reason and without this  
affecting my future medical care    YES     NO  
 
I agree to take part in the study     YES     NO  
 
Participant’s Signature:     ____________________________ Date:   _________ 
 
Participant’s Name in print:  __________________________ 
Witness Signature:     _______________________________ Date:   _________ 
Witness Name in print:     ____________________________ 
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      Investigator’s Signature:     ___________________________ Date:   _________ 
       
      Investigator’s Name in print:     ________________________ 
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Appendix 4 – Data collection record for patients with CDAD 
 
Study ID_______      Date:___________ 
 
 
 
 
 
 
 
 
 
  
Name: Initials  
Location / Ward  
Sex:  Male  ⁮    Female                        Race :  
MRN  
Date of Birth / age   
Date of C Diff positiv   
Admission date    
Admitte from: Home ⁪ Nursing Home ⁪ Rehab Hospital ⁪  
Other ____________________ 
Previous sta on his 
admission in: 
ICU ⁪ HDU ⁪ 
 
Hospitalised in previous 30 
days 
yes⁪ no ⁪ 
Dietetic intervention  Yes         no  
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Weight 
Method 
 
 
Odema present  Yes ⁪ No 
Mild   moderate   severe 
 
 
Yes ⁪ No 
Mild   moderate   severe ⁪  
Usual weight   
 
Reported weight   
 
% Weight loss  
 
Weighthistory   
 
 
Height  
Reported  
 
stadiometer  
 
Ulna length  
 
Ulna length   
 
Mid upper arm circumference  
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Nutritional Intake  
Oral intake in past five days  Normal     ⁪            
Less than normal  ⁪ 
Very little / none ⁪  
Diet Consistency   
Fluid Consistency   
Coeliac Disease  yes ⁪  no ⁪ 
Oral Nutritional Supplements  
Yes ⁪  No ⁪  
 
 
 
 
Enteral feeding  
 
NG NJ PEG RIG  
Date PEG/RIG inserted _______________ 
Date feeding Commenced   
Feed type   
Feed Rate   
TPN  Regimen details  
Total volume  
Date Commenced   
Probiotic charted on drug kardex  
 
 
Previous probiotic se  
Vitamin and mineral supplement   
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 Appendix 5- Data collection sheet for Control group 
Patient 
Number Age Sex 
Type 
of 
ward* 
Diagnostic 
Category** 
Oedema 
Present? 
Has MUST 
been 
completed? 
If MUST 
was done, 
is their 
evidence of 
an 
appropriate 
care plan? 
Weight (Kg) 
 
 
Height (m) - if not available, 
calculate from Ulna Length 
 
 
BMI 
Step 1- 
Score 
 
 Yrs M/F 1-5,*8 1-7** Y/N 
Y/N - if no, 
complete 
tool. If yes - 
give score, 
e.g Y-2. Y/N 
Actual Recalled N/A*** Actual Recalled Calculated 
Kg/m2 
 
 
1               
              
2               
              
3               
              
4               
              
5               
              
6               
              
7               
              
8               
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Patient Number 
Unintentional weight loss (past 
3-6 months) Step 2-Score 
Food 
intake 
over past 
5 days     
Likely 
food 
intake 
over 
next 5 
days     
Step 3 - 
Score 
MUST 
Score  
 
Kg   Normal 
Less than 
normal 
V. little or 
none Normal 
Less than 
normal 
V. 
little 
or 
none      
1 
                      
 
2                      
 
3                      
 
4                      
 
5                      
 
6                      
 
7                      
 
8                      
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A
ppendix 6 – the H
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rotection S
urveillance C
entres infection guidelines for patients 
w
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lostridium
 difficile associated disease (H
P
S
C
, 2008).  
 
z 
PATIENT PLACEMENT 
PATIENT MOVEMENT 
AND TRANSFER 
App~ to all pat ients , residents and dients irnspective of thei' 
perceived infection ri sk 
Indude the potential for transmission of infectious agents in patient 
placement decisions. 
'M1ere possble, place patients.....ho contam nate the environment 
or (Klnot mantain appropriate hygiene in sng le rooms, 
When the patie nt has had at least 48 hours withovt diarrhoea and has 
had a form ed/normal stool for that patient. Contact Precautions can 
b e discontinued , HOWEVER STANDARD PRECAUTIONS MUST BE 
CONTINUED 
Place all patients with suspected or known CDAD in a single room with 
cl inical hand wasting sink and ensloite facili ties. If ensuite facilities are not 
available. dedicate toilet or commode for patients' sole use. 
Place a notice on t he isolation room door advising those entering to report to 
staff-in-charge before entering. 
In an outbreak situation, if the numbel" of patients with CDAD exceeds the 
availability of single rooms, alternative placement options include: 
Cohort ward or bay with a dedicated nursing staff for t he area. 
Isolation / dedicated ward in the event of a large outbreak. 
Limit the moveme nt and transport o f the patient to essentia l purposes 
only, 
Priorto patient transfer 
nform transport personnel (e.g, porters, emergency medical technicioll'l) 
and the receiving departmentlhealthcare facility of the need for Contact 
Precautions. 
Remove contaminated aprons/gowns and gloves and dispose and perform 
hand hygiene prior to transporting patients. 
Don apron/gown and glCNes prior to handling the patient at the transport 
destination . 
Prior to acceptng a patient with CDAD, it is the responsibility of the 
receiving facility to ensure compl iance with single room, clinical hand 
washing sir*, ensuite facilities and Contact Precautions. The receiving ward/ 
department, bed manager must be notified . 
Transport equipment (stretdler, bed, wheeldlair) used for the transfer must 
be cleaned and disinfected before use with another patient/resident. 
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S< 
HAND H YGIENE 
Patients should wash 
their hands after 
toi!eting and before 
meals. Hew should 
provide assistance 
with hand washing for 
those patients who are 
unable to perform hand 
washing independently 
GLOVES 
Should be worn as 
single use items 
Should conform to 
European Community 
Standard s. 
EYE , NASAL AND 
MOUTH PROTECTION 
(e.g., goggles, visors 
and face masks) 
Hand Hygie ne is recommended: 
a ~and .a..fulr. each episode of patie nt contact 
• Betvveen individual patient contacts. 
Aftm: cont act with b lood, body fluids . secretions or excretions, 
whether or not gloves are worn. 
Aft.m handling soiled/contaminated equipment, materials or the 
environment. 
Immediately after removing gloves or o t her protective clothing 
Hand may be decontaminated using both plain soap and warm 
water o r if hands are physically dean, an alcohol based hand ru b. 
Gloves are recommen d ed: 
For all act;...ities that carry a risk of exposure to blood, body fluids, 
secretions o r excre tions, sharp s orcontaminated instruments 
When touching mu cous membranes and n on-intact skin. 
When handling contaminated equipment, e.g. commodes o r 
bedpans. 
Gloves should be: 
Put on immediately before an episode of patient con tact, and 
removed as soon as the activity is completed 
Changed between caring for different patients and between 
different care activities on the same patient. 
Disposed of as health care ris k waste if contaminated with blood, 
body fluids 
Facemasks and eye pro tection are recommended where there is a 
risk of b lood, body fluid s, secret ions or excretions sp lashing into th e 
face or eyes. 
Masks should be single use a nd fl u id resistant. 
In addition to carry ing out ha nd hygiene as required in Standard 
Precautions 
Hand s should be washed before and after each contact with patient 
equ ipment 
Hands should be washed with soap (anti microbial or non-a ntimicrobial) and 
water. I'll 
None of the agents (including alco hols, chlorhexidine, iodophor'S or 
triclosan) used in a nt iseptic ha nd-w ash o r a nt iseptic hand-rub preparations 
are reliably sporicidal against C. diffici le. Th e physical action of rubbi ng 
and rinsing is the only way to re move spores from hands . 
In addition t o wearing g loves as required for Standard Precautions, wear 
gloves wh en entering a room for all interactions that may invowe contact with 
the patient or potentially contaminated areas in the patients environment. 
Remove gloves 
Immediately afte r contact with any infective material 
Before touching non-contaminated items a nd environmental surfaces 
Before leaving the patients environmen t 
Wash hands as above immediately after glove removal. 
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Ii: 
APRONS 
PATIENT CA.RE 
EQUIPMENT 
Disposable plastic aprons should b ewom where there is a risk. 
that clothing or skin may become exposed to blood, body fluids, 
excret ions or secretions. 
Fluid repellent gowns may be required if there is a risk of extensive 
eJq)osure to the above. 
Handle equipment soiled with b lood, body fluids. secretions and 
excret ions in a man ner that preve nts skin and mucous membranes, 
contamination of clothing, and tran sfer of micro-organisms to other 
patients and environments. 
Ensure that reusable equipment is not used by another patie nt 
until it has been cleaned and rep rocessed appropriately. 
In addition to w earing apron/gowns as required (or Standard Precautions, 
wear aprons/gowns when entering a roo m for all interactions that may 
involve contact with the patient or potentially contaminated areas in the 
patient s' e nvironmen t. 
Remove apron/gown 
Immediately after contact with any infective material 
Before leaving the patients environment 
Wash hands as above immediately after apron/ gOlNn removal. 
Dedicate medical devices (e.g., thermometers, s phyg moman ome ters, 
stethoscopes, glucose metres) to single patient use and d isposa b le 
materials used wh e never possible. 
On ly take essential eq uipment and supplies into the room. Do not 
stockpile as unused s tock will have to be discarded on cessation of 
Isolation Contac t Precaut ions. 
Patient charts/records should not be tak e n into the room. 
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g: 
LAUNDRY CARE: 
DECON TAMINATION 
OF MEDICAL DEVIC ES 
Laundry shou ld be handled and transported in a manner that 
prevents transmission of micro-organisms to othe r patie nts, 
HeWs or the environm ent. 
Laundry shou ld be categorised and segregated according t o 
recommended guidel in es 
Staff handling soiled linen sh ould wear gloves and a disposable 
plastic apron. 
Soiled and infectious linen should be carefully placed in an 
a lginate s titc hed o r water sol u ble bag with a tie. Then place 
bag into a colour-c:oded laundry bag which should be secu rely 
closed prior to transport to an approved laundry capable o f 
dealing with potentially contaminated linen 
Staff shou ld not manually sluice or soak so~ed or infected linen 
Idatning because o f the risk of cross in fection~26 
Soiled linen should be tra nsported and stored safely. 
Linen should be h eat disinfected during th e wash p rocess by 
raising the temperature to e ither 6S"C for not less then 1 0 
minutes o r preferably 71 "C for not less then 3 minutes. 
Disinfection o f heat labile materials (according to manufacturer 
instructions) can be achieved at low temp eratures by 
150 ppm of chlorine into t he penultimate rinse. 
Medical d evices designated as "Singl e Use Only" must not be 
re processed or reused under any circumstances (MDA DB 2000), 
(M[x) 93/42/EEC 
2 
This symbol means "Single Use Only " (BS EN 980:1997). 
Reusable medical devices should be cleaned and reprocessed 
according to the manufacturer's in structions and local po li cy. 
In add ition to hand ling a nd tra ns porta t ion of laundry as required for 
Standard Precautions: 
All laundry should be carefully pl aced in an alginate stitched o r water soluble 
bag and then placed into a laundry bag clearly identified with label s, co lour-
coding or o t he r m ethods prior to transp o rt to an approved laundry capab le 
of dealing with contaminated line n . 
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.8' 
MANAG EMENT OF 
HEALTH CARE RI SK 
WASTE : 
Dispose of healthcare risk waste in accordance wit h the 
Department of Health & Children's National Guidelines for Waste 
Disposal,:m whic h outlines the categorisation and segregation of 
health care waste. 
DISPOSAL OF SHARPS: 
Syringes and needles should be disposed o f as a single unit. 
Used sharps shou ld be carefully discarded into designated 
sharps cont ainers at, the poin t o f use. 
Need les should not be re-capped, bent , broke n or 
disassembled . 
Sharps shou ld not be passed from person to person by hand. 
Guidel ines should be availab le at local IeYe I on the management 
of needle stick a nd sharps injuries. 
Waste contaminated with diarrh oea from a suspected or known CDAD 
patient snould be disposed as healthcare risk waste with in a healthcare 
faci lity 
No additional precautions are needed for non-healthcare waste that is being 
removed from rooms of patients on Contact Precautions 
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SPILLA G ES Spillages of blood, urine, faeces or vomit s hould be dealt with 
immediately wea ring protective clot hing (i.e. disposab le gloves 
and apron). 
Fo r spilla g es o f b ody fluid (e.g ., urine, faeces o r vomit), 
Soakup as much afthe visible mate rial as possible with disposab le 
pape r towels. 
Dispose of the soiled paper towels according to national 
guidelin es. 
Clean the area usi ng warm wa ter and general purpose neutral 
detergent. 
Disinfect using a chlori ne-releas ing solution o f 1000ppm, o r 
equivalent according to manufacturers' instructions, rinse and 
d",_ 
Discard gloves and apron according to n a ti onal guidelines. 
Wash and dry hands thoroughly. 
Do not a p ply ch lorine-based disinfectants direct ly onto spillages 
of urine as it may result in t he release of ch lorine vapou r. 
Fo r b lood s p ill ages: 
Decontaminate a ll blood spills wit h a c hlorine based disi nfectant 
(e.g .. powder. g ran ules o r liq uid con taining 10.000ppm available 
chlorine) or suitab le al t erna tive. in li n e with t he man u fac tu rer's 
instructions and local pol icy. 
Wipe up the spillage with disposable paper towels a n d discard 
into a yellow plastic bag . Wash the area with a general purpose 
neu tral d etergent and water. 
Discard gloves and apron according to national g u ideli nes. 
Wash a nd dry hands thoroughly 
For a ll suriaces/items cont aminated with blood or body fluids. 
following deanin g d isinfect using a chlorine-releasing solution of 
1COOppm . o r equivalen t according to manufacturers instru ctions. 
rinse and dry. 
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Appendix 7 – St Vincent’s University Hospital Infection Control guidelines for Clostridium 
difficile associated disease. 
SI Vincent 's Heallhca re Grou p 
10. INFECTIOUS DISEASES 
10.1. Ove n ' jew of Infection Control Management of Infectious Diseases 
The infec tion preve ntion and control (lPe) team should be in formed promptly if any patient 
known or suspected to have any of the following in fections is admitted (ext 4948/4088. bleep 122). 
Duration o f isolation varies accordi ng to the infection with w hich the patient had been diagnosed. 
Some infections require that the patient be iso la ted for the entirely of their hospital stay ; wi th other 
infections. the patient may be removed from isolatio n o nce they have been sy mptom-free for a 
specified time period, or have had appropriate treatment for a spec ified time. Further information 
o n some infec tio ns may be found furthe r on in this section; otherwise. p)easc d iscuss with the IPC 
team. 
Recomme ndatjons may be subject to change following assessment by the IPC team 
For thc llI:1uagcmcnl or pallcnls In Isolalloll , plcase re rcr 10 Guldcllncs on numagcmcnt or 
paticnts in Isolation (Section 30). 
Notm"blc InrccUvc nl<.ltcrl411 AddilIOll<.11 Isolutlon rC(lulrcd 
Dlsc~,sc Precautions 
Campylobacter Yo< Faeces Contact Single room 
Chickenpox No Respiratory secretions Airborne Single room 
(Varicella zoster Lesion secretions Contact 
virus) 
Cholera Yo< Faeces Contact Not required 
Clostridium No Faeces Contact Single room 
dijficUe Faccally contaminated 
objects and surfaces 
Creutzfeldt- Yo< Brdin . spinal, cranial and Seek advice from Not required 
Jakob disease dura mater Infection control 
(CJD) Optic nerve and retina 
Varian! CJD Yo< As above and lymphoid 
(vCJD) tissue 
Diphtheria Yes Oral & nasal discharges Droplet Single room 
Ecoli0157 Yo< Faeces Contact Single room 
Haemophilll.!' Ye, Respiratory secretions Droplet Not required 
illj114e'lzae B 
{invasive) 
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St Vincent's Hea lthcare Group 
10.5. ClostridiulII di/Jicile 
This is a NOTIFIABLE DISEASE 
AGENT: ClostridiulIl cliffici/e 
INCUBA T ION PERIOD: Variable 
TRANSMISSION: Environmental contamination 
Hands of hcalthcarc workers 
Faeca l-oral. 
PREDISPOSING 
FACTORS: 
INFECTIVE 
MATERIAL: 
DURATION OF 
INFECTIVITY: 
PRECAUTIONS: 
T REATMENT: 
PERIOD OF 
ISOLATION: 
Antibiotic therapy. especially ccphlusporins, clindamycin and 
quinolones (e.g., ciprofloxucin) 
Exposure to infected patients 
Faeces 
FaecaUy contaminated objects/surfaces 
While symptomatic, and until free of symptoms for 72 hours 
CONTA CT PRECAUTIONS 
Isolation of the patient in a single room until free of symptoms 
for 72 hours. 
In the event of non-availability of a single room, cohorting of 
patients with C. difficile may have to be considered 
A commode should be secured for the sole use of the infected 
patient. 
Environmental cleaning with I,OOOppm hypochlorite. 
Discontinue anljbiotic therapy if c1jnically feasible. 
Do not use anti-diarrhoeal agents 
Metronidazole ill vancomycin orally, depending on clinical 
severity 
From onset of symptoms, until symptom free for 72 hours 
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Appendix 8 – Cover letter and survey to members of the INDI 
     School of Biological Sciences,  
Kevin Street, 
Dublin 8 
9th of March 2010 
Questionnaire - Dietetic practice in Ireland - The use of probiotics and enteral feeding in 
patients with Clostridium difficile associated diarrhoea 
Dear Member  
I am a dietitian working in St Vincent’s University Hospital and am currently completing a 
Masters degree with the School of Biological Sciences, Dublin Institute of Technology under 
the supervision of Dr. Clare Corish.  
My primary area of research is an investigation of the nutritional status of patients who 
develop Clostridium difficile infection in hospital. However,  in recent years, a number of 
studies have been published on the use of probiotics as an emerging therapy in both the 
prevention of Clostridium difficile (Hickson et al. 2007) and the treatment of patients who 
develop this infection (Mc Farland, 2006).  I now wish to investigate the current use of 
probiotics in dietetic practice focusing on patients with Clostridium difficile. In addition I 
would also like to ascertain Dietitians’/ INDI members’ opinions regarding the use of 
probiotics in the management of Clostridium difficile and other medical conditions. 
To obtain this information, I am circulating this questionnaire to all members of the INDI.  
The questionnaire will collect some demographic data on respondents (e.g. place and area 
of work, years practicing), and information on the use and administration of probiotics in 
patients with Clostridium difficile associated diarrhoea. The questionnaire will also include 
questions relating to the dietetic management of enterally fed patients who develop 
Clostridium difficile associated diarrhoea. 
 
The questionnaire is divided into 4 sections and will take approximately 5 minutes to 
complete. Please complete each section providing me with your opinions and current 
practices and return in the included stamped addressed envelope by the 31st of March 
2010.  
All completed questionnaires will be entered into a draw to win a € 75 One 4all gift 
voucher in appreciation of your help and time with this 
If you have any queries, please do not hesitate to contact me.  
___________________________________ 
Yvonne Hickey y.hickey@st-vincents.ie 
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Section 1 - Baseline Details  
(a) Gender 
Male  Female    
(b) Place of employment  
Hospital   please name hospital: ____________________________
  
Community dietetics  please name HSE area: _____________________________
  
Private practice     
Student  
Other  please state:_____________________________________ 
(c) How many whole time equivalent (WTE) dietitians work in your department? 
_________________________________________ 
(d) How many years have you been working as a qualified dietitian?  
Less than one year  1-5 years   
6-15 years   16-25 years      + 25 years   
(e) Which best describes the patients you work with? 
Paediatrics  
Adults  
(f)What areas of dietetic practice do you currently work in ( e.g. care of the elderly , surgery, 
gastroenterology, etc……) 
___________________________________________________________________________ 
Section 2 – Your Opinions 
(a)Do you think probiotics have a place in dietetic practice in the prevention of 
Clostridium difficile?  
Yes    No     Don’t know 
Please give a reason for your 
answer:____________________________________________________________________
________________________________________________________________________ 
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(b) Do you think probiotics have a place in dietetic practice in the treatment of 
Clostridium difficile?  
Yes     No    Don’t know  
Please give a reason for your 
answer:____________________________________________________________________
___________________________________________________________________________ 
(c) Would you recommend the use of probiotics in your clinical practice in any of the 
following clinical conditions? 
I do not recommend the use of probiotics  
OR  
Liver disease       
Inflammatory bowel disease        
Irritable bowel syndrome    
Small bowel bacterial overgrowth     
Acute gastroenteritis     
Necrotising enterocolitis    
Other conditions: 
__________________________________________________________________ 
___________________________________________________________________ 
 
Section 3 - Probiotics in practice 
(a)Does your hospital/place of work have a policy/guidelines for the use of probiotics?  
Yes    No 
 
(b) Does your hospital/place of work have a policy/guidelines for the use of 
probiotics specifically in patients with Clostridium difficile associated 
diarrhoea? 
 
Yes   No 
 
(c) Does your hospital/place of work use/supply probiotics to patients? 
 Yes   No 
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(d) Do you use probiotics in the prevention of Clostridium difficile associated 
diarrhoea in at risk patients ? 
 Yes No  Occasionally  
(e) Do you use probiotics used in the treatment of Clostridium difficile associated 
diarrhoea? 
 Yes             No Occasionally  
(f) If probiotics are commenced in patients with Clostridium difficile associated diarrhoea, 
who generally recommends their commencement? (Choose more than one option if 
appropriate)  
Not applicable   Microbiologist     
Dietitian/clinical nutritionist          Nursing Staff      
Medical staff             Pharmacist   
Other ____________________ 
(g) If probiotics are commenced, who recommends their commencement most often?   
(Please classify 1-4, 1 being the most often, 4 not as often)  
Not applicable  
1. ____________________2.____________________ 
3.____________________    4.____________________ 
(h) In what form are the probiotics given? 
Yogurts containing probiotics  Tablet / Capsule 
Yogurt drinks containing probiotics 
(i) What different brand(s) of products are used (please specify product and type eg 
yogurt and brand  
___________________________________________________________________________ 
___________________________________________________________________________ 
(j) If probiotics are used, what strain(s) of probiotic is used?  
Unknown 
Strain(s):___________________________________________________________________
___________________________________________________________________________ 
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(k) If probiotics are used, what determines the strain of probiotic or brand of products 
used in patients with Clostridium difficile associated diarrhoea? (More than one option 
can be chosen) 
The clinical evidence  
The product supplied by catering  
The product supplied by pharmacy  
Hospital guidelines  
Medical/ Microbiological opinions  
Other:_____________________________________ 
(l) Do you recommend administration of probiotics to patients who develop diarrhoea? If 
the diarrhoea is not caused by Clostridium difficile and who are on antibiotics? 
Yes  No Occasionally  
(m) Do you recommend administration of probiotics to patients who develop diarrhoea? 
If the diarrhoea is not caused by Clostridium difficile  and is of  unknown origin? 
Yes  No Occasionally  
(n) Would you recommend the commencement of a multivitamin or mineral supplement 
in a patient who is Clostridium difficile positive? (more than one option can be chosen) 
Yes, always  Would depend on patient’s diagnosis 
Would depend on patient’s nutritional status   
Other reason: ________________________________________ _____________________ 
 
Section 4– Enteral feeding 
(a) Do you recommend  administration of  probiotics via enteral tubes if a patient being 
tube fed gets Clostridium difficile associated diarrhoea? 
Yes  No  Occasionally   Not applicable 
 
(b) Do you recommend  administration of  probiotics via enteral tubes to patients with 
other clinical conditions ? 
Yes     No  Occasionally  Not applicable 
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(c)If a tube fed patient develops Clostridium difficile what type of feed would you use 
most often?  
Fibre containing   Semi elemental 
Non fibre containing       Elemental 
A mixture of fibre and non fibre containing     Feeding is withheld 
Parenteral nutrition is commenced 
Please provide any further comments you may have on the use of probiotics and/or 
nutritional management in patients with Clostridium difficile associated diarrhoea?  
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_______________________________________________________________ 
Thank you for taking the time to complete this questionnaire.   
Your response and time is greatly appreciated. 
Please return in included envelope 
Yvonne Hickey ,Dietitian 
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Appendix 9 – Irish Hospitals represented by responses from dietitians.  
Hospital  
Adelaide and Meath Hospital Incorporating The National Childrens 
Hospital  
Beaumont Hospital  
Bons Secours Cork 
Bons Secours Dublin 
Cavan General Hospital 
Connolly Hospital Blanchardstown 
Cork University Hospital 
Kerry General Hospital   
Letterkenny General Hospital  
Mary’s Hospital Phoneix Park  
Mater Misericordiae University Hospital 
Mater Private Hospital  
Mayo General Hospital  
Mercy Univeristy Hospital Cork 
Merlin Park University Hospital Galway 
Mid Western Regional Hospital Dooradoyle 
Midland Regional Hospital Mullingar 
Midland Regional Hospital Portlaoise 
Midland Regional Hospital Tullamore 
Monaghan General Hospital  
Mount Carmel Hospital  
Mount Carmel Hospital  
Naas General Hospital  
Our Lady’s of Lourdes Hospital Drogheda 
Our Ladys Children Hospital Crumlin 
Portiuncula Hospital  
Roscommon County Hospital  
Sligo General Hospital  
South Infirmary Victoria Univeristy Hospital Cork 
South Tipperary General Hospital  
St Columcille’s Hospital  
St Finbarrs Hospital, Cork 
St James Hospital 
St Lukes  Hospital Rathgar 
St Lukes Kilkenny 
St Michaels Hospital Dun Laoghaire 
St Vincent’s Private Hospital  
St Vincent’s University Hospital  
Temple Street Childrens Univeristy Hospital  
The National Maternity Hospital  
University Hospital Galway 
UPMC Beacon Hospital  
Waterford Regional Hospital   
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Appendix 10 - Probiotic products supplied in hospitals 
Product 
name and 
manufacturer 
Probiotic 
Genus , species, strain(commercial 
strain designation) in the product 
Form 
Everybody  
Yoplait 
Lactobacillus rhamnosus GG Yogurt drink  
Actimel 
Danone 
Lactobacillus bulgaricus 
Streptococcus thermophilus  
Lactobacillus caesi Imunittas ( DN114001) 
Yogurt drink  
Yakult  
Yakult  
Lactobacillus caesi Shirota Yogurt drink 
Udos Super 8  Lactobacillus acidophilus 
Lactobacillus rhamnosus 
Streptococcus thermophilius 
Lactobacillus plantarum 
Bifidobactermium bifidum 
Bifidobacterium longum 
Lactobacillus bulgaricus 
Lactobacillus salivarius 
 
 
Capsules  
Acidophilus 
Complete  
Sona 
Lactobacillus Lactis 
Lactobacillus Acidophilus 
Lactobacillus Para Casei  
 
Capsules 
VSL # 3  
Living Shield  
 
Streptococcus thermophilus  
Bifibobacterium breve  
Bifibobacterium longum 
Bifibobacterium infantis 
Lactobacillus acidophilus  
Lactobacillus plantus 
Lactobacillus paracasei 
Lactobacillus bulgaricus 
 
Sachet  
To be added to water  
Old Mac 
Donnells 
Farm Natural 
Yoghurt   
Old Mac 
Donnells 
Farm 
Lactobacillus bulgaricus, Streptococcus 
thermophillus, Bifidobacterium longum ,  
Lactobacillus acidophilus 
Yogurt 
Activa  
Danone 
Lactobacillus bulgaricus 
Streptococcus thermophilus 
Bifidobacterium Acti Regularis  
Yogurt  
Mixed seeds 
yogurt  
Yoplait 
Bifidobacterium BB12 r Yogurt  
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Product 
name and 
manufacturer 
Probiotic 
Genus , species, strain(commercial 
strain designation) in the product 
Form 
Yogurt  
Glenisk  
Adults products 
Active cultures –Streptococcus thermophilus, 
Lactobacillus bulgaricus 
Probiotic cultures – Lactobacillus casei, 
Bifidus 
Childrens products 
Lactobacillus casei 
Yogurt  
Restore  
Protexin  
Lactobacilus casei 
Lactobacillus rhamnosus 
Streptococcus thermophilus  
Bifibobacterium breve  
Lactobacillus acidophilus  
Bifidobacterium infantis 
Lactobacillus bulgaricus 
Sachet added to fluid  
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